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Summary 
Mycoplasma bovis (M. bovis) is an opportunistic pathogen that can cause disease and production 
losses in cattle of all ages. It has primarily been associated with mastitis and arthritis in cows, and 
respiratory disease, arthritis and otitis media in calves. Over the last two decades, M. bovis has 
gained more attention due to its apparent increasing prevalence, but also due to increasing 
antibiotic resistance in recovered M. bovis isolates. Little attention has been paid to M. bovis in Denmark since its first detection in 1981, and during the 1980’s and 1990’s it was primarily 
associated with outbreaks of a mastitis syndrome that had not previously been seen in Denmark. 
However, new types of severe outbreaks of M. bovis-associated disease appeared in 2011, 
characterised by many arthritis cases and swollen legs in addition to the clinical signs that had been 
more traditionally recognised. A longitudinal field study involving 39 Danish dairy herds was 
initiated in 2013 as an industry-driven initiative with the aim of clarifying the importance and 
limiting the impact of M. bovis infections at both individual animal and herd level. However, 
difficulties with the interpretation of the available diagnostic test results led to requests for more 
research, and this PhD project was conceived to provide interpretation and recommendations 
based on the on-going data collection activities.  
Enzyme-linked immunosorbent assays (ELISA) are diagnostic tests that are relatively inexpensive 
and easy to perform. In Denmark, ELISAs are routinely used for diagnostic purposes as well as in 
control and eradication programmes at both animal and herd level. However, there are few studies 
describing the use of M. bovis antibody measurements as a diagnostic tool, most of which describe 
the test as being useful for group-level rather than individual diagnosis. The published literature 
mainly reports on experimental studies that do not necessarily reflect the antibody response 
patterns that would be observed in naturally infected herds. Field studies investigating antibody 
measurements at animal and herd level would improve the understanding of how to use antibody 
detecting ELISAs as diagnostic tools, but might also lead towards a better understanding of the 
infection dynamics of M. bovis within affected herds. 
The aim of the work presented in this thesis was to improve the understanding and interpretation 
of antibody measurements in relation to the clinical epidemiology of M. bovis, with the end goal 
being understanding of how to apply this diagnostic test method for control of M. bovis infections. 
Data were available from the longitudinal field study mentioned above in which the 39 Danish dairy 
herds were visited four times each at approximately 3-month intervals, with blood samples 
collected from young stock and milk samples from lactating cows (sampling activity #1), as well as a 
clinical epidemiology study in four Danish dairy herds with new outbreaks of M. bovis-associated 
disease. These four herds were visited five times at approximately 3-week intervals and clinical 
signs were registered and blood and milk samples were collected from groups of diseased and non-
diseased cows and calves (sampling activity #2).  
The first study that was carried out based on sampling activity #1 identified herd-level risk factors 
that were associated with bulk tank milk (BTM) ELISA optical density measurements (ODC%) using 
the commercially available BioX K302 ELISA kit (BioX). A reasonably strong association was found 
between BTM ELISA ODC% and the apparent prevalence of antibody-positive lactating cows based 
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on individual milk sample test results, with the BTM results increasing on average 9 ODC% for 
every 10% increase in the prevalence of antibody-positive lactating cows. However, it became 
obvious that clinical signs consistent with M. bovis were reported by farmers even in herds during 
periods with low ODC%-values measured in BTM, and it was decided to pursue explanations for the 
apparent lack of test accuracy. 
The patterns in antibody responses in naturally infected animals with different clinical signs of M. 
bovis-associated disease were analysed by modelling antibodies directed against M. bovis in serum 
and milk from cows and serum from calves from sampling activity #2. To analyse the antibody 
response relative to the time since clinical signs started, all cows were divided into disease groups 
based on clinical examinations. The antibody response measured by the BioX ELISA was generally 
very dynamic, short-lived and dependent upon the observed clinical signs. Even in diseased cows, 
the mean estimated ELISA ODC% was below the recommended cut-off 60-70 days after clinical 
signs were observed. The ODC% in serum was not elevated for all the cows with clinical signs of 
systemic M. bovis-associated disease, while the ODC% in milk was mostly elevated in cows with 
PCR-positive M. bovis mastitis. The findings relating to the BioX ELISA results in calves differed from 
the cows. The clinical signs were not associated with antibody ODC%, but herd and time of expected 
M. bovis exposure were. Calves exposed to M. bovis at a young age did not appear to rise in antibody 
level until the age of 3 months, on average.  
An alternative ELISA (known as the MilA ELISA) developed at University of Melbourne was applied 
to the samples from sampling activity #2 for comparison with the BioX ELISA. The MilA ELISA 
detected antibodies in calves shortly after birth, but were not associated with clinical signs. This 
suggests that the MilA ELISA is a sensitive test that can demonstrate exposure in calves older than 3 
weeks. It was not possible to analyse the MilA ELISA results from the cows with statistical 
modelling, which means that the results are less generalizable than for the BioX ELISA. All serum 
MilA ELISA results were above the recommended cut-off in cows both with and without clinical 
signs of M. bovis-associated disease, whereas for milk, only cows with M. bovis mastitis seemed to 
have high reactions in the MilA ELISA. Although the sensitivity of MilA seems promising, an 
evaluation of the specificity in herds without M. bovis-infections is warranted. 
Finally, the knowledge gained from the above-mentioned studies was used to evaluate the 
association between antibody-positivity to M. bovis using the BioX ELISA and the incidence rate of 
undesired early departures (i.e. slaughter, euthanasia or death) in cohorts of 636 heifers from 36 of 
the dairy herds included in sampling activity #1. The used Poisson regression model accounted for 
confounders and clustering effects at both animal and herd level. Increasing seroprevalence in the 
group of calves 3-12 months old was the primary factor found to increase the risk of undesired early departures of heifers, along with a weak association with the heifer’s own animal-level ODC% 
corrected for age. This indicates that M. bovis has a prolonged effect on the health and performance 
of young stock. 
In conclusion, the results of this PhD project have contributed new knowledge that improve our 
understanding of the antibody responses to M. bovis in dairy herds. This allows some updated 
recommendations to be made regarding the use of ELISAs for diagnosing M. bovis-associated 
disease. The antibody response to M. bovis is very dynamic and short-lived, excretion in milk and 
serum depends on the clinical signs in adult cows, and is primarily found in diseased cows, which 
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means that using antibody testing for detecting of M. bovis infections in dairy herds should be based 
on group testing rather than individual testing of cattle. It also limits the usefulness of BTM ELISA 
testing for M. bovis as this primarily reflects the presence of M. bovis udder infections in the herd. 
Antibody measurements in young calves are even more challenging due to a lack of or a slowly 
developing antibody response using the BioX ELISA. The MilA ELISA is apparently sensitive for 
measuring exposure to M. bovis, and can be applied from 3 weeks of age, but the specificity could 
not be determined with the samples available for the project. Infection with M. bovis in young stock 
seems to be associated with decreased heifer survival, so M. bovis infections in dairy herds should 
be regarded as serious, and control measures should be applied if diseased or antibody-positive 
animals are found.
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Sammendrag 
Mycoplasma bovis (M. bovis) er et opportunistisk patogen, der kan forårsage sygdom og 
produktionstab hos kvæg i alle aldre. De typiske kliniske tegn hos køer er yverbetændelse og 
ledbetændelse, mens kalve ofte får luftvejsinfektioner, ledbetændelse og mellemørebetændelse. I 
løbet af de seneste to årtier er der kommet mere fokus på M. bovis dels på grund af en 
tilsyneladende stigende prævalens, men også på grund af øget antibiotikaresistens i de isolerede 
stammer. Siden 1980´erne har der ikke været meget fokus på M. bovis i Danmark, som op gennem 1980’erne og 1990’erne mest var associeret med en række udbrud af atypisk yverbetændelse. I 
2011 opstod en række alvorlige M. bovis-relaterede sygdomsudbrud, som ud over yverbetændelse, 
også var karakteriseret ved ledbetændelse og hævede ben. Et longitudinelt feltstudium i 39 danske 
malkekvægsbesætninger blev igangsat i 2013 med det formål at afklare betydningen og begrænse 
konsekvenserne af M. bovis infektioner på individ- og besætningsniveau. Fortolkningen af de 
tilgængelige diagnostiske tests var dog ikke lige til, hvilket gjorde det nødvendigt at gennemføre 
mere forskning, og dette ph.d.-projekt blev tilknyttet den igangværende dataindsamling. ‘Enzyme-linked immunosorbent assays’ (ELISA) er en relativt billig diagnostisk testmetode, der er 
let at udføre. I Danmark bruges ELISA rutinemæssigt til diagnostik i besætninger, samt i kontrol og 
bekæmpelses-programmer, både på individ- og besætningsniveau. Brugen af antistofmålinger til 
diagnostik af M. bovis er dog sparsomt beskrevet i litteraturen. Oftest beskrives testmetoden som 
ikke anvendelig til individuel diagnostik, men brugbar til diagnostik på gruppeniveau. Dog er de 
fleste studier lavet på eksperimentelt inficerede dyr, og det observerede antistofrespons er ikke 
nødvendigvis sammenligneligt med det, man ville observere i naturligt inficerede besætninger. Det 
var forventningen, at undersøgelser af antistofresponset både på individ- og gruppeniveau i 
naturligt inficerede besætninger kunne forbedre fortolkningen af ELISA-resultater til brug ved 
diagnostik og kan medvirke til at øge forståelsen af smittedynamikken i smittede besætninger.  
Formålet med dette ph.d.-projekt, var at forbedre forståelsen af, hvordan antistofmålinger kan 
bruges til at fortolke den kliniske epidemiologi med henblik på at anvende ELISA som diagnostisk 
metode som led i bekæmpelsen af M. bovis infektioner i kvægbesætninger. Udover det før nævnte 
longitudinelle studium, hvor 39 danske malkekvægsbesætninger blev besøgt 4 gange med ca. 3 
måneders mellemrum, og fik udtaget blodprøver fra ungdyr og mælkeprøver fra lakterende køer 
(Dataindsamling #1), blev data fra et klinisk epidemiologisk studium i fire udbrudsbesætninger 
tilvejebragt i løbet af ph.d. projektperioden. Disse fire malkekvægsbesætninger havde alle akut 
udbrud af M. bovis-relateret sygdom og blev besøgt fem gange med ca. 3 ugers mellemrum, hvor 
kliniske tegn blev registreret på dyreniveau, samt blod- og mælkeprøver fra grupper af syge og 
ikke-syge dyr blev udtaget (Dataindsamling #2). 
Den første undersøgelse baseret på Dataindsamling #1 undersøgte hvilke besætningsfaktorer, der 
var associeret med tankmælks ELISAs optiske densitetsmålinger (ODC%) målt med BioX K302 
ELISA testkit (BioX). Der blev fundet en fornuftig sammenhæng mellem tankmælks ELISA ODC% og 
prævalensen af antistofpositive køer i mælk. Tankmælksværdien steg med 9 ODC% for hver 10 % 
stigning i prævalensen af antistofpositive lakterende køer. Det viste sig dog, at landmændene 
fortalte, at de havde oplevet kliniske tegn forenelige med M. bovis i deres malkekvægsbesætninger i 
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perioder, hvor tankmælkens antistofværdier lå lavt. Det blev derfor besluttet at forsøge at 
undersøge denne tilsyneladende mangel på diagnostisk sikkerhed nærmere. 
Dette blev gjort ved at undersøge M. bovis-antistofdynamikken i serum og mælk hos køer og serum 
fra kalve fra Dataindsamling #2. Ved at opdele køerne i grupper efter deres kliniske tegn, kunne 
antistofresponset relateres til tiden siden de kliniske tegn startede. Antistofresponset målt med BioX ELISA’en var meget fluktuerende og kortvarigt, og afhang af kategorien af kliniske tegn hos 
køerne. Selv hos køer med kliniske tegn på sygdom var den estimerede gennemsnitlige ODC% 
under den anbefalede grænseværdi allerede 60-70 dage efter de kliniske tegn startede. I serum var 
ODC% kun høj hos køer med tegn på systemisk spredning af M. bovis, mens ODC% i mælk primært 
var høj hos køer med yverbetændelse forårsaget af M. bovis. BioX ELISA’en opførte sig noget 
anderledes hos kalve. Her var de kliniske tegn ikke associeret med antistofresponset, men det var 
besætning og tidspunkt for forventet eksponering for M. bovis til gengæld. Kalve der blev 
eksponeret mens de var meget unge, steg ikke i antistof niveau før de i gennemsnit var omkring 3 
måneder gamle, selvom de sandsynligvis blev eksponeret før den alder. 
Prøverne fra Dataindsamling #2 blev også testet med en ELISA (kaldet MilA ELISA) udviklet på University of Melbourne, for sammenligning med BioX ELISA’ en. Hos kalve kunne MilA ELISA’en 
måle antistoffer kort tid efter fødslen, men ligesom for BioX ELISA’en var der ikke forskel på om 
kalven havde kliniske tegn eller ej. Dette indikerer, at MilA ELISAen kan være en sensitiv test, der 
kan påvise eksponering for M. bovis blandt kalve > 3 uger. Resultaterne fra MilA ELISA’en hos 
køerne kunne ikke analyseres med en statistisk model, så resultaterne er mindre generaliserbare end resultaterne fra BioX ELISA’en. Alle antistof målinger i serum hos køer var over den anbefalede 
grænseværdi, både hos køer med og uden kliniske tegn på sygdom, mens det i mælk primært var 
køer med M. bovis yverbetændelse, der lå højt i antistofniveau. På trods af at MilA ELISA’en er en 
lovende følsom test, så mangler der en evaluering af specificiteten i besætninger uden M. bovis 
infektion. 
Til sidst blev resultaterne af de ovenfor nævnte studier brugt til at undersøge sammenhængen mellem antistofpositivitet (ved brug af BioX ELISA’en) og incidensraten for tidlig afgang fra 
besætningen (dvs. til slagtning, aflivning eller død) i en kohorte på 636 kvier fra 36 af 
malkekvægsbesætningerne, der indgik i Dataindsamling #1. Der blev taget højde for konfunderende 
variable og cluster-effekter både på individ- og besætningsniveau. Af de undersøgte faktorer havde 
seroprævalensen blandt gruppen af ungdyr på 3-12 måneder størst betydning for tidlig udsætning, 
mens den individuelle ODC%, der var afhængig af alder, var mindre betydningsfuld. Dette indikerer, 
at M. bovis har en langvarig effekt på kviernes sundhed og præstation.  
Dette ph.d.-projekt har bidraget med ny viden til at øge forståelse af M. bovis antistofresponset og 
har medført opdaterede retningslinjer for brug af ELISA ved diagnostik af M. bovis-relateret 
sygdom. Antistofresponset er meget fluktuerende og kortvarigt, og udskillelsen i serum og mælk 
afhænger af, hvilke kliniske tegn koen udviser og findes primært hos syge køer, hvilket medfører at 
antistofmålinger til påvisning af M. bovis-infektioner ved sygdom i malkekvægsbesætninger bør 
baseres på gruppediagnostik snarere end enkeltdyrsdiagnostik. Det betyder også, at anvendelsen af 
ELISA ODC% i tankmælk er af begrænset diagnostisk værdi, da det kun afspejler tilstedeværelsen af 
M. bovis yver-infektioner i besætningen. Antistofmålinger med BioX ELISA’en i kalve er udfordrende 
på grund af manglende antistofrespons særligt i helt unge kalve. MilA ELISA’en er potentielt en 
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følsom alternativ test, der reagerer på eksponering for M. bovis i dyr > 3 uger, men specificiteten for 
denne test er endnu ikke undersøgt. Infektion med M. bovis kan reducere overlevelsen hos kvier, og 
derfor skal M. bovis infektioner i malkekvægsbesætninger håndteres bedst muligt, og 
kontrolforanstaltninger bør iværksættes, hvis der findes syge eller antistofpositive dyr i 
besætningen.
List of abbreviations and terms 
XV 
 
List of abbreviations and terms 
BC bacterial culture 
BioX ELISA ‘BIO K 302’ from Bio X Diagnostics 
BRD bovine respiratory disease 
BTM bulk tank milk  
BVDV bovine viral diarrhoea virus 
Ct cycle threshold 
DCD Danish Cattle Database 
ELISA  enzyme-linked immunosorbent assay 
GAMM generalised additive mixed model 
Ig immunoglobulin 
M. bovis  Mycoplasma bovis 
MilA in-house ELISA developed at the University of Melbourne 
ODC optical density coefficient 
PCR polymerase chain reaction 
PCI posterior credibility interval 
SampAct#1 sampling activity #1 
SampAct#2 sampling activity #2 
SEGES             name of the Danish farmer-owned knowledge, consultancy and technology centre 
that provides services to all Danish farmers1 
 
UED undesired early departure 
Vsp variable surface protein
                                                          
1 https://www.seges.dk/en 
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1 Introduction 
1.1 Background and motivation 
A series of severe outbreaks of Mycoplasma bovis (M. bovis)-associated disease emerged in 2011 in 
Danish cattle herds. Prior to this, animals with clinical signs of M. bovis were only sporadically seen 
in Denmark, and mostly before 2002. Visits to ten herds with suspected M. bovis outbreaks in 2011 
and a repeated serological testing in a pilot project in 3 case and 3 control herds in 2012 were 
inconclusive regarding causal factors and underlying mechanisms for the observed varying clinical 
patterns (Aalbæk et al., 2012).   
Since the first isolation in the USA in 1961, M. bovis has been recognised as a pathogen primarily 
responsible for mastitis (Fox, 2012). It has since spread to many countries and is now endemic in 
Europe (Nicholas and Ayling, 2003). At the same time, awareness of M. bovis has increased, which 
may lead to an apparent increase in reporting that may not reflect a true underlying increased 
prevalence. M. bovis was first isolated in Denmark in 1981 from lung tissue from cattle (Friis and 
Krogh, 1983). A few years later, 80-100 animals from 15 herds experienced a previously unknown 
mastitis syndrome and M. bovis was found to be the causative agent (Friis, 1984). During the 1990s, 
M. bovis was not considered a major pathogen, and was only found in 1 of 51 lung samples from 
calves with pneumonia submitted to the Danish Veterinary Laboratory for diagnostic purposes in 
1993-94 (Tegtmeier et al., 1999). By 1997-99, the occurrence had apparently increased, as 12 out of 
50 lung samples from calves with pneumonia were positive for M. bovis (Kusiluka et al., 2000). 
These samples were also submitted the Danish Veterinary Laboratory, but no further reports about 
either outbreaks or general disease status were published. 
The M. bovis situation in Denmark dramatically changed in 2011 when cattle herds began to 
experience severe disease outbreaks (Worsøe, 2011). In addition to the known clinical manifesta-
tions (such as mastitis in cows and pneumonia and otitis media in calves), these outbreaks were 
characterised by arthritis as well as more diffusely swollen legs in both adults and young stock. 
Some herds were severely affected in all age groups, leading to loss of animal welfare, frustrations 
with lack of knowledge about how to manage infected herds and large insurance claims from 
farmers who had to cull many sick animals. Knowledge of many aspects of M. bovis was lacking and 
farmers, veterinarians and cattle consultants were requesting more information about diagnostics, 
prevention, treatment and control options.     
The extent of M. bovis infections was not known, and difficulties in interpreting the diagnostic tests 
led to requests for more research. A longitudinal field study involving a relatively large collection of 
data from 39 Danish dairy herds was initiated in 2013 by the Danish cattle industry in collaboration 
with two universities. The aim of the project was to clarify the importance of M. bovis infections in 
joints, udders and lungs, and limit the impact of the infection at individual animal and herd level. If 
possible, a control programme for M. bovis would be developed to limit the further spread of 
infection. This PhD project was later connected to the field project that provided access to this data 
collection allowing for epidemiological analyses to improve the interpretation of diagnostic test 
results in the hope of supporting the development of a control programme.  
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In Denmark, other control and eradication programmes for cattle diseases rely on antibody 
measurements in serum and/or milk, e.g. the bovine viral diarrhoea virus (BVDV) and Salmonella 
Dublin eradication programmes (Houe et al., 2006; Warnick et al., 2006). ELISAs are easy to 
perform, provide additional information for some infections and (at least in Denmark) are relatively 
inexpensive per test compared to e.g. polymerase chain reaction (PCR) or bacterial culture (BC). 
The general convenience of ELISA tests warranted investigations into the usefulness of available M. 
bovis ELISAs as a diagnostic tool. However, antibody measurements used as a diagnostic tool for M. 
bovis are sparsely described in the published literature. They are mostly described as not being 
useful for individual diagnosis, but useful for group-level diagnostics (Maunsell and Donovan, 
2009). However, this statement is based on little published literature, which mainly reports on 
experimental studies and does not necessarily reflect the situation in naturally infected farms.  
National bulk tank milk (BTM) screenings involve testing all Danish dairy herds four times a year 
for the surveillance of BVDV and Salmonella Dublin. In 2013 and 2014, four national screenings for 
antibodies against M. bovis in BTM from all Danish dairy herds were also performed. However, it 
became apparent that the interpretation was unclear and there were no field studies to clarify 
whether the recommended individual animal level cut-off of the used ELISA was useful for inter-
pretation of the BTM-result. 
In order to develop guidelines for the use of diagnostic tests in outbreak situations or for a control 
programme relevant to Danish farmers, commercially available tests needed to be investigated. 
Increased knowledge about the characteristics of the measured antibody responses to M. bovis 
infection contracted under natural conditions and an interpretation of ELISA test results in 
individual animals with different disease syndromes as well as in BTM would improve our under-
standing of the limitations and merits of the ELISA as a diagnostic tool. Furthermore, antibody 
responses combined with other diagnostic test results and clinical investigations might lead to a 
better understanding of the pathogenesis of the disease and the infection dynamics within affected 
herds. 
1.2 Aim and objectives 
The aim of the work presented in this thesis was to improve our understanding of how to interpret 
antibody measurements in relation to the clinical epidemiology of M. bovis and as a diagnostic test 
method of relevance for the control of M. bovis infection in the Danish cattle population. Under the 
hypothesis that cattle will respond to M. bovis infections by raising an antibody response, the 
following specific objectives were pursued: 
1. To improve the interpretation of herd-level diagnostics by investigating the correlation 
between bulk tank milk antibody test results and the within-herd prevalence of 
antibody-positive and clinically ill animals 
2. To investigate the dynamics of antibodies against M. bovis in serum and milk from dairy 
cows with different clinical signs of M. bovis-associated disease 
3. To investigate the dynamics of antibodies against M. bovis in serum from dairy calves 
with different clinical signs of M. bovis-associated disease 
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4. To compare the dynamics of antibody responses in serum and milk as measured by two 
different ELISAs 
5. To determine the association between antibody test-positivity to M. bovis and heifer 
survival in dairy herds 
1.3 Outline of the thesis 
The rest of this thesis contains the following chapters: 
Chapter 2 contains a literature review that presents current knowledge about M. bovis, with an 
emphasis on diagnostic methods – in particular antibody measurements and knowledge important 
for the interpretation of these. 
Chapter 3 gives an overview of the sampling activities and other information sources that provided 
the data for analysis in this thesis. An overview of the statistical methods used is also presented. 
Chapter 4 presents the main findings. 
Chapters 5 and 6 contain a general discussion, conclusions and perspectives of the presented 
work. 
Chapter 7 contains the references. 
Chapter 8 contains the following four manuscripts: 
Manuscript I: Factors associated with variation in bulk tank milk Mycoplasma bovis 
antibody-ELISA responses in dairy herds. 
Manuscript II: A longitudinal observational study of the dynamics of Mycoplasma bovis 
antibodies in naturally exposed and diseased dairy cows. 
Manuscript III: Mycoplasma bovis antibody dynamics in naturally exposed dairy calves 
according to two diagnostic tests. 
Manuscript IV: Increased incidence rate of undesired early heifer departure in Mycoplasma 
bovis-antibody positive Danish dairy cattle herds.  
Chapter 9 includes the appendices, with the questionnaire used for the first field sampling activity 
(SampAct#1) and the clinical protocol used for the second field sampling activity (SampAct#2). 
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2 Literature review 
2.1 Mycoplasma bovis – an overview 
The purpose of this literature review is to provide an overview of the pathogenesis and relevant 
diagnostic methods of M. bovis-associated disease of relevance for diagnosis and control, in 
particular antibody measurements and knowledge important for the interpretation of these. 
2.1.1 Aetiology and pathogenesis 
Mycoplasmas are microorganisms in the class Mollicutes, and are the smallest prokaryotic cells 
capable of self-replicating. They do not possess a cell wall and are therefore innately resistant to 
antibiotics that interfere with the synthesis of the bacterial wall, such as penicillin (Nicholas and 
Ayling, 2003). Mycoplasma bovis (M. bovis) was formerly known as Mycoplasma agalactiae subsp. 
bovis, but the name was changed in 1976 when it was concluded that M. bovis and Mycoplasma 
agalactiae should be regarded as two different species (Askaa and Ernoe, 1976). 
Mycoplasmas inhabit mucosal surfaces, and their relationship with the host varies between 
commensal, primary and secondary pathogen (Maunsell and Donovan, 2009). Due to the small 
genome of M. bovis, the bacterium is dependent on the host to provide essential substances such as 
amino acids, lipoproteins and nucleotides (Burki et al., 2015). Adhesion to the host’s epithelium 
cells is therefore very important for successful invasion of the host, and the membrane proteins are 
essential for colonising and survival within the host (Adamu et al., 2013). Modification of adhesion properties could potentially alter the mycoplasma from a ‘local’ to a ‘systemic’ stage capable of 
producing different clinical disease manifestations. Some mycoplasmas can invade non-phagocytic 
host cells, and thereby have the opportunity to resist host defences and selective antibiotic 
treatment, and establish chronic infections (Rosengarten et al., 2000). The interaction between M. 
bovis and the host is complex, and despite much attention being paid, many mechanisms are still to 
be determined. The variable surface protein antigens (Vsp) are probably the most well-
characterised immune modulatory effects of M. bovis. The Vsp are highly variable and can maintain 
diversity in a M. bovis population within the host. This mechanism challenges the host’s recognition 
and elimination of the bacterium, and allows M. bovis to evade the immune system, contributing to 
the chronic nature of M. bovis infections (Buchenau et al., 2010). Some Vsp have been shown to 
interfere with adhesion to the host cell, while others are involved in biofilm production. However, 
the disease severity, site of infection and bacterial genotype have not been associated with Vsp 
(Maunsell et al., 2009). The precise role of the Vsp therefore remains to be elucidated. Overall, M. 
bovis can interfere with the immune system in different ways in order to enhance survival within 
the host. 
Uptake and spread of the bacteria in the host 
The uptake of M. bovis occurs through the respiratory tract, oral ingestion or ascending via the teat 
end canal into the udder. Figure 2.1 gives an overview of the uptake and spread of M. bovis in calves 
and cows.  
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M. bovis is considered to be a contagious mastitis pathogen that spreads from udder to udder e.g. in 
the milking parlour. Many experimental studies have produced clinical signs of mastitis through the 
inoculation of M. bovis in the udder (Bennett and Jasper, 1978a; Biddle et al., 2003; Byrne et al., 
2005) and after intra-mammary inoculation, M. bovis was isolated from different areas such as 
various lymph nodes, uterus, synovial fluid etc., which suggests some systemic involvement (Jain et 
al., 1967). Dissemination from one quarter to another one or several quarters is a typical clinical 
sign in M. bovis mastitis (Biddle et al., 2003) and possibly occurs via haematogenous or lymphogenic 
routes. However, it has not been determined whether haematogenous spread from the udder to 
other body sites is important in the epidemiology of M. bovis infections. 
Uptake of the bacterium through the oropharynx can spread via the Eustachian tubes to the middle 
ear, with development of otitis media possible. Oral uptake seems to predispose for colonisation of 
the tonsils, which contributes to the development of otitis media. This was observed in comparison 
to transtracheal inoculation, which caused lower respiratory infection, but not upper respiratory 
tract infection (Maunsell et al., 2012). A recent study showed the development of typical lung 
lesions after exposure to an aerosolised culture of M. bovis, suggesting that nebulisation can be used 
to produce M. bovis respiratory infections (Kanci et al., 2017). Dissemination to the joints occurs via 
the haematogenous route, and both calves and cows can develop arthritis after intravenous 
administration of M. bovis (Chima et al., 1981; Stalheim and Page, 1975). However, it is not known 
whether the respiratory or oral infection route predisposes to arthritis development, or if arthritis 
can also develop after an infection ascending through the udder. 
Excretion of bacteria from the host 
Mycoplasmas typically inhabit mucosal surfaces, and the respiratory tract and the udder seem to be 
the most important sites for colonisation and shedding of M. bovis (Maunsell et al., 2011).  
In experimental studies, M. bovis was shed in milk 3-4 days after inoculation in the inoculated 
quarters, and all four quarters shed M. bovis 17-19 days after inoculation into one quarter of the 
udder (Bennett and Jasper, 1978a). The duration of shedding M. bovis in milk after mastitis is not 
clear. Shedding of the bacteria in milk has been reported to last for up to 12 months after naturally 
occurring mastitis (Jasper et al., 1966; Ruhnke et al., 1976). However, other authors were not able 
to detect M. bovis in repeated milk samples from cows within 75 days (+/- 20) after the cows had 
had clinical mastitis and had been tested positive using PCR on milk samples (Aebi et al., 2015). The 
duration of shedding might be influenced by unknown host factors and may differ between 
naturally occurring and experimentally induced infections. Cows with mycoplasma mastitis tend to 
have an inconsistent daily shedding pattern, where the organism is not isolated on some days, and 
is isolated in high numbers on others (Biddle et al., 2003). This indicates that it might be beneficial 
to use composite milk samples or to test the cow repeatedly in order to increase the likelihood of 
mycoplasma detection at individual animal level.  
M. bovis can be detected in the nasal cavity and respiratory tract of cattle of all ages, but the 
duration and causes of continued shedding have not been elucidated. Both clinically affected and 
asymptomatic carrier animals can harbour and shed the bacteria from the nasal cavity (Bennett and 
Jasper, 1977; Punyapornwithaya et al., 2010; Soehnlen et al., 2012). 
Literature review 
7 
  
Although M. bovis can be detected from other areas of the body such as the conjunctiva and the 
vulvovaginal tract (Fox et al., 2008; Punyapornwithaya et al., 2010), the duration and shedding 
patterns from these anatomical sites have not been elucidated. Information about possible shedding 
routes in faeces and urine is lacking. Bennett and Jasper (1978a) state that, ‘occasionally, isolations were made from… bladder urine’, but did not elaborate further. 
 
 
 
Figure 2.1: Overview of the uptake, transmission and clinical signs of Mycoplasma bovis in calves 
and cows. Clinically ill or asymptomatic carriers may clear the infection or continue to shed. 
(Petersen et al. Mycoplasma bovis – hvad ved vi egentlig. Dansk Veterinærtidskrift. 2, 2015, pages 
14-18, with permission) 
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Clinical signs 
Cows 
In adult cattle, M. bovis primarily manifests as mastitis, arthritis and pneumonia (Maunsell et al., 
2011; Pfutzner and Sachse, 1996).  
M. bovis mastitis can be clinical or subclinical. The clinical signs are not specific, but a lack of 
response to treatment, with more than one quarter affected, sometimes all four, is typical (Biddle et 
al., 2003; Gonzalez and Wilson, 2003; Pfutzner and Sachse, 1996). Cows in all lactation stages, 
heifers and dry cows can all be affected (Bicknell et al., 1978; Fox et al., 2008). After experimental 
inoculation with 70 cell forming units/ml of M. bovis into the udder, the first clinical changes 
(including watery milk) were observed 5-6 days after inoculation, all four quarters showed clinical 
signs 19-21 days after inoculation, and 11 out of 16 cows still had clinical signs 56 days after 
inoculation (Bennett and Jasper, 1978a).   
In the past, M. bovis was primarily associated with mastitis in adult cows, but more reports of joints 
and surrounding tissues being affected have been published over the last decade. M. bovis has been 
associated with arthritis (Gharagozlou et al., 2004; Henderson and Ball, 1999; Holzhauer and 
Engelen, 2016; Houlihan et al., 2007; Stalheim and Page, 1975; Szacawa et al., 2015), diffuse 
subcutaneous oedema and lameness (Wilson et al., 2007). The primarily affected joints seem to be 
the carpal and fetlock joints in the front legs (Henderson and Ball, 1999; Holzhauer and Engelen, 
2016; Wilson et al., 2007). The reason for this apparent change in the clinical picture and 
predilection for joints in the front legs is not clear.  
M. bovis has also been associated with keratoconjunctivitis (Alberti et al., 2006; Kirby and Nicholas, 
1996), postsurgical seromas in beef cattle (Gille et al., 2016) and genital disorders (Pfutzner and 
Sachse, 1996). However, these associations are rarely reported, and their extent and importance are 
not clear. 
Calves 
In young calves, M. bovis is commonly associated with pneumonia, arthritis, otitis media or any 
combination of these (Maunsell and Donovan, 2009; Nicholas and Ayling, 2003).   
M. bovis is part of the complex of bacteria and viruses that cause bovine respiratory disease (BRD) 
in calves, but can also be the primary pathogen in pneumonia (Thomas et al., 1986). Pneumonia and 
otitis media often co-occur, probably because bacteria from the oropharynx proliferate though the 
Eustachian tubes to the middle ear (Francoz et al., 2004; Lamm et al., 2004; Maunsell et al., 2012). 
Arthritis can be the sole clinical sign of M. bovis infection in calves, but often follows pneumonia 
and/or otitis media. The carpus and the stifle are often affected (Mahmood et al., 2017).  
M. bovis has also been isolated from calves with keratoconjunctivitis (Levisohn et al., 2004; Schnee 
et al., 2015), decubital abscesses (Kinde et al., 1993) and from brain tissue in calves with clinical 
signs associated with M. bovis (Ayling et al., 2005; Maeda et al., 2003). As with cows, however, these 
clinical signs are rarely reported and the extent and importance are not clear. 
There are no pathognomonic clinical signs for cows or calves, and this combined with other factors 
described below makes the recognition and diagnosis of M. bovis infection challenging. 
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Interaction with other pathogens 
The relationship between mycoplasmas and the host varies from commensal to opportunistic or 
primary pathogens (Maunsell and Donovan, 2009). M. bovis has been isolated as the only pathogen 
from pneumonic lung lesions, but has also been isolated from healthy lungs and pneumonic lung 
lesions associated with other bacterial or viral causes. M. bovis can be isolated from arthritic as well 
as non-arthritic joints, suggesting that isolation does not always imply a causal relationship (Gagea 
et al., 2006). In natural respiratory infections, M. bovis is often detected with other pathogens, 
suggesting a degree of synergy. M. bovis is often found in combination with the common respiratory 
pathogens Pasteurella multicida, Histophilus somni, Mannheimia haemolytica, bovine respiratory 
syncytial virus, bovine herpes virus 1 or parainfluenza virus type 3. In respiratory infections, M. 
bovis can predispose to more severe symptoms in calves that are subsequently infected with 
Pasteurella multocida (Gourlay and Houghton, 1985), and can also cause lesions in tissue that has 
previously been damaged by Pasteurella multocida, Histophilus somni and Mannheimia haemolytica 
(Gagea et al., 2006). These interactions are thought to be responsible for the more severe and 
chronic lung lesions seen in older calves with BRD compared to younger calves affected only by M. 
bovis (Burki et al., 2015). These unclear causalities between M. bovis being present without causing 
disease and being either a primary or a secondary pathogen might also contribute to the difficulties 
faced in diagnosing M. bovis, as well as the unrewarding effect of treatment of M. bovis-associated 
disease, as described in Section 2.1.3.  
2.1.2 Immune response 
Basic concepts of the immune system 
The immune system is complex and it is beyond the scope of this thesis to review all aspects of it, 
but the following sections contain a brief description of some basic concepts relevant to 
understanding the development of humoral immunity related to the objectives of this thesis.  
The immune system consists of two primary components: the innate (also called non-specific) 
immune system and the acquired (also called specific) immune system. The two systems can work 
independently, but usually work together to combat invading bacteria and viruses. The innate 
immune system is available all the time or induced rapidly, but has no immunogenic memory. The 
immunity that develops based on antibodies is called the humoral immunity and is part of the 
acquired immune system. In short, when the immune system is presented with a foreign antigen 
(e.g. a bacterium), B-cells proliferate, differentiate to plasma cells and produce antibodies specific to 
the antigen presented. Antibodies are also called immunoglobulins (Ig) and are divided into five 
subclasses: IgA, IgG, IgM, IgD and IgE. IgG are the most abundant Ig class found in serum and are a 
major component in passive maternal antibody transfer. IgA are primarily found in different 
secretions such as milk or saliva. After a bacterium or virus has entered the body, the production of 
specific measurable antibodies can be expected in serum and other secretions.  
The development and maturation of the immune system takes time, and the immune response in 
young animals can be different from that in adult animals. During pregnancy, the immune system of 
the calf develops and when the calf is born, it is capable of responding to various antigens, though 
not as many as when it is fully mature. The immune response in the new-born calf is usually slower, 
with low concentrations of immunoglobulins being produced (Barrington and Parish, 2001). 
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Protection of the young calf occurs primarily through the transfer of maternal antibodies from the 
dam through ingestion of colostrum, and maternal antibodies are measurable in serum after uptake.  
Antibody response to Mycoplasma bovis  
The antibody response against M. bovis in serum and milk, as well as the association between 
serostatus and disease are described in this section. 
Antibodies such as IgG directed against M. bovis can be detected in serum 1-2 weeks following 
inoculation through the respiratory route of young calves (Howard et al., 1986; Kanci et al., 2017; 
Nicholas et al., 2002; Zhang et al., 2014), and 1-2 weeks after intramammary inoculation with M. 
bovis (Boothby et al., 1987; Byrne et al., 2005). In a structured literature review, the authors were 
able to find just four studies on the time to seroconversion. They reported a median time to 
seroconversion of 21 days and a median time to peak IgG levels in serum of 28 days for M. bovis-
associated respiratory disease (Grissett et al., 2015).  
Little is known about the duration of high levels of antibodies against M. bovis in serum post 
infection. Vaccinated calves had high ELISA titres (155% of the positive control) 6 months after 
vaccination without any challenge (Nicholas et al., 2002), but these vaccinated calves did not 
necessarily mimic the situation for calves infected under natural conditions. The challenged calves 
were only followed for 21 days, but the antibody titres remained high during this period. In another 
study, serum antibody levels remained elevated from the baseline for 18 weeks (Boothby et al., 
1987), and IgG in both milk and serum remained above the positive cut-off for at least 45 days after 
intramammary inoculation (Byrne et al., 2005). Nicholas and Ayling (2003) stated that, “serological 
detection of antibodies by ELISA against M. bovis remains high for many months”, but there was no 
clarification as to how many months or what was considered high. 
Howard and Gourlay (1983) compared the immune response of calves of varying ages to M. dispar 
and M. bovis following subcutaneous injection of killed vaccines. They found that the youngest 
calves, injected at around 16 days of age, reached a lower antibody maximum and it that took a 
longer time to reach the maximum than for older calves injected at around 150 days of age (Howard 
and Gourlay, 1983). This was particularly evident for M. dispar, but was also found to be the case for 
M. bovis, suggesting that the immune system might have difficulty producing antibodies against 
mycoplasmas in young calves. This is in agreement with Virtala et al. (2000), who found that calves 
less than 3 months old often failed to seroconvert to pathogens commonly associated with BRD, 
including mycoplasmas. 
Cows shed large amounts of antibodies in milk after both experimental (Bennett and Jasper, 1978b; 
Boothby et al., 1987) and natural M. bovis infection (Byrne et al., 2000). Antibodies against M. bovis 
can be detected in milk 1-2 weeks after intramammary inoculation (Boothby et al., 1987; Byrne et 
al., 2005). Antibodies have been detected in milk samples from both infected and uninfected 
quarters 9 weeks after initial isolation, but after 20 weeks, antibodies were only detected in milk 
samples from quarters that were previously infected with M. bovis (Byrne et al., 2000). Is not known 
whether cows with other clinical signs of M. bovis-associated disease (e.g. arthritis) also excrete 
antibodies in milk. However, this would be of particular interest if an ELISA were to be applicable as 
a diagnostic test for M. bovis-associated disease. 
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The extent to which maternal antibodies against M. bovis are important in calves and whether they 
have a protective effect against M. bovis-associated disease remains unclear. One study found low 
titres for M. bovis in young calves from dairy herds, indicating either low exposure or failure of 
passive transfer. They also found that there was no association between antibodies against M. bovis 
in the first 2 weeks of life and the occurrence of pneumonia in colostrum-fed dairy calves (Van 
Donkersgoed et al., 1993), which indicates little or no protective effect of maternally derived 
antibodies in calves. 
In conclusion, studies of serology under field conditions are sparse, and the findings of experimental 
studies are not directly comparabe to natural infections. 
Studies on the association between serostatus and M. bovis-associated disease in calves and cows 
are limited and the findings are not clear. Martin et al. (1990) found an association between the 
incidence risk of M. bovis seroconversion and BRD incidence risk at group level, but not at 
individual calf level, over the first 4 weeks after entry to Canadian feedlots. In contrast, the 
individual M. bovis serostatus upon arrival in a veal calf setting was not a predictor for the 
development of BRD in two-week-old veal calves (Pardon et al., 2015). The herd serum prevalence 
of M. bovis in heifers and cows did not have an impact on the incidence of respiratory disease in 
calves (Raaperi et al., 2012). It is also unclear whether the serostatus is associated with production 
losses in calves. A tendency for lower weight gain has been found in seropositive weaned beef 
calves (Hanzlicek et al., 2011), while another study found no association between seroconversion 
and weight gain (Martin et al., 1989). There have been no studies on the association between 
serostatus and longevity in cows or calves, but information about the possible long-term 
consequences of M. bovis infection would be valuable in advising farmers both during and after an 
outbreak of M. bovis-associated disease. 
2.1.3 Treatment options 
Treatment of M. bovis-associated disease is difficult. In general, it is mostly unresponsive to 
antimicrobial treatment, and culling is often the last resort (Nicholas et al., 2016). This makes 
correct diagnosis and control measures even more important. 
M. bovis bacteria are innately resistant to antibiotics that interfere with the cell wall, such as 
penicillins and cephalosporins. They do not synthesise folic acid and are therefore also resistant to 
sulphonamides (Heuvelink et al., 2016). Several studies have reported the in vitro sensitivity of M. 
bovis to different types of antimicrobials such as enrofloxacin, tulathromycin and oxytetracycline 
(Ayling et al., 2000; Ayling et al., 2014; Klein et al., 2017). However, in vivo studies of the treatment 
of pneumonia and otitis media with, among others, in vitro sensitive compounds have found varying 
results with little or no effect, or treatment had to be continued for a long period to be effective 
(Allen et al., 1991; Francoz et al., 2004; Gosselin et al., 2012; Poumarat et al., 2001). This difference 
is probably due to the fact that animals in experimental studies are often treated early in the disease 
process and naturally acquired respiratory infections are often mixed infections identified later in 
the disease development, when tissue damage has already occurred. This is supported by the 
findings of Romváry et al. (1977b), who concluded that that to be effective antibiotic treatment 
should be initiated at the onset of the febrile course preceding the symptoms of pneumonia and 
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always with high doses. In addition, failure to treat M. bovis infection has increasingly been 
attributed to antimicrobial resistance (Lysnyansky and Ayling, 2016). In Denmark, antibiotics 
containing florfenicol, enrofloxacin, doxycycline, tulathromycin, tilmicosin and tylosin are approved 
for the treatment of cattle with mycoplasma-associated disease (Anonymous, 2017a). However, in 
some countries (including Denmark), several of these antibiotics are not recommended as first 
choice so that they can be reserved for use in humans, and proof of the infectious agent being 
resistant to other antimicrobials is required before they can be prescribed (Anonymous, 2013). In 
practice, there is a lack of effective antibiotics on the market, and the required duration of treatment 
and the lack of treatment effect can often result in antibiotic treatment of M. bovis infections being 
futile.  
2.1.4 Molecular epidemiology 
Different molecular typing methods can be used to study genetic diversity among M. bovis bacteria 
isolated from e.g. different time periods, geographical locations, anatomical sites, as well as diseased 
versus non-diseased carrier animals. This would improve our understanding of the pathogenesis 
and bacterial determinants of the disease, as well as its resistance to treatment. The degree of 
diversity can also be used to determine and understand pathogen transmission and spread of the 
disease.  
Whole genome sequencing recently indicated that 78 M. bovis isolates collected between 1981 and 
2014 from Denmark could be divided into two clusters. Isolates collected before 2010 were 
genetically different from isolates collected after 2010, suggesting a shift in the dominant strain 
during the 2000s (Strube and Lindegaard, 2018). A similar pattern was found in France, where 
different sub-typing methods found that isolates collected over the last 35 years consisted of two 
clusters – one with isolates collected before 2000 and the other with isolates collected after 2000 
(Becker et al., 2015). Multilocus sequence typing analysis found two major lineages of M. bovis in 
Switzerland and Austria, which consisted of isolates before and after 2007 (Burki et al., 2016). The 
shift in the M. bovis population from the old to the recent subtype occurred at the same time as or 
following the development of increased antimicrobial resistance (Khalil et al., 2017). Based on these 
studies, it is likely that the M. bovis disease outbreak that started in Denmark in 2011 was caused by 
either the introduction of a new strain or alterations in the existing strain. It could not be 
determined whether there was a difference between isolates from different anatomical sites in the 
Danish material, as the anatomical site of origin was not recorded for a sufficient number of the 78 
samples (Strube and Lindegaard, 2018). Parker et al. (2016) investigated this connection further 
using whole genome sequencing for 94 Australian M. bovis isolates collected between 2005 and 
2015 from different body sites including the nose, prepuce, semen, vagina, joints, milk, lungs and 
lymph nodes. They found minimal variation in gene content between isolates collected several 
years apart, isolates collected from different anatomical sites, between animals with different 
disease status, or across different geographical locations. This suggests that host and environmental 
factors are responsible for the diverse disease pattern and difference in outbreak severity among 
herds, although it is still possible that the expression of genes responsible for virulence and/or 
antibiotic resistance might play a role. 
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2.1.5 Transmission pathways 
Transmission pathways can be divided into within-herd and between-herd transmission. The 
within-herd transmission is important once M. bovis is present in the herd, and understanding the 
infection dynamics can help prevent further dissemination of disease in the herd. Understanding 
how the between-herd transmission occurs is important in reducing the spread of M. bovis to or 
from other herds and for deciding upon external biosecurity actions for infected herds in control 
programmes. 
Transmission between animals within the herd occurs through an exchange of respiratory 
secretions, udder-to-udder spread during milking and the ingestion of M. bovis-contaminated milk. 
Apparently healthy animals can harbour the organism in the upper respiratory tract for long 
periods of time, acting as a reservoir for infection in the herd (Bennett and Jasper, 1977; Pfutzner 
and Sachse, 1996). If segregation and biosecurity is not adequate then close contact between 
animals or indirect contact via feed or water can occur both between age groups and between 
animals of the same age group that are housed together. M. bovis is considered a contagious mastitis 
pathogen that can spread from udder to udder. Clinical changes in the milk were not observed until 
5-6 days after inoculation (Bennett and Jasper, 1978a), and this delay between shedding 
mycoplasma and clinical changes in the milk could represent an important source of cow-to-cow 
spread that is difficult to control.  
 
A major transmission route of M. bovis from cows to calves is thought to be ingestion of 
contaminated milk. Colonisation of the respiratory tract has been shown to occur more often in 
calves fed milk infected with M. bovis compared to calves fed non-infected milk (Bennett and Jasper, 
1977). In addition, clinical disease was found to follow feeding with M. bovis-contaminated waste 
milk (Butler et al., 2000; Walz et al., 1997). Vertical transmission is rarely reported, although M. 
bovis has been isolated from vaginal secretions of cows at calving (Feenstra et al., 1991), from 
aborted foetuses and placentae (Hassan and Dokhan, 2004; Langford, 1975), and has been 
associated with congenital disease in calves (Bocklisch et al., 1986; Stipkovits et al., 1993). The role 
of vertical transmission in the spread of M. bovis is therefore unknown.  
Introduction of asymptomatic carriers is thought to be the main risk associated with M. bovis being 
introduced into cattle herds (Gonzalez and Wilson, 2003; Maunsell et al., 2011). It is challenging to 
identify these asymptomatic carrier animals and control the between-herd spread of M. bovis. 
M. bovis has been cultured from bull semen, and antibodies against M. bovis have been detected in 
sera from aborted cows inseminated with semen containing M. bovis (Stipkovits et al., 1983). Semen 
and bulls was recently proposed as a potential way of introducing M. bovis into a naïve herd 
(Haapala et al., 2018; Hazelton et al., 2018a). However, this route of infection must be supported by 
further studies to determine its role in transmission. 
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2.1.6 Control measures 
The primary recommended control measure for M. bovis is to maintain a closed herd and not 
introduce potentially infected carrier animals (Maunsell et al., 2011). If purchase cannot be avoided, 
the M. bovis status of the herd from which new animals are purchased should be established. This 
can be challenging, and no well-documented recommendations are available to classify source 
herds before purchase. Therefore, the best method may be to combine different diagnostic tests and 
take a clinical history of all age groups in the herd. 
Herd-management practices are important in the control of M. bovis. Cow-to-cow transmission can 
be reduced by improving milking hygiene and culling or at least segregating cows known to be 
diseased (Maunsell et al., 2011). Calves should also be fed milk free from M. bovis – either by 
pasteurising the milk (Butler et al., 2000) or feeding milk replacer. As M. bovis is shed from the 
nares, good sectioning between groups of housed calves, and segregation of diseased calves should 
be performed in order to reduce nose-to-nose transmission. In addition, maintaining a low stocking 
density will reduce the spread of the bacterium (Nicholas, 2011).  
Development of an effective vaccine against M. bovis is a possible way to control the disease, yet 
vaccination against M. bovis has shown varying results. Zhang et al. (2014) found a protective effect 
of vaccination for cattle aged 5-6 months. In contrast, Prysliak et al. (2013) found no protection 
against clinical disease when vaccinating calves aged 6-8 months, and an increased incidence of 
otitis media was seen in one herd after vaccination with a commercial vaccine (Maunsell et al., 
2009). This study also found that vaccination stimulated a systemic antibody response, but most 
clinical disease occurred prior to this response. Development of a vaccine is therefore challenging, 
and a better understanding of antigens and the immune response to M. bovis (especially in young 
calves) is needed if vaccination is to be an effective way of controlling M.bovis-associated disease 
(Maunsell and Donovan, 2009). 
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2.2 Diagnostic tests 
2.2.1 Enzyme-linked immunosorbent assay (ELISA) 
Two commercial ELISA kits (BioX Bio K 260 and Bio K 302) for the detection of antibodies (IgG) 
against M. bovis are available from BioX Diagnostics in Belgium. This section covers what is known 
about the performance of these tests at both individual animal and herd level according to the 
available literature. 
Another company, BioVet in Canada, have a commercial M. bovis ELISA test and other research 
groups have developed in-house ELISAs (Fu et al., 2014; Wawegama et al., 2014). However, only the 
BioX tests are commercially available in Europe, which is why they are used for the projects 
presented in this thesis. 
Animal level 
The antigen used in the two BioX ELISAs is a recombinant M. bovis protein expressed by E. coli, but 
the identity of the specific antigen(s) has been kept secret. BioX K260 has a negative control for 
each sample well, which should reduce the number of false positives, while the BioX K302 has one 
negative control on each plate. The BioX K302 uses the recommended cut-off of 37 ODC%, and the 
sensitivity and specificity are reported to be 100% by the manufacturer, based on 14 
experimentally exposed and 16 non-infected animals (Anonymous, 2017b). 
In experimentally infected animals, the sensitivity and specificity of BioX K260 has been found to be 
0.28 (95% CI: 0.01-0.92) and 1 (95%CI: 0.93-1), respectively, measured 24-68 days after 
experimental infection (Schibrowski et al., 2018). The BioX K260 has been shown to have little 
correlation with the occurrence of disease and with PCR and bacterial culture results (Szacawa et 
al., 2015; Szacawa et al., 2016). However, those studies were cross-sectional, with the aim of 
comparing results of different diagnostic tests, and did not provide sensitivity and specificity 
estimates.  
Wawegama et al. (2016) estimated the sensitivity of BioX K302 to be 0.37 (95% CI: 0.22-0.54) and 
the specificity to be 0.95 (95% CI: 0.83-0.99) in experimentally infected animals at the cut-off value 
37 ODC%, as recommended by the manufacturer. This was in line with the results of Schibrowski et 
al. (2018), who found the sensitivity and specificity to be 0.47 (95% CI: 0.10-0.87) and 0.96 (95% 
CI: 0.87-0.99), respectively. These studies are based on experimentally infected animals and 
because they lack independence between observations and there is variation in the immunological 
responses of experimentally and naturally infected animals, they do not necessarily reflect the 
situation in naturally infected animals (Schibrowski et al., 2018). In addition, no animal-level field 
study evaluations of cut-off values are available in the literature, and the cut-off at 37 ODC% is 
generally used in practice despite a lack of substantial documentation of the validity of this 
threshold for the dichotomisation of test results. Field studies of ELISA performance in terms of 
detecting antibodies against M. bovis are therefore needed. 
Bulk tank milk 
Little is known about antibodies in BTM for herd-level diagnosis. The manufacturer of the BioX 302 
ELISA does not provide any guidelines for its use in BTM, but some authors have investigated 
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different aspects of this (Nielsen et al., 2015; Parker et al., 2017a). By using latent class analysis, 
Nielsen et al. (2015) found that in order to lower the number of false positive herds in prevalence 
estimations at a national level, it might be beneficial to raise the cut-off for herd-level diagnosis in 
BTM to 50 ODC%. This resulted in a sensitivity of 0.44 (95% posterior credibility interval (PCI): 
0.21-0.93) and a specificity of 0.996 (95% PCI: 0.99-1) compared with 0.60 (95% PCI: 0.38-0.96) 
and 0.97 (95% PCI: 0.94-0.998) when applying 37 ODC% as the cut-off. However, the optimal cut-
off value depends on the purpose of testing. 
Parker et al. (2017a) found that an increased time since the start of the calving period and increased 
time since the initial M. bovis outbreak were associated with decreasing BTM ODC%, while the time 
since the most recent positive M. bovis culture or PCR and herd size did not affect the BTM ODC%. 
The time since the start of the calving period could be explained by the fact that M. bovis-associated 
disease is often observed post-partum, due to increased stress around calving, and therefore the 
BTM was generally higher around calving season when collected in dairy herds with seasonal 
calving patterns. It is likely that the lack of association between BTM ODC% and M. bovis culture, 
PCR or herd size is due to the difference between the presence of M. bovis and a disease outbreak – 
i.e. M. bovis may be present in the herd without causing disease.  
In conclusion, the use of antibody measurements in BTM for herd diagnosis or surveillance of M. 
bovis needs further investigation. 
2.2.2 Other diagnostic tests 
BC has been used for culturing samples from both individual animals as well as BTM samples, and is 
still considered the gold standard. However, culturing mycoplasmas requires special media and 
equipment, and can take up to 7-10 days. Careful sampling, handling and transportation is essential 
for optimal culture conditions (Wawegama and Browning, 2017) and in Denmark, BC is expensive 
and not always readily available, making the diagnosis of M. bovis by BC cumbersome. 
Compared to culture, PCR can amplify viable as well as non-viable DNA and is less time consuming. 
Several PCR assays have been described in the literature as being useful for detecting M. bovis in 
milk and other body fluids. The sensitivity of PCR has been reported at 0.77-0.89 and the specificity 
at 0.96-1, which is equivalent to or better than BC (Cai et al., 2005; Clothier et al., 2010; Justice-Allen 
et al., 2011; Parker et al., 2017b; Pinnow et al., 2001).  
Common to both BC and PCR is the difficulty in obtaining the diagnostic material used for isolation, 
especially from calves that require swabs, transtracheal wash and/or joint fluid. This also applies to 
cows with arthritis, since it is not known whether they excrete M. bovis in measurable amounts in 
milk or the respiratory system. This results in some limitations in the use of BC and PCR for 
diagnosis in practice.
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3 Materials and Methods 
3.1 Data collection 
Data available for the studies presented in this thesis were collected as part of two longitudinal 
observational sampling activities originating from separate projects performed as a collaboration 
between SEGES, the Technical University of Denmark and the University of Copenhagen. This 
chapter provides an overview of the activities and the data that were made available to meet the 
objectives addressed in this thesis. 
3.1.1 Sampling of suspected case and control herds – sampling activity #1  
Sampling activity #1 (SampAct#1) was initiated in spring 2013 by SEGES, which is a farmer-owned 
knowledge, consultancy and technology centre that provides services to all Danish farmers. This 
was before the start of this PhD project (December 2013). The overall purpose of the project behind 
SampAct#1 was to clarify the importance of M. bovis infections in Denmark and to limit the impact 
of the disease by characterising bacterial isolates, increasing the understanding of diagnostic test 
results, providing knowledge about risk factors and reducing the spread of infection within and 
between herds. This PhD project was connected to the main project, focusing on studying the 
within-herd dynamics of M. bovis mainly based on antibody responses directed against M. bovis. The 
microbiological characterisation and between-herd spread of infection were covered by other 
researchers. 
Herd selection 
The recruitment of herds was conducted by a veterinarian at SEGES. Selecting the study herds was 
not an easy task due to differences in the perceptions and reporting of clinical signs by local 
veterinarians and farmers, use of different diagnostic tests and difficulties in the interpretation of 
the results. 
 
The aim was to include 40 dairy herds that would represent a wide distribution of herds with 
different histories of M. bovis-associated disease (suspected case herds) and some with no history of 
M. bovis-associated disease (control herds). No attempt was made to include a representative 
sample of Danish dairy herds, because this would have resulted in the inclusion of too few herds 
with an ongoing or recent M. bovis infection. Information about clinical disease and previously 
performed diagnostic tests were obtained from the local herd veterinarian, who in many cases was 
the first to contact SEGES about a possible disease outbreak. In addition, the veterinarian from 
SEGES had prior knowledge of the herds from national BTM screening rounds, where all Danish 
dairy herds were tested for antibodies against M. bovis with the BioX Bio K 302 ELISA kit (BioX 
Diagnostics, Rochefort, Belgium) and the PathoProof Major-3 PCR kit (Thermofischer Scientific, 
Waltham, USA) in 2011-12 and 2013. The national prevalence of PCR-positive dairy herds was 1.8% 
in January 2012 (Aalbæk et al., 2012). In the autumn of 2013, the prevalence of ELISA and PCR-
positive herds was found to be 7.2% and 1.6%, respectively, using the recommended cut-offs 
(Nielsen et al., 2015). This corresponds to 245 ELISA-positive dairy herds and 58 PCR-positive dairy 
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herds in that screening round. To be included in the study, herds also had to be enrolled in the 
voluntary milk recording system RYK2 (which includes approximately 90% of Danish dairy herds), 
and only herds with a least 100 cows were included to make sure the herd had enough young stock 
to sample.  
 
SamtAct#1 included 39 Danish dairy herds. To ensure a diverse representation of clinical signs, 
infection status and test results, herds were classified for enrolment purposes as one of four predefined groups: ‘Acute’, ‘Previously infected’, ‘BTM-positive’ and ‘Control’. The initial M. bovis 
diagnosis was made by the farmer and his veterinarian, and the M. bovis infection status was not 
further investigated before the sampling was initiated. The following farms met the basic inclusion 
criteria: 
 ‘Acute’ (n=14): consisted of herds with recent suspected M. bovis-associated disease. 
 ‘Previously infected’ (n=7): consisted of herds that previously had M. bovis test-positive, 
clinically ill animals, but currently had no acutely diseased animals.  
 ‘BTM-positive’ (n=10): consisted of herds selected among those with the highest BTM ODC% 
(ranging from 68-110) in the most recent Danish national screening of all dairy herds in 
summer 2013.  
 Control (n=8): consisted of herds with no history of clinical disease related to M. bovis for the 
past 3 years and were negative prior to inclusion in PCR, ELISA and BC. 
Sampling and information collection procedures 
Each of the 39 participating herds were visited four times approximately 3 months apart during the 
period March 2013 to December 2014 (Figure 3.1). Calves in the age groups 0-3, 3-6, 6-9 and 9-12 
months old were blood sampled at each herd visit. At the first herd visit, a cohort of 20 calves 
between 0 and 3 months of age were sampled and these calves were followed with repeated blood 
samplings at subsequent herd visits (Figure 3.1). The cohort was selected randomly by the SEGES 
veterinarian before the first herd visit. At each herd visit, 15 calves in each of the other age groups 
were sampled. These calves were chosen at each herd visit by the sampling veterinarian and the 
farmer. Conjunctival swabs for bacteriological culture were collected from a varying number of 
young calves primarily at the first herd visit.  
At the milk recording date closest to the herd visit, milk samples were collected from 50 lactating 
cows and a BTM sample was taken by the milk truck drivers as part of the milk control scheme. The 
50 lactating cows were selected randomly by the SEGES veterinarian. All samples were analysed for 
antibodies against M. bovis at Eurofins Steins Laboratory in Vejen with the indirect ELISA test from 
BioX, as described in section 3.2. 
As part of the sampling procedure, all herds were visited by the author of this thesis to get an 
overview of the farm, management procedures and details about the extent and duration of M. 
bovis-associated disease within the herd. The farmers were interviewed in a semi-structured way 
regarding the disease outbreak, diagnostics, duration, handling of the outbreak, number of dead and 
slaughtered animals, as well as some management questions primarily focusing on contact between 
animals, animal movement and feeding the calves. The questions are provided in Appendix I. In 
                                                          
2 https://www.landbrugsinfo.dk/Kvaeg/RYK/Sider/Startside.aspx 
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almost all herds, the author and farmer talked about the questions while walking through the herd 
and attempting to see as much of the herd as possible.  
 
 
Figure 3.1: Timeline and sampling procedure for sampling activity #1. (* cohort calves, Mo=Months old). 
In addition to the samples shown here, eye swabs were collected from the youngest calves from all 
herds to obtain bacterial isolates for molecular investigation. 
 
3.1.2 Clinical epidemiology study - sampling activity #2 
It became evident during SampAct#1 that there was not enough information available at animal 
level to develop a sufficient understanding of the antibody responses at herd level. Furthermore, the 
intervals between herd visits in SampAct#1 were too long to capture the rapid dynamics of M. bovis. 
Therefore, another sampling activity was organised, in which animals showing clinical signs of M. 
bovis-associated disease and healthy animals in herds experiencing an acute disease outbreak were 
examined and sampled to investigate the antibody responses associated with the clinical signs 
expressed by the animals (SampAct #2). It was decided that the this sampling activity would give 
priority to thorough clinical examinations of the individual animals, rather than inclusion of a large 
number of animals and herds, taking into account the budget and resources available. Therefore, 
SampAct#2 involved a smaller number of farms and smaller number of animals within each farm 
than SampAct#1.  
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Herd selection 
The herds were enrolled from July 2015 to January 2016. Cattle practitioners in Denmark were 
informed and asked to contact the author if they attended herds with signs of acute M. bovis-
associated disease among the cows and/or calves. The presence of M. bovis in the herds was 
confirmed by ELISA and PCR testing before enrolment in the study. The aim was to visit the herds 
no longer than 3 weeks after clinical signs of M. bovis-associated disease started, and to follow the 
herds with five visits approximately 3 weeks apart. The information obtained about the farms prior 
to enrolment is shown in Table 3.1. 
 
Table 3.1: Knowledge about the herds in sampling activity #2 prior to enrolment. 
Herd no. Herd A Herd B Herd C Herd D 
Herd size (cows)  177 174 182 391 
 
Primary clinical 
signs in cows 
Mastitis, 
pneumonia 
Mastitis,  
arthritis 
Arthritis Mastitis,  
arthritis 
Positive ELISAa Yes Yes Yes Yes 
Positive PCRb Yes Yes No Yes 
     
Primary clinical 
signs in calves 
Pneumonia Arthritis, otitis 
media 
No clinical signs 
observed 
Arthritis, otitis 
media, 
pneumonia 
Outbreak start 
(according to the 
farmer) 
Early June  
2015 
Early July  
2015 
Late November 
2015 
Mid December 
2015 
a ODC% values > 37 for M. bovis antibodies in BioX Bio K 302 or 260 (BioX Diagnostics, Belgium)  
b Ct value ≤ 37 for M. bovis in PathoProof Mastitis Major-3 (ThermoFischer Scientific, USA) 
 
The project budget allowed for the inclusion of approximately 80 cows and 80 calves in total, with 
each animal being tested five times. However, it is likely during an outbreak of M. bovis-associated 
disease that some animals would be culled due to clinical disease, so we attempted to compensate 
for this by either including more than 20 animals at the first visit or recruiting additional animals at 
consecutive visits. Accordingly, a minimum of 20 cows and 20 calves were identified from each farm 
during the first herd visit with the help of the farmer. The animals were sampled strategically while 
attempting to ensure that a sufficiently high number of animals both with and without suspected M. 
bovis-associated disease were included. New animals suspected of having M. bovis-associated 
disease at subsequent visits were also included. The rationale behind this targeted (non-random) 
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sampling strategy was to maximise the probability of including a sufficient number of animals to be 
able to compare the antibody responses between groups with and without different clinical signs 
indicating M. bovis. 
Sampling procedure 
At each herd visit, all selected animals were subject to a clinical examination with a focus on the 
respiratory, musculoskeletal, nervous system and, for cows, udders. See Appendix II for the clinical 
protocol used. Blood samples from all animals and composite milk samples from all lactating 
quarters of the cow were collected. All samples were transported to Eurofins Steins Laboratory in 
Vejen within 48 hours and analysed for antibodies against M. bovis with an indirect ELISA, and milk 
samples were also analysed for the presence of M. bovis DNA with a PCR test, both described in 
section 3.2. 
All clinical examinations and sampling were performed by a veterinarian with assistance from 
veterinary students. The author of this thesis and a practicing veterinarian developed the clinical 
protocol and one or both of them were present at all herd visits. In addition, one other veterinarian 
performed the clinical examinations at two herd visits. 
3.2 Laboratory procedures 
All samples in the two data collection activities were transported to and analysed at Eurofins Steins 
Laboratory in Vejen, Denmark. The ELISA test used was the BioX Bio K 302 from BioX Diagnostics, 
Rochefort, Belgium (in the rest of the thesis referred to as BioX). It was performed according to the manufacturer’s recommendation (Anonymous, 2017b) and the optical density coefficient (ODC%) 
was calculated as: 
 ODC% = (ODsample – ODnegative control) / (ODpositive control – ODnegative control) x 100% 
where OD is the optical density measured by the ELISA reader relating to each test sample, as well 
as the positive and negative controls on the sample ELISA plate. An ODC% ≥ 37 was considered 
positive, as recommended by the manufacturer. The reported sensitivity and specificity of the test 
at this cut-off was estimated at 100% based on a small sample of experimentally infected calves and 
uninfected control calves (Anonymous, 2017b). However, as described in section 2.1.1, other 
authors have found the sensitivity and specificity to be lower, and it was anticipated that they 
would also be lower in naturally infected cattle. 
The PCR test used was the PathoProof® Mastitis Major-3 kit from ThermoFischer Scientific, 
Waltham, MA. It was performed according to the manufacturers’ recommendation and a cycle 
threshold (Ct) ≤ 37 was considered positive. Bacterial DNA is detected in high quantities when Ct < 
22; in moderate quantities when Ct is 22-32 and in low quantities when Ct is 32-37 (Anonymous, 
2017c). This translates to Ct 30≈1,400 genome copies in qPCR reaction and Ct 20≈1,400,000 
genome copies in qPCR reaction. The genome numbers roughly translate to: Ct 30≈80,000 genomic 
copies/ml of milk and Ct 20≈80,000,000 genomic copies/ml of milk (Mika Silvennoinen, Finland, 
personal communication). 
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Both the BioX ELISA test and the PathoProof PCR test are commercially available tests routinely 
used in Danish cattle practice and by SEGES for surveillance. 
After analysis, the samples from SampAct#2 were frozen and stored at Eurofins Steins Laboratory 
in Vejen. Unfortunately, samples from the first visit to Herd A were lost after initial analysis and 
therefore could not be re-analysed later. During autumn 2016, the samples were retested by 
Nadeeka Wawegama (University of Melbourne) using an in-house ELISA (known as the MilA ELISA) 
(Wawegama et al., 2014). The mean antibody concentration in antibody units (AU) was calculated 
by plotting the OD values on a standard curve derived from a set of known positive-control sera 
included on each plate. The sensitivity and specificity of this assay were estimated in feedlot cattle 
with BRD at 0.943 (95%CI: 0.899-0.996) and 0.944 (95%CI: 0.903-0.996), respectively, using 105 
AU as the cut-off (Wawegama et al., 2016). However, the authors now recommend using AU > 135 
as a cut-off for a test-positive interpretation, and this cut-off is therefore used in this thesis.  
Bacterial culture 
Eye swabs from calves and samples from diseased cows sampled during the sampling period were 
analysed at the Veterinary Institute at the Technical University of Denmark. Bacterial culture was 
performed with the special requirements necessary for M. bovis (Nicholas and Baker, 1998).  
3.3 Databases 
Animal characteristics and calving dates were collected from the Danish Cattle Database (DCD). 
Data registered in the DCD comes from different sources, e.g. farmers, veterinarians and 
laboratories (Bundgaard, 2005). The data used in this thesis included date of birth, dam’s ID-
number, date of departure from the herd, departure destination and calving dates. Data entry for 
these variables is done by the farmer and is required by law. An agreement was signed by the 
farmer of each participating herd to make these data available for this research. 
3.4 Creation of datasets for analysis 
All data management was carried out in the statistical program R (R Core Team, 2016). All data 
from the laboratory analysis were received in Excel spreadsheets that also contained information 
about sampling date, individual animal identification, herd identification number and birth date of 
the animal. Clinical data collected at herd visits for SampAct#2 were registered in pre-prepared 
registration forms (Appendix II). Data from these forms were entered to an Excel spreadsheet by 
the author of this thesis and continually checked for missing or implausible values.  
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Five datasets were generated based on SampAct#1 and SampAct#2 (Figure 3.2): 
Three datasets were created from SampAct#1 for the 39 dairy herds: 
1. Data from BTM samples 
2. Individual milk samples from selected lactating cows and blood samples from selected 
calves 
3. Blood samples from the cohort of calves  
Two datasets were created from SampAct#2 for the four dairy herds: 
4. Clinical recordings, milk test results and blood test results from the cows sampled  
5. Clinical recordings and blood test results from the calves sampled 
Relevant data from DCD were merged into all datasets. 
 
 
Figure 3.2: Overview of the datasets and their contents based on Sampling activities #1 and #2 created 
to meet the objectives of this thesis.   
3.5 Statistical analyses 
All statistical analyses were carried out in the statistical program R (R Core Team, 2016).  
Table 3.2 provides an overview of the datasets used and the statistical analyses performed based on 
each specific objective. Details of the analyses can be found in Manuscripts I-IV.
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Table 3.2: Overview of objectives, study designs, materials and methods used in this thesis. Cow-prevalence = milk prevalence of antibody-positive cows, YS-prevalence = 
seroprevalence of antibody-positive young stock. 
Objective Description and study design Data sources and types Methods of analysis Comments 
1 
Factors influencing BTM ODC% 
 
Study design: Observational 
longitudinal 
 
Data: ELISA BTM test results combined with 
individual blood and milk samples aggregated 
to herd level (Datasets 1 and 2) 
Outcome variable: BTM ODC% (continuous) 
Predictors: Cow-prevalence, YS-
seroprevalence, herd size 
Linear mixed model 
Random effect of herd ID 
All details provided in 
Manuscript I and sections 
3.1.1, 4.1 and 4.3 
 
2 
 
Dynamics of antibodies in cows 
 
Study design: Observational 
longitudinal with repeated sampling 
of individual animals 
Data: ELISA blood test results combined with 
clinical data from cows (Dataset 4) 
Outcome variable: ODC% for the individual 
cow (continuous) 
Predictor: Days from disease onset 
Generalised additive mixed 
models (GAMM) 
One model for each of the four disease groups: ‘Mastitis’, ‘Systemic’, ‘Non-specific’ and ‘None’ 
Random effect of animal ID and 
herd ID  
All details provided in 
Manuscript II and sections 
3.1.2 and 4.4 
3 
Dynamics of antibodies in calves 
 
Study design: Observational 
longitudinal with repeated sampling 
of individual calves 
Data: ELISA blood test results combined with 
clinical data from calves (Dataset 5) 
Outcome variable: ODC% for the individual 
calf (continuous) 
Predictors: Days from disease onset,  
disease group, herd ID 
Linear mixed model  
Random effect of animal ID 
All details provided in 
Manuscript III and sections 
3.1.2 and 4.5 
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Table 3.2: Overview of objectives, study designs, materials and methods used in this thesis. Cow-prevalence = milk prevalence of antibody-positive cows, YS-prevalence = 
seroprevalence of antibody-positive young stock. 
Objective Description and study design Data sources and types Methods of analysis Comments 
1 
Factors influencing BTM ODC% 
 
Study design: Observational 
longitudinal 
 
Data: ELISA BTM test results combined with 
individual blood and milk samples aggregated 
to herd level (Datasets 1 and 2) 
Outcome variable: BTM ODC% (continuous) 
Predictors: Cow-prevalence, YS-
seroprevalence, herd size 
Linear mixed model 
Random effect of herd ID 
All details provided in 
Manuscript I and sections 
3.1.1, 4.1 and 4.3 
 
2 
 
Dynamics of antibodies in cows 
 
Study design: Observational 
longitudinal with repeated sampling 
of individual animals 
Data: ELISA blood test results combined with 
clinical data from cows (Dataset 4) 
Outcome variable: ODC% for the individual 
cow (continuous) 
Predictor: Days from disease onset 
Generalised additive mixed 
models (GAMM) 
One model for each of the four disease groups: ‘Mastitis’, ‘Systemic’, ‘Non-specific’ and ‘None’ 
Random effect of animal ID and 
herd ID  
All details provided in 
Manuscript II and sections 
3.1.2 and 4.4 
3 
Dynamics of antibodies in calves 
 
Study design: Observational 
longitudinal with repeated sampling 
of individual calves 
Data: ELISA blood test results combined with 
clinical data from calves (Dataset 5) 
Outcome variable: ODC% for the individual 
calf (continuous) 
Predictors: Days f om disease onset,  
disease group, herd ID 
Linear mixed model  
Random effect of animal ID 
All details provided in 
Manuscript III and sections 
3.1.2 and 4.5 
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4 Results 
The main results from the work conducted during this PhD project are presented in this section. 
Firstly, descriptive results from SampAct#1 and SampAct#2 are given, followed by results from the 
statistical analysis of factors influencing the BTM ELISA ODC% (Manuscript I). Thirdly, results from 
the investigation of antibody responses against M. bovis in individual cows and calves (Manuscripts 
II and III) are given. Results of antibody testing with the in-house MilA ELISA in calves (Manuscript 
III) and cows are then presented. Finally, knowledge on the use of diagnostic testing with the BioX 
ELISA obtained in Manuscripts II and III was used to investigate the association between antibody 
positivity and undesired early heifer departure from the herds in SampAct#1 (Manuscript IV).  
4.1 Descriptive results from suspected case and control herds 
The 39 dairy herds participating in SampAct#1 were included based on different inclusion criteria 
for each of the four groups described in Section 3.1.1.  
At the time of inclusion in 2013, little was known about the development of M. bovis-associated 
disease outbreaks in Denmark or the interpretation of diagnostic test results, risk factors and 
management procedures needed to control an outbreak. There was no clear protocol to indicate 
which diagnostic tests should be used or how to confirm the presence of M. bovis in the herds, apart 
from bacteriological culture from infected body sites such as milk or joint fluid and BTM. A 
standardised set of M. bovis laboratory results was therefore not available from the herds before the 
project sampling was initiated. In addition, information about the disease outbreak had not been 
systematically collected at the time of enrolment, and a feasible way to obtain this information was 
through the farmer interviews. A detailed description of the duration of outbreaks and clinical signs 
as experienced and reported by the farmers in SampAct#1 are summarised in Table 4.1. The 
descriptive results of the ELISA testing performed in SampAct#1 in individual animals are 
summarised in Figure 4.1 as within-herd prevalence of positive milk samples (with error bars), and 
the same applies for serum samples from calves in Figure 4.2. The distribution of BTM samples from 
the herds stratified according to enrolment group is shown in Figure 1 in Manuscript I. There are 
more than four BTM samples per herd due to other sampling activities such as national screening 
rounds and extra farmer-requested BTM samples outside SampAct#1.   
The distribution of ODC% in the BTM samples varied across enrolment groups and no clear pattern 
was seen (Figure 1, Manuscript I). Some herds had a very dynamic ODC% over time, while others 
showed a more stable pattern and in some herds, especially some of the ‘Acute’ herds, it appeared 
to decline over time. The ‘Acute’ herds and ‘Previously infected’ herds were difficult to separate based on information 
about disease outbreaks from the farmer interview (Table 4.1). Nearly all reported having 
experienced an outbreak of diagnosed M. bovis-associated disease, but the time from onset of 
clinical signs to the first herd visit was more than 2 months in all but one herd, and was not clearly different between the two groups. The ‘BTM-positive’ herds were a mixture of herds that had a 
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disease outbreak and herds with farmers who reported not having experienced M. bovis-associated disease. Among the ‘Control’ herds, no farmers reported having had M. bovis-associated disease 
before enrolment, but one herd experienced a disease outbreak while enrolled in the study (Table 
4.1). In addition, the duration of outbreaks differed markedly among the herds, ranging from 1 
month to at least 18 months with an ongoing outbreak situation at the time of questioning. There 
was therefore no obvious distinction between the herds in terms of disease outbreak. 
In addition, no clear distinction was seen between the enrolment groups when comparing the milk 
prevalence of antibody-positive lactating cows, as measured at each of the four herd visits. The prevalence in the ‘Control’ herds was generally lower than the other enrolment groups. However, 
no clear difference was seen among the other enrolment groups. A pattern of declining prevalence 
(as seen for Herds 2 and 29) and a more stable pattern (as seen for Herds 5, 20 and 26) were found 
across the three case enrolment groups (Figure 4.1). 
In terms of the seroprevalence in calves there was even less difference between the herds in the three case groups than for the cows. Some of the ‘Acute’, ‘Previously infected’ and ‘BTM positive’ 
herds had stable pattern of seroprevalence (e.g. Herds 4, 20 and 28), while others had a very 
dynamic pattern (e.g. Herds 9, 16 and 29). The ‘Control’ herds seemed to have lower 
seroprevalence, with the exception of Herds 35 and 39 (Figure 4.2). Herd 39 will be discussed in 
more detail in section 5.1.1. 
Overall, this indicates that there were subjective differences between the herds originally enrolled as suspected case herds and ‘Control’ herds, yet no clear, systematic difference was evident among 
the three suspected-case groups. It is also clear that there is substantial variation among herds 
within the same classification group. The presence of M. bovis-associated disease at some point in 
time and the ability of the herd and animals to clear the infection will influence the antibody 
response, but the exact relationship is not clear based on this data. There are also differences in the 
expression and duration of antibodies between cows and calves, at least when measured in milk 
and serum, and this warrants further investigation. 
The descriptive results showed that while the enrolment groups were a useful way of ensuring a 
diverse representation of clinical signs, infection status and test pattern among the enrolled herds, 
there was little merit in using these classifications to further stratify the herds for the purposes of 
the studies presented in this thesis. Data arising from SampAct#1 and data from DCD were used 
analytically to meet Objectives 1 and 5 in Manuscripts I and IV, and the results are summarised in 
sections 4.3 and 4.7, respectively.
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Figure 4.1: Prevalence of antibody-positive lactating cows (ODC% > 37) in milk in each of the four sampling rounds for the 39 Danish dairy herds from 
sampling activity #1. The graphs are coloured according to enrolment group. Error bars indicate lower and upper 95% confidence intervals for the 
prevalence obtained using a Bayesian approach. The number of samples per round varied between 29 and 203 (median 49) [Six of the herds were 
concurrently enrolled in another small study involving samples being taken from 200 cows on one of the sampling dates].   
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Figure 4.1: Prevalence of antibody-positive lactating cows (ODC% > 37) in milk in each of the four sampling rounds for the 39 Danish dairy herds from 
sampling activity #1. The graphs are coloured according to enrolment group. Error bars indicate lower and upper 95% confidence intervals for the 
prevalence obtained using a Bayesian approach. The number of samples per round varied between 29 and 203 (median 49) [Six of the herds were 
concurrently enrolled in another small study involving samples being taken from 200 cows on one of the sampling dates].   
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4.2 Descriptive results from the clinical epidemiology study of outbreak 
herds  
Data originating from SampAct#2 were used to investigate antibody responses in animals with and 
without different clinical signs of M. bovis-associated disease and healthy animals. An overview of 
the knowledge and data obtained by the investigators during the study period is given in Table 4.2. 
A detailed description of inclusion criteria and descriptive results for cows and calves can be found 
in the Results sections of Manuscripts II and III, respectively. 
 
Table 4.2: Overview of knowledge about the four Danish dairy herds in sampling Activity #2, 
obtained by the investigators in the study period 1st July to 5th April 2016. Modified from Table 1, 
Manuscript II and Table 1, Manuscript III. 
Herd no. Herd A Herd B Herd C Herd D 
Data collection 
period 
1st July  
2015 - 
16th September 
2016 
20th July  
2015 - 
6th October  
2015 
8th December  
2015 - 
23th February  
2016 
20th January  
2016 - 
5th April  
2016 
Primary affected 
age group   
 
Cows 
 
Cows and calves 
 
Cows 
 
Cows and calves 
Number of animals/serum samples 
(milk samples)  
   
Cows 29/120(119) 25/98(87) 32/134(131) 34/95(94) 
Calves 15/51 22/101 20/89 26/93 
Primary clinical 
signs 
 
Cows Mastitis Mastitis, arthritis Arthritis Mastitis, arthritis 
Calves Pneumonia, 
otitis media 
Arthritis,  
otitis media, 
pneumonia 
Few cases of 
arthritis and 
otitis media 
Arthritis,  
otitis media, 
pneumonia 
Positive 
bacteriological 
cultures of M.bovis 
(necropsied calves) 
 
0 
 
1 
 
0 
 
2 
 
Results 
35 
  
4.3 Factors influencing the antibody response in bulk tank milk 
The diverse and dynamic antibody responses in BTM from the 39 herds in SampAct#1 described in 
section 4.1 called for an investigation of the individual antibody responses in animals within these 
herds to clarify whether the fluctuations in BTM could be explained by within-herd milk prevalence 
of test-positive animals as an indicator of ongoing M. bovis infection. It was therefore important to 
investigate whether it was only cow-related factors that influenced the BTM ODC%, or if the 
infection level among young stock also played a role. This was investigated in Manuscript I. 
Manuscript I revealed that for each 10% increase in the milk prevalence of antibody-positive 
lactating cows, the BTM OCD% rose by 9 ODC% and the seroprevalence of young stock was not 
associated with the BTM ODC%. Despite this fairly good correlation between predicted BTM ODC% 
and the apparent milk prevalence of antibody-positive lactating cows, there was some inconsistency 
when adding information on clinical signs observed in the herd when BTM samples were collected. 
Based on information from the farmer interviews, observations were colour-coded according to 
whether or not there were clinical signs at the time the samples were collected, or if it was less than 
4 months since there had been observed clinical signs (Figure 4.3). Herds with high BTM ODC% and 
a high apparent milk prevalence of antibody-positive lactating cows were in general sampled within 
4 months of clinical signs becoming evident, but samples from herds with low BTM ODC% and low 
apparent prevalence were taken from a mixture of herds with and without clinical signs. To gain a 
better understanding of how to interpret the observed dynamics of BTM ODC% and associations 
with underlying infection patterns, an investigation of the antibody responses in cows with 
different disease manifestations is warranted.   
 
Figure 4.3: Descriptive statistics showing the bulk tank milk Mycoplasma bovis ELISA optical density 
measurement (ODC%) plotted against the apparent milk prevalence of antibody-positive lactating 
cows. Modified from Figure 2 in Petersen et al. 2016, Factors associated with variation in bulk tank 
milk Mycoplasma bovis antibody-ELISA results in dairy herds. J. Dairy Sci. 99:3815-3823 (included 
as Manuscript I in this thesis). 
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4.4 Antibody dynamics in individual cows 
Data from SampAct#2 were used to study the dynamics of antibody responses in cows with 
different clinical signs of M. bovis-associated disease. In total, 120 cows were included and all cows were assigned to one or two of the four disease groups: ‘Mastitis’, ‘Systemic’, ‘None’ or ‘Non-specific’, as described in Manuscript II. Eight cows were included in both the ‘Mastitis’ and ‘Systemic’ group, because they had clinical signs of M. bovis mastitis and arthritis, these were referred to as the ‘dual-syndrome’ cows.    
The ELISA response in serum differed among the four disease groups (Manuscript II). In particular, cows in the ‘Systemic’ group generally had a higher estimated antibody response than cows in the ‘None’ and ‘Non-specific’ groups (Figure 4.4). The confidence intervals for the ‘Systemic’ and ‘None’ groups did not overlap from disease onset to 70 days after disease onset. The ‘Mastitis’ group was 
too small to include in a model. However, the cows with M. bovis mastitis primarily had a rise in antibodies around and shortly after disease onset if they also had signs of systemic disease (‘dual-syndrome’ cows) (Figure 1, Manuscript II).  
 
 
Figure 4.4: Estimated mean antibody response in serum (solid line) and 95% confidence intervals (shaded area) as measured by the BioX ELISA Bio K302. Red represents the ‘Systemic’ group, blue is the ‘None’ group and black is the ‘Non-specific’ group. The dotted red line shows the recommended 
ELISA cut-off (37 ODC%). Modified from Figure 3 in Petersen et al. 2018, A longitudinal 
observational study of the dynamics of Mycoplasma bovis antibodies in naturally exposed and 
diseased dairy cows. J. Dairy Sci. https://doi.org/10.3168/jds.2017-14340 (included as Manuscript 
II in this thesis). 
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The difference in the ELISA response in serum was greater than the response in milk among the 
four disease groups. Only cows with clinical M. bovis mastitis seemed to have increased ODC% in 
milk (Manuscript II). Cows with e.g. arthritis as the only clinical sign did not have an elevated ELISA 
ODC% in milk.  
4.5 Antibody dynamics in individual calves 
Data from SampAct#2 were also used to study the dynamics of the antibody response in calves with 
different clinical signs of M. bovis-associated disease. In total, 83 calves were included and assigned to one of the three disease groups: ‘M. bovis’, ‘Respiratory’ and ‘None’, as described in Manuscript III.  
The antibody responses in calves seemed to differ among herds, but not among calves with different 
clinical signs within the same herd. BioX ELISA rarely detected antibodies in calves under the age of 
3 months (Manuscript III). The estimated mean ELISA ODC% response did not rise above the 
recommended cut-off for the entire study period in three of the four herds, with Herd 4 having a 
rise in mean ODC% at around day 100-120 (Figure 4.5). However, this apparent difference was 
driven by few observations, which is also evident by the broad 95% confidence interval. 
 
Figure 4.5: Estimated mean antibody response in serum (solid line) and 95% confidence intervals 
(shaded area) as measured by the BioX ELISA Bio K302 assay for the herd-specific age ranges for 
which observations were available. Herd 1 is grey, Herd 2 is black, Herd 3 is blue and Herd 4 is 
green. The dashed line shows the recommended individual animal ELISA cut-off (37 ODC%). From 
Petersen et al. Mycoplasma bovis antibody dynamics in naturally exposed dairy calves according to 
two diagnostic tests. Submitted to BMC Veterinary Research (included as Manuscript III in this 
thesis). 
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4.6 The MilA ELISA results 
In addition to the commercial BioX ELISA, blood and milk samples from SampAct#2 were also 
analysed with the in-house MilA ELISA, as described in section 3.2. The following section presents 
the antibody dynamics measured by the MilA in cows (i.e. results that were not included in any of 
the manuscripts in this thesis) and in calves, as described in Manuscript III. The MilA ELISA 
antibody response was analysed in the same way as described for the BioX ELISA and the animals 
were divided into the same disease groups as described in Manuscripts II and III. 
Graphs of the raw data of serum MilA ELISA measurements in cows are shown in Figure 4.6. There 
were very few negative samples when a cut-off of 135 AU was applied and the antibody response 
was rather dynamic – both within and between cows. No apparent differences were seen among 
disease groups or herds. Satisfactory model fit could not be achieved for serum MilA ELISA 
responses in cows due to the extreme variability within the raw data.  
 
 
Figure 4.6: Distribution of serum MilA ELISA measurements for antibodies directed against 
Mycoplasma bovis in the four disease groups of dairy cows from four Danish herds: A: ‘Mastitis’, B: ‘Systemic’, C: ‘None’, D: ‘Non-specific’. Grey dots represent the ‘dual-syndrome’ cows. Horizontal 
dotted lines show the recommended ELISA cut-off (135 AU). AU = antibody units. Results from the 
same cow are linked by lines. 
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The MilA antibody response was rather different in milk compared to serum (Figure 4.7). Many 
cows were below the cut-off throughout the study period, especially in the ‘None’ and ‘Non-specific’ 
groups. As for the BioX ELISA it seemed to show that only cows with clinical M. bovis mastitis 
secreted antibodies in milk.  
 
 
Figure 4.7: Distribution of milk MilA ELISA measurements for antibodies directed against 
Mycoplasma bovis in the four disease groups of dairy cows from four Danish herds: A: ‘Mastitis’, B: ‘Systemic’, C: ‘None’, D: ‘Non-specific’. Grey dots represent the ‘dual-syndrome’ cows. Horizontal 
dotted lines show the recommended ELISA cut-off (135 AU). AU = antibody units. Results from the 
same cow are linked by lines. 
 
In calves, there was no difference in antibody response in serum from calves with different clinical 
signs, but there was a difference when including herd as a fixed effect (Manuscript III). Based on the 
raw data shown in Figure 2 in Manuscript III, the results from Herds 2 and 4 showed that the MilA 
ELISA can be used to evaluate antibodies in calves shortly after birth. In addition, the results from 
Herd 3 showed that the MilA ELISA could be below the cut-off at 135 AU in several calves for more 
than one sampling. The estimated mean AU response increased rapidly to above the recommend 
cut-off for the entire study period in two of the four herds (Figure 4.8). The calves in Herd 3 stayed 
below the cut-off until approximately 80 days of age, while the calves in Herd 1 were older at 
sampling, so it was not possible to see the early antibody response in these calves. However, the 
shape of the curve seemed to mimic Herds 2 and 4, but at an older age (Figure 4.8). 
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Figure 4.8: Estimated mean antibody response in serum (solid line) and 95% confidence intervals 
(shaded area) as measured by the in-house MilA ELISA for the herd-specific age ranges for which 
observations were available. Herd 1 is grey, Herd 2 is black, Herd 3 is blue and Herd 4 is green. The 
dashed line shows the recommended individual animal ELISA cut-off (135 AU). From Petersen et al. 
Mycoplasma bovis antibody dynamics in naturally exposed dairy calves according to two diagnostic 
tests. Submitted to BMC Veterinary Research (included as Manuscript III in this thesis). 
 
4.7 The association between antibody-positivity for M. bovis and undesired 
early heifer departure 
A cohort of 636 heifer calves from 36 of the 39 herds enrolled in SampAct#1 were used, along with 
antibody measurements from lactating cows and other calves in the herds, to study the association 
between antibody-positivity and undesired early departure (UED) in heifer calves as described in 
Manuscript IV. 
The association between antibody-positivity to M. bovis using the BioX ELISA and the incidence rate 
of UED (i.e. slaughter, euthanasia or death) was performed using a Poisson regression model 
adjusting for the confounding effects of age and mortality percentage. Increasing seroprevalence in 
the group of calves 3-12 months old was the primary factor found to increase the risk of UED of 
heifers. For a 10% increase in seroprevalence the incidence rate of UED increased by 23%. A 
weaker association with the interaction between individual ELISA ODC% and age was significant, 
which means that effect of individual ELISA ODC% was different depending on age of the heifer. For 
a 10% increase in individual ELISA ODC%, the incidence rate of UED increased by 27% for heifers 
aged 9-12 months and decreased by 23% for heifers aged > 27 months (Table 3, Manuscript IV).
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5 General discussion and conclusions 
The main aim of this PhD project was to improve the use of antibody testing for animal- and herd-
level diagnostics by improving our understanding of how to interpret antibody measurements in 
relation to the clinical epidemiology of M. bovis and control of the disease. Although antibody 
measurements in both individual animals and BTM are being used to screen herds for or diagnose 
animals with M. bovis infection, the interpretation of the results from available commercial ELISA 
kits have not been sufficiently substantiated by field studies. In addition, the question of how to 
manage antibody-positive animals in infected herds is often raised by farmers and veterinarians.  
Results from this project show that there are limitations and therefore precautions that need to be 
taken when using BTM ODC% as a herd-level test mainly due to lack of sensitivity (Objective 1). The 
antibody responses measured by BioX ELISA in both milk and serum upon infection of cows with M. 
bovis are very dynamic and depend on which clinical signs the cow exhibits (Objective 2), while in 
calves, the antibody responses depend highly on age and exposure rather than disease (Objective 
3). The MilA ELISA seems to be a relevant and more sensitive alternative diagnostic antibody test 
for use in both adult dairy cattle and calves (Objective 4). Finally, increased seroprevalence in 
calves below one year old was found associated with decreased survival of heifers, whereas the 
individual antibody response in the calves was only associated with early departure from the herd 
in some time-periods of the heifer’s life (Objective 5).  
More detailed discussion of the specific findings of the different studies can be found in Manuscripts 
I-IV. The findings can be used in different combinations to improve the diagnosis of M. bovis 
infections in dairy herds depending on the purpose of testing and the herd-specific situation. 
Defining the intended purpose of testing is very important when assessing the performance of a 
diagnostic assay (Nielsen et al., 2011). The study results will be discussed in the following sections, 
with focus on the applicability of M. bovis antibody measurements in individual animals and at 
group level as well as the clinical implications of the findings. 
5.1  Applicability of bulk tank milk antibody testing 
The following section addresses the antibody response against M. bovis measured in BTM as a herd-
level screening tool to define the status of the herd, as well as the challenges associated with this.  
The antibody response in BTM can provide information about the disease status of a dairy herd for 
diseases such as Salmonella Dublin, BVDV and Coxiella Burnetii (Beaudeau et al., 2001; Nielsen, 
2003; Taurel et al., 2012). In Denmark, antibody measurements in BTM are part of several disease 
control programmes, e.g. for Salmonella Dublin and BVDV (Houe et al., 2006; Warnick et al., 2006), 
and there has been a desire from different stakeholders in the Danish cattle industry to use it for 
surveillance and pre-movement screening of cattle herds. For the ELISA response in a BTM sample 
to be useful (e.g. for classifying the herd into different risk groups), it needs to be representative of 
the herd and reflect the infection status of the animals within it.  
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The ELISA ODC% in milk from individual animals was only above the cut-off in cows with M. bovis 
mastitis (Manuscript II). As M. bovis can give rise to other clinical signs such as arthritis, this 
suggests that the antibody level in BTM mainly reflects the presence of udder infections associated 
with M. bovis, rather than M. bovis-associated disease in general. This is probably partly why there 
was some inconsistency between BTM antibody response and farmer-reported clinical signs in the 
herds in SampAct#1 (Figure 4.3). It is likely that herds with arthritis as the primary clinical sign of 
M. bovis reported clinical signs when the BTM ODC% was low. In fact, many of the M. bovis disease 
outbreaks reported in Denmark since 2011 were characterised by a high incidence of arthritis cases 
(Jensen, 2015). Another important issue is that as milk from cows with clinical mastitis must not be 
milked into the bulk tank, the BTM antibody response could merely reflect the presence of 
subclinical M. bovis udder infections within the herd.   
Parker et al. (2017a) investigated the BTM M. bovis BioX ODC% as a biosecurity tool in Australian 
dairy herds. They found a significant association between the seroprevalence of lactating cows and 
BTM ODC%. However, their model explained less of the variation than the model in Manuscript I, 
where the milk prevalence of antibody-positive lactating cows was associated with BTM ODC%. 
This also suggests that the BTM ODC% mainly reflects udder infections and not other disease 
manifestations of M. bovis. In the Australian study, the hospital herd within a large dairy herd was 
also found to have a higher antibody level in the BTM than the milking herd (Parker et al., 2017a). 
This suggests that the antibody response in milk primarily comes from diseased or at least animals 
separated away from the herd milking for delivery of milk for human consumption. Different 
management, treatment and culling strategies can therefore influence which cows are milked into 
the bulk tank and have a large impact on the diagnostic value of a BTM sample from the milking 
herd. This reduces the sensitivity and hence validity of the BTM test method for surveillance 
purposes. 
Another challenge with BTM testing is that the BTM ODC% for M. bovis seems to be more dynamic 
than for other cattle diseases such as Salmonella Dublin (Nielsen, 2003) or BVDV (Houe, 1999). In 
one study, the mean BTM BioX ODC% was found back below 37 ODC% less than 1 year after the 
disease outbreak started (Parker et al., 2017a). This is in line with Herd 39 from SampAct#1. This herd was unique as it was originally enrolled in the study as a ‘Control herd’ in November 2013, but 
clinical signs of M. bovis-associated arthritis began to present among the cows in February 2014. As 
a consequence of this opportunity, BTM samples were collected every second week to be able to 
follow the development of the antibody dynamics in BTM before, during and after an outbreak of M. 
bovis-associated disease. The BTM went from being negative to positive in both PCR and ELISA tests 
when clinical signs of M. bovis appeared in the herd (Figure 5.1). Within 6 months of clinical signs 
appearing, both PCR and ELISA in BTM were below the recommended cut-off again, and clinical 
signs were no longer present. The outbreak period was approximately 4 months. However, the BTM 
BioX ODC% was below 37 ODC% even before the clinical signs had ceased which further underpins 
the poor sensitivity of BTM testing for herd classification. 
Parker et al. (2017a) studied BTM ELISA response as a biosecurity tool for detecting dairy herds 
with past exposure to M. bovis, and they were also challenged by the fact that the antibodies against 
M. bovis are dynamic. They found that the greatest probability of identifying a herd with past 
exposure was between 0 and 8 months after the initial disease outbreak. In addition, the BTM 
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ODC% was below the cut-off 12 months after disease outbreak, despite positive BC or PCR results 
for M. bovis being found in the herd.  
 
 
Figure 5.1: The dynamics of the bulk tank milk antibody responses against Mycoplasma bovis 
measured by the BioX K302 ELISA (red dots and red dashed line) and PCR ct values measured by 
PathoProof® Mastitis Major-3 (blue dots and blue dashed line) for Herd 39. The red solid bar 
indicates the time period during which the farmer reported observing clinical signs of Mycoplasma 
bovis-associated disease in the herd. 
 
This implies that very frequent monitoring of the ODC% in BTM would be necessary in order to 
detect M. bovis infection emergence in a herd. However, more frequent testing would increase the 
probability of false-positive test results, because none of the available tests have perfect specificity 
(Nielsen et al., 2015; Schibrowski et al., 2018). Nielsen et al. (2015) estimated a sensitivity of 0.604 
and a specificity of 0.973 at cut-off 37 ODC% and a sensitivity of 0.435 and a specificity of 0.997 at 
cut-off 50 ODC% for the BioX ELISA, compared with the PathoProof® Mastitis Major-3 PCR kit at 
cut-off 37 Ct in a latent class analysis in BTM. However, the estimates were quite uncertain (large 
Posterior Credibility Intervals) and based on the work presented in this theses, it is likely that the 
underlying disease definition for the herds covered mainly presence of M. bovis udder infections. 
As the seroprevalence among young stock was not associated with the BTM level (Manuscript I), a 
group-level marker for this age group would also be needed if the herd testing procedure was to be 
improved.  
In conclusion, the use of antibody testing in BTM for detecting M. bovis is questionable because: 1) 
not all clinical symptoms in cows will be reflected in the BTM; 2) the antibody response in BTM is 
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very dynamic, making continuous and frequent monitoring necessary in order to detect new 
infections in due time; 3) another test strategy must be implemented to monitor the status of the 
calves and young stock within the herd.  
5.2 Interpretation of antibody responses in individual cows 
The use of antibody responses in different diagnostic materials from individual animals can be used 
to confirm suspected clinical cases or to estimate the prevalence of infection or exposure . The 
target condition depends on the purpose of testing (Nielsen et al., 2011) and could include animals 
with clinical signs associated with M. bovis or infected animals without clinical signs. The target 
condition in the studies of individual animals (SampAct#2) in this thesis was an animal with clinical 
signs likely to be associated with M. bovis infection.  
The usual way to evaluate diagnostic tests is to provide estimates of sensitivity and specificity, as 
done by e.g. Schibrowski et al. (2018). However, to the author’s knowledge no information on the 
dynamics of M. bovis antibodies in individual animals under field conditions is available from the 
published literature, and without this, the estimates of sensitivity and specificity are difficult to 
understand and use. For antibodies against M. bovis to be used for diagnostic testing in either serum 
or milk, the first step is to know the dynamics of antibodies in the different diagnostic materials in 
animals with different clinical disease syndromes. The following section therefore contains a 
discussion of the dynamics of antibodies in serum and milk in cows for the purposes of diagnosing 
individual diseased animals, as well as being an indicator of disease at group-level. 
5.2.1 Antibody response in serum 
There were many sick cows with continuously low BioX ODC%, particularly in the group of cows 
with systemic disease, and reasons for this are discussed in Manuscript II. Whatever the reason, this 
indicates a low sensitivity of the BioX ELISA, which has also been reported by others, who found the 
sensitivity to be 0.47-0.50 in experimentally infected animals (Schibrowski et al., 2018; Wawegama 
et al., 2016). In order to improve the diagnostic sensitivity of the herd testing procedures using the 
BioX ELISA, it is therefore recommended to test a group of cows or combine antibody 
measurements with other diagnostic tests.  
The antibody response in serum seems to be more dynamic than often seen for other infectious 
disease in cattle e.g. Salmonella Dublin (Nielsen, 2003) and BVDV, where the level of antibodies 
remains elevated for up to 3 years (Fredriksen et al., 1999). The antibody response in serum in the 
group of cows with systemic M. bovis-associated disease was significantly different from the group 
of cows with no clinical signs of M. bovis during the entire study period (Manuscript II), which 
indicates that it would be possible to differentiate diseased from non-diseased cows based on the 
BioX ELISA. However, this was only evident for 60-70 days after disease onset, following which the 
antibody level was already below the recommended cut-off. This means that the period during 
which it is possible to diagnose M. bovis-associated disease or recent disease with antibody tests in 
serum is short. This also has implications for group-level diagnostics, as it can make it challenging 
to identify groups of animals or herds with recent circulation of M. bovis infection that may still 
constitute a contact risk. Recently, Hazelton et al. (2018a) measured the seroprevalence of 50 cows 
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in four herds to evaluate the serological profile of the herd. They found the lowest seroprevalence in 
the herd with the longest history of M. bovis-associated disease, while the highest was found in the 
herd with the most recent history of disease.  
The results of Manuscript II also indicate that differentiation between the clinical manifestations of 
M. bovis (such as mastitis, arthritis and respiratory disease or a combination of these) is essential in 
order to diagnose M. bovis-associated disease. It was difficult to form a conclusion on the ‘Mastitis’ 
group in Manuscript II since the majority of cows were euthanised after being identified with 
mastitis, so repeated samples were only available from seven cows. This also meant that it was not possible to run a statistical model for the ‘Mastitis’ group. However, the raw data (Figure 1 in Manuscript II) suggest that it is primarily the ‘dual-syndrome’ cows that have high antibody 
responses in serum in the ‘Mastitis’ group, so it is likely that it is the systemic component of the 
disease syndrome that causes a high level of antibodies in serum. This leaves us with unanswered 
questions regarding how M. bovis disseminates in the host. Mastitis might be mainly a local infection 
in the udder originating from uptake via the teat canal, whereas haematogenous spread to the joints 
is more likely to be a sequela to uptake via the respiratory route, as seen in calves (Mahmood et al., 
2017; Romvary et al., 1977a). On the other hand, it cannot be ruled out that a sufficiently high 
infectious dose in the udder can lead to systemic disease, as suggested by Pfutzner and Sachse 
(1996). Arthritis has been seen after both intraarticular and intravenous inoculation of M. bovis, but 
arthritis did not develop after inoculation of M. bovis into the udder (Pfutzner and Sachse, 1996; 
Stalheim and Page, 1975), and no published literature has been identified in which arthritis was 
reported to follow mastitis. This does not prove that arthritis cannot develop after uptake through 
the teat canal, but in combination with an apparently different antibody response in cows with 
mastitis and arthritis, it gives weight to different pathogeneses producing the different clinical 
syndromes.  
In conclusion, to use the BioX ELISA for antibody measurements in serum, the following precautions 
should be considered: 1) only cows with systemic disease can be expected to have measurable 
antibodies in serum, 2) the time period during which high antibody response results in a positive 
diagnosis is relatively short – only 60-70 days after disease onset, 3) it is preferable to test groups 
rather than individual animals in order to increase the sensitivity of testing procedure to confirm 
suspected M. bovis-associated disease in a cattle herd. More work needs to be done to determine the 
most optimal testing strategies with regard to sample sizes and target groups depending on clinical 
signs and herd structures. 
5.2.2 Antibody response in milk 
The antibodies in milk seemed to be even more dynamic and short-lasting than in serum, making it 
a less suitable material for diagnosing M. bovis-associated disease in general, even though it is often 
more convenient to collect from lactating cows. 
The BioX ELISA mainly detected antibodies in milk from cows with clinical M. bovis mastitis, and since the ‘Mastitis’ group was small it was not possible to analyse and conclude much about cows 
with M. bovis mastitis (Manuscript II). As mentioned above, repeated samples were only available 
from seven cows, mainly due to the euthanasia of affected cows, which could have introduced bias 
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to these estimates. If the more severely diseased cows were removed from the study, a potential 
underestimation of the antibody response might have been seen in the ‘Mastitis’ group. A reliable 
estimate of the antibody response in severely diseased animals might be impossible to obtain, as 
one of the recommendations for the control of M. bovis is culling affected animals (Maunsell et al., 
2011; Pfutzner and Sachse, 1996), in addition to the welfare issues associated with keeping these 
animals alive.  
A direct comparison between serum and milk BioX ODC% in cows has been performed by others. 
Approximately 200 cows in each of eight of the Danish dairy herds with recent M. bovis-associated 
disease occurrence also enrolled in SampAct#1 were sampled, with paired blood and milk samples 
taken on the same day and analysed with the BioX ELISA (Nielsen, 2014). The results of that study 
are shown in Figure 5.2. The milk ODC% was generally lower than the serum ODC% from the same 
cow, and a coefficient of determination (r2) at 0.47 indicates disagreement among many 
observations. Combined with information from Manuscript II, this discrepancy can be explained by 
different underlying disease manifestations in the cows. The cows with very high ODC% in milk but 
not in serum are likely to have M. bovis udder infections, while the opposite scenario (high serum 
and low milk ODC%) is likely to represent a systemic M. bovis infection. In addition, the majority of 
sampled cows were low in ODC% in serum and milk, despite that herds had recent M. bovis-
associated disease occurrence (Nielsen, 2014). This can be explained by the short lasting antibody 
responses and the fact that antibodies to M. bovis are primarily produced by diseased cows, as 
shown in Manuscript II. These findings highlight the importance of performing longitudinal studies 
including clinical recordings to improve the interpretation of diagnostic test results, as will be 
discussed further in Section 5.7.  
 
Figure 5.2: The correlation between BioX K302 ELISA values in serum and milk from cows in eight 
Danish dairy herds (serumELISA =2.5 + 0.7*milkELISA, r2= 0.47), red line = regression line, blue line 
= lowess line (from Nielsen, 2014 with permission). 
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5.3 Interpretation of antibody responses in individual calves 
Interpretation of the antibody responses seemed to be different in calves compared to cows. There 
was no apparent difference in antibody response between the different disease groups in the BioX 
ELISA, but differences were found between herds, which may be related to different ages at 
exposure to M. bovis (Manuscript III).  
It is important to note that the use of the BioX ELISA was not useful for testing calves less than 3 
months of age (Manuscript III). This deduction is primarily based on results from Herds 2 and 4. 
These were heavily infected herds with severe disease problems among the calves, likely associated 
with M. bovis, which was detected by PCR in necropsied calves from the herds. There was little or no 
segregation between cows and calves, and the calves were fed non-pasteurised whole milk, at least 
at the beginning of the disease outbreak. Despite this, the mean estimated ODC% was not above the 
recommended cut-off in either herd (Figure 4.5). In contrast, the estimated ODC% in calves from 
Herd 3 rose very sharply around the age of 3 months. There were few clinical signs suggestive of M. 
bovis among the young calves in this herd and they were separated from the cows, suggesting that 
they were not exposed to M. bovis until the age of around 90 days, when the sharp increase in 
antibodies was seen. At this age, calves are suspected to be more immunocompetent, which may 
influence their ability to respond to M. bovis (Barrington and Parish, 2001). This apparent age-
related response to M. bovis exposure is important as the calves are thought to be a reservoir, 
maintaining M. bovis infection within the dairy herd (Maunsell et al., 2011). To diagnose a group of 
calves with M. bovis-associated disease, either the cut-off of the BioX ELISA should be adjusted to a 
lower ODC% level, or another diagnostic method should be applied for the young calves. 
No difference was found between calves with different clinical signs of disease; the primary 
difference was seen between herds, this most likely relates to the age of exposure to M. bovis. This 
suggests that the BioX ELISA reflects exposure in a group of calves, rather than clinical disease in 
the individual calf. This is in line with the findings of Martin et al. (1990), who concluded that the 
antibody level in a group of calves (rather than individuals) was indicative of disease being present 
in the group.  
In conclusion, to use and interpret BioX antibody measurements in serum from calves, one should 
bear in mind: 1) the age of the calves tested, 2) that the antibody response is not related to clinical 
signs in calves, and 3) that the antibody response is not a good indicator of disease in the individual 
calf, but is likely to be a good group-level test for exposure to M. bovis. 
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5.4 Comparison of the BioX and MilA ELISA results 
Differences and similarities between the antibody responses measured by the BioX and MilA ELISAs 
in the samples available for in the work presented in this thesis will be discussed in the following 
section. A schematic overview of diagnostic opportunities for both tests in cows and calves will be 
also given. 
As described in section 3.2, the samples from SampAct#2 were analysed with the in-house MilA 
ELISA, developed at the University of Melbourne (in addition to the BioX ELISA). Raw data are 
shown in Figures 4.6 and 4.7. An attempt was made to analyse the MilA ELISA measurements in 
cows with statistical models for each disease group, as was done for the BioX ELISA measurements. 
However, the statistical models did not converge, probably due to sparse and highly variable data 
indicating a dynamic antibody response, with the same cows changing from less than 500 AU to 
more than 1500 AU and back to 500 AU over three sampling rounds. The lack of evaluation based 
on statistical modelling is not optimal and means that evaluation of the MilA ELISA in cows cannot 
be generalised to the same degree as the BioX ELISA. The units and scales on which the two ELISAs 
are currently applied are very different. The BioX uses a back-ground corrected sample-to-positive 
control ratio, which results in a semi-quantitative scale, and the antibody units for the MilA ELISA 
are antibody concentrations calculated based on a series of standards included in the kit 
(Wawegama et al., 2016), which can lead to more dynamic results. To make more accurate 
comparisons, both ELISAs should be evaluated on similar scales. 
As with the BioX ELISA, the MilA ELISA did not detect antibodies in milk from cows other than the 
ones with M. bovis mastitis. This supports the hypothesis that antibodies in milk are mostly 
produced locally and the extent of filtering from the serum is minimal. This is interesting, among 
other reasons because it is different from what is seen for other pathogens where it was found that 
the Ig in milk was primarily serum-derived (Caffin and Poutrel, 1988; Spier et al., 1991). 
Nearly all cows were above the recommended cut-off in the MilA ELISA in serum, regardless of 
disease group (Figure 4.6). All cows in SampAct#2 were expected to be exposed to M. bovis since all 
herds experienced clinical signs of M. bovis-associated disease among cows, and M. bovis is an 
infectious pathogen that is widespread in infected herds (Maunsell and Donovan, 2009). This 
suggests that the MilA is a more sensitive test, detecting exposure to M. bovis. This is supported by 
others, who found the sensitivity to be 0.943 in feedlot cattle with BRD (Wawegama et al., 2016). 
However, it is important to question whether the MilA ELISA is sufficiently specific. As all of the 
herds in SampAct#2 were outbreak herds, the data were not appropriate to quantify the test 
specificity. In order to do this, M. bovis-free herds should be tested and specificity estimates 
deducted from those. However, the young calves in Herd 3 were nearly all low in antibodies for the 
first 60 days (Figure 2, Manuscript III), and there were few clinical signs suggestive of M. bovis 
among the calves in this herd, as described in Section 5.3. In combination with generally good 
management practices and pasteurisation of milk given to the calves, this probably contributed to 
lower exposure for the calves until around 80 days of age, when the antibody response in the MilA 
ELISA rose. This suggests that the MilA ELISA might have a reasonable specificity, as also suggested 
by Wawegama et al. (2016), who estimated the specificity at 0.944 in naturally infected feedlot 
cattle. Still, further investigationx of truly non-infected cattle populations must be performed. 
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In contrast to the BioX ELISA, the MilA ELISA detected antibodies in many calves from the two 
heavily infected herds from as early as around 20 days of age. It therefore seems as though the MilA 
ELISA can be applied to cattle > 3 weeks of age and used at herd level to classify herds. If the 
reported sensitivity of 0.90 (Wawegama et al., 2016) is also valid in field studies, fewer animals 
would be needed for testing in each group if the MilA ELISA were used as a group-level test. 
However, further studies including statistical modelling are needed to better understand the 
dynamics of the test results, especially in naïve herds, before it is applied in e.g. control 
programmes.  
Based on the knowledge gained from Manuscripts I-III, Table 5.1 summarises the findings of 
antibody responses against M. bovis in cows and calves using the two different ELISAs, BioX and 
MilA. 
5.5 Association between antibody-positivity and survival in heifers  
The applicability of the BioX ELISA in cows and calves in field studies has now been evaluated. To 
assess the long-term effect of antibody positivity in calves, which is a question often raised by 
farmers and veterinarians, the following section contains a discussion of the association between M. 
bovis antibody positivity and dairy heifer survival.  
The finding that it was primarily the serostatus of the group of young stock that was associated with 
UED is in agreement with the limited published literature, as described in Manuscript IV. The 
impact of the direct presence of M. bovis has been investigated by others. In a study of respiratory 
pathogens and their relationship with clinical status and weight gain in dairy calves, only isolation 
of M. bovis from the nasal cavity was associated with a higher odds of clinical signs and lower daily 
weight gain (Francoz et al., 2015). In a study in white veal calves, respiratory disease and arthritis 
were associated with higher mortality risk and lower carcass weight. Otitis media alone was not 
associated with high mortality or decrease in carcass traits in white veal calf production, but the 
simultaneous presence of arthritis and otitis was associated with lower carcass weight (Pardon et 
al., 2013). However, caution should be taken to interpret these results, since the number of arthritis 
and otitis cases were low in that study. Even though the study did not investigate the aetiology of 
the lesions, M. bovis is associated with BRD, arthritis and otitis. Together this suggest that there is a 
negative effect of having M. bovis circulating and causing disease among calves in dairy herds. 
The herd-level variable included in the analysis to account for the infection level among the adult 
cows was the milk prevalence of antibody-positive lactating cows. As discussed in Manuscript IV, it 
would have been highly relevant to also include the seroprevalence of lactating cows, as this would 
have added a measure of systemic M. bovis-associated disease and not only accounting for the 
presence of udder-infections. Raaperi et al. (2012) have investigated the association between BRD 
in calves and different management factors, as well as presence of other infections. They did include 
the seroprevalence of M. bovis antibody positive heifers and cows, but found no association with 
BRD among the calves. One reason for not finding an association could be the number of animals 
chosen and sampled. A rather small sample of maximum 25 heifers and 10 cows were randomly 
sampled. If these were not sick cows, they are not expected to have an elevated antibody response 
in the BioX ELISA (Manuscript III). A specific description of which animals were sampled lacks, so it   
G
en
er
al
 d
is
cu
ss
io
n 
an
d 
co
nc
lu
si
on
s 
50
 
 
 
 Ta
bl
e 
5
.1
: S
um
m
ar
y 
of
 th
e 
ad
va
nt
ag
es
, d
is
ad
va
nt
ag
es
 a
nd
 u
se
fu
ln
es
s 
of
 M
yc
op
la
sm
a 
bo
vi
s 
an
ti
bo
dy
 m
ea
su
re
m
en
ts
 in
 d
if
fe
re
nt
 m
at
er
ia
ls
 fo
r 
di
ag
no
si
ng
 M
yc
op
la
sm
a 
bo
vi
s 
in
 
da
ir
y 
he
rd
s.
 T
he
 s
um
m
ar
y 
is
 b
as
ed
 o
n 
re
su
lt
s 
fr
om
 th
e 
st
ud
ie
s 
in
 th
is
 th
es
is
 c
om
bi
ne
d 
w
it
h 
pu
bl
is
he
d 
ex
pe
ri
m
en
ta
l a
nd
 o
bs
er
va
ti
on
al
 s
tu
di
es
 b
y 
ot
he
rs
 a
s 
de
sc
ri
be
d 
in
 
se
ct
io
ns
 5
.1
-5
.4
 o
f t
hi
s 
th
es
is
. B
io
X
 =
 B
io
X
 K
 3
02
, M
ilA
 =
 in
-h
ou
se
 E
LI
SA
 d
ev
el
op
ed
 a
t U
ni
ve
rs
it
y 
of
 M
el
bo
ur
ne
. 
 
A
d
va
n
ta
ge
s 
D
is
ad
va
n
ta
ge
s 
B
T
M
 
In
d
iv
id
u
al
 c
ow
s 
In
d
iv
id
u
al
 c
al
ve
s 
 
 
 
 
Se
ru
m
 
M
il
k 
Se
ru
m
 
   B
io
X
 E
LI
SA
 
Co
m
m
er
ci
al
ly
 
av
ai
la
bl
e 
G
oo
d 
sp
ec
if
ic
it
y  
P
er
fo
rm
an
ce
 o
n 
in
di
vi
du
al
 a
nd
 
B
T
M
 le
ve
l h
as
 
be
en
 e
va
lu
at
ed
 
Lo
w
 s
en
si
ti
vi
ty
 
Sh
or
t a
nt
ib
od
y 
re
sp
on
se
,  
ev
en
 in
 d
is
ea
se
d 
an
im
al
s 
Fa
ir
ly
 g
oo
d 
as
so
ci
at
io
n 
be
tw
ee
n 
B
T
M
 O
D
C%
 
an
d 
th
e 
pr
ev
al
en
ce
 o
f 
te
st
-p
os
it
iv
e 
la
ct
at
in
g 
co
w
s 
in
 m
ilk
 
M
ai
nl
y 
re
fl
ec
ts
 th
e 
pr
es
en
ce
 o
f M
. b
ov
is
 
ud
de
r 
in
fe
ct
io
ns
  
in
 th
e 
he
rd
 
R
ef
le
ct
s 
sy
st
em
ic
  
M
. b
ov
is
-a
ss
oc
ia
te
d 
di
se
as
e 
in
 th
e 
co
w
 
w
he
n 
se
ro
po
si
ti
ve
 
N
ot
 u
se
fu
l f
or
 
in
di
vi
du
al
 d
ia
gn
os
is
 
U
se
fu
l a
t g
ro
up
-l
ev
el
 
to
 c
on
fi
rm
 M
. b
ov
is
 
in
fe
ct
io
n 
R
ef
le
ct
s 
M
. b
ov
is
 u
dd
er
 
in
fe
ct
io
n 
 
in
 th
e 
co
w
  
w
he
n 
po
si
ti
ve
 
  
  
N
ot
 u
se
fu
l f
or
 c
al
ve
s 
< 
3 
m
on
th
s 
ol
d
 
N
ot
 u
se
fu
l f
or
 
in
di
vi
du
al
 d
ia
gn
os
is
 
U
se
fu
l a
t g
ro
up
 le
ve
l 
fo
r 
ca
lv
es
 >
 3
 m
on
th
s 
ol
d 
Cu
t-
of
f m
ig
ht
 n
ee
d 
to
 
be
 lo
w
er
ed
 fo
r 
ca
lf
 
di
ag
no
si
s 
  M
il
A
 E
LI
SA
 
A
 s
en
si
ti
ve
 te
st
 o
f 
ex
po
su
re
 to
  
 M
. b
ov
is
 
 
N
ot
 c
om
m
er
ci
al
ly
 
av
ai
la
bl
e 
 
(s
oo
n 
to
 b
e)
 
Fu
rt
he
r 
st
ud
ie
s 
 
ar
e 
ne
ed
ed
 
to
 d
et
er
m
in
e 
 
th
e 
sp
ec
if
ic
it
y 
St
ud
ie
s 
ar
e 
la
ck
in
g 
Li
ke
ly
 r
ef
le
ct
s 
ex
po
su
re
 to
 M
. b
ov
is
 
an
d 
no
t d
is
ea
se
 
N
ot
 u
se
fu
l f
or
 
in
di
vi
du
al
 d
ia
gn
os
is
 
P
ro
ba
bl
y 
us
ef
ul
 fo
r 
gr
ou
p-
le
ve
l d
ia
gn
os
is
 
R
ef
le
ct
s 
M
. b
ov
is
 u
dd
er
 
in
fe
ct
io
n 
 
in
 th
e 
co
w
  
w
he
n 
po
si
ti
ve
 
 
Ca
n 
de
te
ct
 a
nt
ib
od
ie
s 
in
 c
al
ve
s 
w
it
hi
n 
20
 
da
ys
 a
ft
er
 b
ir
th
 
U
se
fu
l a
t g
ro
up
 le
ve
l 
fo
r 
ex
po
su
re
 to
 M
. 
bo
vi
s 
 
 
50
General discussion and conclusions 
51 
  
 is difficult to compare and conclude further on whether the sample is representative and indicative 
of M. bovis status of the herd and hence if this is the real association between circulating M. bovis 
among the cows and BRD in calves. 
It could be discussed whether another method than the Poisson regression chosen would be more 
suitable, because there were few events in several of the age groups. Therefore, the association was 
also analysed using Cox regression, however, the assumption of proportional hazards was violated 
and is therefore not reported. 
The findings of Manuscript IV support the findings of Manuscripts II and III and published literature 
(Martin et al., 1990; Maunsell et al., 2011; Maunsell and Donovan, 2009) that suggests that the 
antibody response to M. bovis is only useful for group-level diagnostics. In the individual animal the 
relationship between mycoplasmas and the host varies from commensal to opportunistic or 
primary pathogens (Maunsell and Donovan, 2009). This shifting between primary and secondary 
pathogen probably makes it difficult to isolate the effect of M. bovis in the individual animal, which 
supports that the ELISA response in individual animals provides limited information on the health 
of the tested animals. The co-infections with other pathogens are often seen in older calves and are 
thought to be responsible for severe and chronic lung lesions (Burki et al., 2015). If M. bovis is 
circulating in a group of animals some will have an antibody response and the seroprevalence will 
depend on the infection pressure of M. bovis, whereas the clinical disease and severity hereof, will 
also depend on which other pathogens are present. 
5.6 Data quality 
The epidemiological studies performed in this thesis were based on two sample activities, 
SampAct#1 and SampAct#2. The following sections will discuss the quality of the data obtained. 
5.6.1 Sampling of suspected case and control herds 
In SampAct#1, the herds were selected to represent a broad spectrum of clinical signs, infection 
status and test results. Less was known about M. bovis disease outbreaks and diagnostic testing in 
Denmark at the time when the field studies were initiated than is known today, so it was difficult to 
present specific inclusion criteria and unify representative groups of herds. However, diversity is 
also a characteristic of M. bovis infections and disease outbreaks. In fact, the diversity in herd type 
and M. bovis occurrence in the data from the 39 enrolled herds made them suitable for evaluating 
factors that affect the BTM ODC%, interpretation of diagnostic test results and decision-making 
based on antibody positivity in young stock in a way that would not have been achieved with more 
restrictive case definitions, while still being representative of the range of infections seen in the 
Danish cattle population.  
Ideally, the BTM samples collected in SampAct#1 should have been collected on the same day as the 
randomly sampled lactating cows. However, this was not possible due to practicalities such as 
unpredictable milk truck arrival times. It is likely that this could have influenced the findings of 
Manuscript I, given the dynamic antibody response in individual cows found in Manuscript II. On 
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the other hand, narrowing the time span between individual samples and BTM from 30 to 14 days 
did not influence the results, as described in Manuscript I.   
Based on the findings in Manuscript II, the conclusions in Manuscript IV might have been different 
had it been possible to include a herd-level variable measuring systemic M. bovis-associated disease 
in cows as a measure of infection pressure in the herd, instead of only including the level of M. bovis 
udder infections among the cows. The low number of events observed might also have influenced 
the result. More events and/or samples from more calves than the cohort of 20 calves would have 
been preferable.  
5.6.2 Sampling in the clinical epidemiology study 
The budget for SampAct#2 was limited, leading to either fewer herds being sampled, fewer animals 
sampled within more herds, or a reduced number of times each animal was sampled. It was 
considered to be important to follow the antibody dynamics in individual animals closely, as we 
expected that it was more dynamic than for other diseases. To be able to compare antibody 
responses among animals in the same herds, a reasonable number of animals from each herd was 
required. Altogether, given the budget available only four herds could be included, even though 
more herds would have been preferable. Having said this, due to the rather specific inclusion 
criteria and the rarity of major M. bovis herd outbreaks in Denmark, only six herds were considered 
for the project over the recruitment period of 9 months, and only four of these were found to be 
suitable. In addition, this kind of intensive, longitudinal sampling scheme is seldom seen in field 
studies, and there was limited information about antibody dynamics in the literature. From this 
perspective, the data available from SampAct#2 are deemed suitable for the performed 
investigations of antibody dynamics and can form the basis for further investigations of diagnostic 
test validity and interpretation.  
Herd 1 from SampAct#2 differed from the other three herds. The farmer stated that the disease 
outbreak started 1 month prior to the first herd visit. However, the clinical signs observed by the 
veterinarians collecting the samples in this herd were less severe than those observed in the other 
three participating herds. It is possible that other management and health issues masked the true 
time of the outbreak, which is likely to have been earlier than that stated by the farmer. For this 
reason, we considered excluding Herd 1 from the analyses. However, after running all models 
without this herd, we drew the same overall conclusions as when it had been included, but with 
more uncertainty due to a lower number of samples and test results. We therefore decided to keep 
Herd 1 in the dataset. 
An interesting additional finding from Manuscript II was that the antibody response in cows was 
apparently high at the time clinical signs were present (Figure 4.4). This could indicate that M. bovis 
was present in the herds for at least 1-2 weeks before causing clinical signs, because antibodies are 
developed 1-2 weeks after exposure (Byrne et al., 2005; Kanci et al., 2017). The variable ‘Days from 
disease onset’ could also have influenced this. Total accuracy could not be obtained because of the 
three-week intervals between herd visits, and the varying time from onset of the outbreak to the 
first herd visit. The onset of clinical signs might have been reported later than they first presented, 
especially if they were detected at the first herd visit, since the outbreak had already lasted for some 
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time. Despite this uncertainty, it remains likely that M. bovis is present for some time in the herd 
before clinical disease becomes evident. 
The herd visits in both sampling activities were performed by a small number of individuals, the 
samples were delivered to the laboratory within 2 days of sampling, and in general, few samples 
were missing because of either laboratory or data errors. Although milk samples were not collected 
during six herd visits in SampAct#1, and the MilA ELISA was not performed on samples from the 
first herd visit to Herd 1 in SampAct#2, continual data editing resulted in comprehensive datasets 
that were generally suitable for their purposes.  
 
5.7 Reflections on the clinical epidemiology of Mycoplasma bovis   
Having worked intensively with many aspects of M. bovis over the last 4½ years through herd visits, 
reading the literature, working with Master thesis students, analysing and discussing data and 
results of epidemiological analyses, some general considerations worth sharing emerged across all 
these activities.  
When diagnosing M. bovis, I generally find it necessary to distinguish between M. bovis being 
present in the herd and herds with disease problems caused by M. bovis (e.g. a disease outbreak 
among many animals in the herd in one or more age groups/sections). These are two very different 
situations. It is likely that M. bovis can be present in many herds without causing disease, while it 
causes severe disease problems in other herds. Having said this, it is unclear why this difference 
arises. It could be due to management factors in the herd (Aebi et al., 2015; Fox et al., 2003; Jensen, 
2015), characteristics of the bacteria or the host, and most likely a combination of these. This 
distinction between the presence of bacteria and clinical disease is very important when evaluating 
diagnostic tests, and a specific purpose and target condition is always important. M. bovis is no 
exception, and a lack of knowledge about many aspects of its pathogenesis and epidemiology 
further complicates this distinction.  
Arthritis and swollen legs were common clinical findings in herds with an outbreak of M. bovis-
associated disease in both the clinical epidemiology study and in Denmark in general (Jensen, 
2015). ‘Dual-syndrome’ cows (i.e. cows with both arthritis and mastitis) were particularly common 
in Herd 4 in the clinical epidemiological study. These combined clinical signs are perhaps not well 
recognised in cows, and the presence of one or a combination of these should alert veterinarians 
and farmers to investigate whether M. bovis might be the cause of disease. Similarly, diagnosis of M. 
bovis (or animals with antibodies against M. bovis) within a herd necessitates further investigation 
of possibly sick animals and additional diagnostics to confirm or rule-out M. bovis-associated 
disease. 
M. bovis-associated disease is usually regarded as chronic, yet many cows with arthritis and swollen 
legs actually recovered over time, especially in Herd 3. The farmer culled cows where it was 
deemed necessary from a welfare perspective, but kept many of the less severe cases on soft 
bedding for a period, after which they were returned to the milking herd. The infectiousness of the 
cows was not assessed, and whether it is wise to let the cows remain in the herd in this respect is 
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unknown. However, from an animal welfare perspective, it seems as though the cows were capable 
of recovery.  
Severe otitis media and arthritis were present among the calves in Herds 2 and 4. In the published 
literature, no experimental studies report otitis media and arthritis to the extent seen in natural 
infections. This may be a result of the different infection routes. Many of the experimental infections 
are produced by respiratory inoculation, which results in respiratory disease, while Maunsell et al. 
(2012) developed an oral inoculation model in which several calves developed otitis media, 
suggesting that this inoculation route might reflect natural exposure more accurately. Several calves 
in Herd 2 had more severe otitis media and arthritis, and as they were fed unpasteurised milk, it is 
likely that they were infected orally. One calf had more severe arthrosis in several joints at the age 
of 4 months, and according to the farmer, the calf was born with swollen joints. It is possible that 
this calf might have been infected in utero, considering the severity of lesions at this early age, the 
disease history and the fact that M. bovis have been isolated from aborted foetuses (Byrne et al., 
1999; Hassan and Dokhan, 2004). In addition to pathogenesis considerations in cows (described in 
section 5.2.1), the pathogenesis in relation to different M. bovis disease syndromes should also be 
investigated in order to gain a better understanding of the diagnostic tests.  
The very dynamic nature of the antibody response to M. bovis and the clear difference in antibody 
responses related to different clinical signs were previously unclear. This lack of basic knowledge 
hindered the author of this thesis during the data analysis for Manuscript I, as well as other authors 
(Hazelton et al., 2018a; Hazelton et al., 2018b; Nielsen, 2014; Szacawa et al., 2016), making the 
conclusions on their cross-sectional studies difficult to interpret. This demonstrates the value of 
basic longitudinal studies before more sophisticated epidemiologic analysis can be applied and 
interpreted appropriately. If a basic understanding of the material or diagnostic test is lacking, 
interpretation in different contexts and for different purposes will be challenging, and 
recommendations based on these might be incomplete. 
 
5.8 Conclusions and recommendations for diagnosing Mycoplasma bovis 
with antibody measurements 
The thesis was based on the hypothesis that cattle produce antibodies against M. bovis, but the 
conclusions of the thesis are that the observed antibody responses are dynamic and relatively 
short-termed and their dependence on clinical disease in cows make diagnosing M. bovis–associated 
disease based on antibody measurements challenging. As many animals with clinical signs of M. 
bovis do not test positive, the BioX ELISA cannot be recommended for individual diagnosis in calves 
or cows. However, use of the BioX ELISA for diagnosing M. bovis at group level for both cows and 
calves is feasible. However, this requires knowledge about clinical signs, age groups affected and 
management to be able to choose appropriate sampling materials and the age groups from which to 
sample. In terms of diagnosing cows using the BioX ELISA, ill cows should be chosen, but when 
interpreting the results of antibody laboratory results for calves, knowing the age and estimating 
the likely time of expected exposure is more important. Within each affected herd, the farmer and 
veterinarian must then decide which animals and diagnostic materials are suitable for diagnosing 
General discussion and conclusions 
55 
  
the clinical problems specific to that herd. For example, if arthritis among cows is the major 
problem, serum samples from affected cows should be chosen, while suspected M. bovis udder 
infections require milk samples. This complicates the definition of a general sampling scheme (e.g. 
for a control programme based on antibody measurements), and it might not be economically 
feasible to implement if many age and disease syndrome groups must be tested.  
The MilA ELISA might be a good alternative test. The ability to detect antibodies that are not 
maternally derived in very young calves and to detect exposure to M. bovis rather than clinical 
disease makes the MilA ELISA a promising candidate for surveillance purposes. However, further 
studies are needed to determine the sensitivity and specificity of non-diseased, exposed animals, as 
well as non-exposed animals and herds. 
Table 5.2 summarises the recommendations for investigating whether M. bovis is the likely cause of 
disease in a herd experiencing clinical signs suspected of being associated with M. bovis using ELISA. 
This does not preclude that other diagnostic tests can be preferred in some or more of the below 
mentioned situations, but it is beyond the scope of this thesis to evaluate other diagnostic tests. The recommendations are based on the research presented in this thesis along with the author’s 
experiences and other published literature. The recommendation for the farmer with seropositive 
young stock is to focus on initiatives for reducing the M. bovis infection among calves in the group, 
rather than focusing on the individual calf.  
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Table 5.2: Recommendations for investigating whether Mycoplasma bovis is the likely cause of disease in a herd experiencing clinical signs suspected 
of being caused by Mycoplasma bovis, using ELISA. The recom endations are based on the research presented in this thesis along with the author’s 
experiences and other published literature. 
Age group 
 
How to sample How to analyse Interpretation 
 
 
 
 
 
Cows 
 
 
 
Serum samples from a 
group of cows with 
clinical signs of systemic 
disease, e.g. arthritis 
 
 
 
BioX K302 
 
If mean ODC% ≥ 37 = likely M. bovis-associated systemic disease 
among the cows in he herd 
If mean ODC% < 37 = not likely that M. bovis-associated systemic 
disease among the cows in the herd 
If mean ODC% < 3 , but one or more individual cows > 37 ODC% = 
inconclusive, M. bovis-associated systemic disease might be in the herd, 
more samples from diseased cows are needed, or combine with 
alternative tests 
 
Milk samples from cows  
with mastitis 
 
 
 
BioX K302 
 
If one or more is ≥ 37 ODC%  = likely M. bovis mastitis present in the 
herd 
If all samples are < 37 ODC% = not likely M. bovis mastitis present in 
the herd 
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Table 5.2: Recommendations for investigating whether Mycoplasma bovis is the likely cause of disease in a herd experiencing clinical signs suspected 
of being caused by Mycoplasma bovis, using ELISA. The recomm ndations are based on the research presented in this thesis along with the author’s 
experiences and other published literature. 
Age group 
 
How to sample How to analyse Interpretation 
 
 
 
 
 
Cows 
 
 
 
Serum samples from a 
group of cows with 
clinical signs of systemic 
disease, e.g. arthritis 
 
 
 
BioX K302 
 
If mean ODC% ≥ 37 = likely M. bovis-associated systemic disease 
among the cows in the herd 
If mean ODC% < 37 = not likely that M. bovis-associated systemic 
disease among the cows in the herd 
If mean ODC% < 37, but one or more individual cows > 37 ODC% = 
inconclusive, M. bovis-associated systemic disease might be in the herd, 
more samples from diseased cows are needed, or combine with 
alternative tests 
 
Milk samples from cows  
with mastitis 
 
 
 
BioX K302 
 
If one or ore is ≥ 37 ODC%  = likely M. bovis mastitis present in the 
herd 
If all samples are < 37 ODC% = not likely M. bovis mastitis present in 
the herd 
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6 Perspectives 
The results of this thesis have contributed new knowledge about the clinical epidemiology of M. 
bovis and how antibody measurements can be useful in decision-making processes in dairy herds. A 
better understanding of antibody responses in both individual animals and BTM was gained. 
However, these are only small pieces in the big M. bovis puzzle. Many more questions require 
answers and new ones have emerged.  
Having specific guidelines for testing with ELISA (including sample size considerations and 
combinations with other test methods) would be very helpful for farmers and veterinarians. In 
order to provide these, further studies are needed on the number of animals required for testing at 
group level, with optimisation of sensitivity and specificity at different underlying levels of 
prevalence of infection and maybe using different cut-off values than recommended today.  
Further studies of the MilA ELISA would be interesting and relevant, especially because the ELISA 
will soon be made commercially available. From the data presented in this thesis, an insight into the 
short-term dynamics and the ability to differentiate between clinical signs modelled as for the BioX 
ELISA would aid in our understanding of the MilA ELISA in naturally infected animals. By 
calculating the ODC% instead of using AU as the unit for test-results, data might be less scattered 
and fluctuate less over time, and the statistical models explaining differences between disease 
groups and risk factors might work more effectively. As also mentioned above, further studies in 
truly non-infected herds are warranted to assess the specificity in under field conditions.  
The work presented in this thesis was based on animals displaying clinical disease or measurable 
antibodies. M. bovis is thought to spread through asymptomatic carrier animals. Hence, another 
interesting research area would be to determine the best testing strategy to identify infectious 
animals. More knowledge is required on risk factors for development of subclinical carrier animals, 
determine of how long they are infectious and which factors influences the excretion of M. bovis. 
This would represent an important step in developing a test scheme to certify the risk at herd level 
and would, together with improved knowledge about the diagnostic tests, make herd-level risk 
factor studies easier to conduct. All with the aim of preventing spread of M. bovis within and among 
cattle herds and thereby reduce the consequences for animal welfare and farm economics.  
The pathogenesis for different clinical syndromes in cows and calves needs more investigation. This 
would improve the understanding of diagnostic tests and aid in development of control measures. 
Further studies are also warranted for decision making in dairy herds. Analysis of other outcomes, 
e.g. disease among cows is needed. These studies would aid in giving the farmer more advice about 
how to handle test-positive individual animals, as well as which animals to keep or cull/slaughter 
during a disease outbreak. This is important information for both economic and welfare reasons.
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Abstract 
The relevance and limitations for using measurements of antibodies against Mycoplasma bovis (M. 
bovis) in bulk tank milk (BTM) as a potentially cost-effective diagnostic tool for herd classification 
has not been evaluated before. Assuming that an increasing or high sero-prevalence is a result of 
on-going or recent spread of M. bovis in a dairy herd, we tested the hypothesis that increasing 
prevalences of antibody positive cows and young stock are associated with increasing BTM 
antibody ELISA values against M. bovis in Danish dairy herds with different courses of M. bovis 
infection. Furthermore, we tested whether herd size was associated with variations in the BTM 
responses. 
Thirty-nine Danish dairy herds selected to represent four different herd level infection groups (8 
control herds, 14 acute outbreak herds, 7 herd with previous outbreaks and 10 herds with elevated 
BTM ELISA-values directed against M. bovis (>64 ODC%)) were visited 4-5 times approximately 3 m 
apart. At each visit 65 young stock were blood sampled. At the milk recording date closest to the 
herd visit date, 50 milk recording samples from individual lactating cows were randomly selected. 
In addition a BTM sample was collected as a representative sample directly from the bulk tank by the dairies’ milk truck drivers as part of the mandatory milk quality control scheme. Blood and milk 
samples were tested for antibodies against M. bovis with a commercially available ELISA test (Bio-X 
BIO K 302, Bio-X Diagnostics, Rochefort, Belgium).  
A linear mixed effects model was used to analyse the effects of the prevalence of antibody positive 
lactating cows and young stock and herd size on the BTM M. bovis ELISA results. Herd was included 
as a random effect to account for clustering of BTM samples originating from the same herd.   
Increasing prevalence of antibody positive lactating cows was the only variable associated with 
increasing M. bovis BTM ELISA optical density measurement (ODC%). In contrast, the prevalence of 
antibody positive young stock did not correlate with the BTM ODC%.  
In conclusion, some M. bovis associated herd infections are detectable by BTM ELISA-testing, but 
there are limitations and further investigations of the effect of different clinical disease expressions 
in the herds are warranted. 
 
Key words: Mycoplasma bovis, enzyme-limked immunosorbent assay (ELISA), bulk tank milk, 
antibody. 
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Introduction 
Mycoplasma bovis (M. bovis) can cause severe disease and production losses in both dairy and beef 
producing cattle herds. In adult cattle M. bovis infection is often associated with mastitis, but also 
arthritis and pneumonia can be seen. In calves the typical disease manifestations are otitis media, 
pneumonia and/or arthritis (Maunsell et al., 2011). M. bovis seems to be an emerging pathogen in 
countries all over the world, and even though M. bovis was first isolated in Denmark in 1981 (Friis, 
1984), it has not been considered a major pathogen in Danish cattle prior to 2011. However, the 
Danish cattle industry has had increased focus on this infection over the last couple of years due to 
an increase in the number of severe outbreaks of M. bovis associated disease on herd-level. 
Traditionally M. bovis has been detected by bacteriological culture (BC) from either individual milk 
samples or bulk tank milk (BTM) samples. In recent years detection by polymerase chain reaction 
(PCR) has become more widely used, since it is less time consuming and apparently can produce 
similar sensitivity and specificity to conventional BC methods (Pinnow et al., 2001; Cai et al., 2005). 
At individual level, antibodies directed against M. bovis can be detected in serum and milk 1-2 
weeks after uptake of the bacteria (Boothby et al., 1987; Byrne et al., 2005), but the use for 
diagnosis in individual animals is not always straight forward (Maunsell et al., 2011). M. bovis can 
also be isolated from asymptomatic carrier animals (Punyapornwithaya et al., 2010), but it is not 
known how the antibody response in these animals reacts compared to clinically ill animals. 
However, in beef cattle, group-level antibody titers and seroconversion can be associated with 
active infection (Martin et al., 1990), and spread of the disease in a dairy herd could therefore be 
expected to lead to a marked increase in seroprevalence. Except for Nielsen et al. (2015), who 
evaluated the performance of an antibody detecting enzyme linked immunosorbent assay (ELISA) 
against PCR for BTM for national screening purposes, the use of antibodies in BTM for diagnosing 
either disease or presence of M. bovis in specific dairy herds has not been addressed in published 
literature. Antibody measurements on BTM have been used as a diagnostic tool for the control of 
other infectious diseases, because it can be easy and inexpensive to use in national surveillance 
programs (Lindberg and Alenius, 1999; Nielsen, 2013). But in order to use antibodies against M. 
bovis in BTM for surveillance purposes it is essential to know which factors influence the antibody 
level in BTM. 
The use of ELISA on BTM samples to classify or monitor dairy herds for M. bovis infection will, in a 
setting such as the Danish, be of interest since the sampling can be automated via a mandatory milk 
quality control scheme, and is inexpensive compared to BC and PCR. A requirement for BTM 
antibody testing to be useful is that there must be a good correlation between the BTM antibody 
level and the prevalence of infection in individual cattle in the herd. In the case of other infectious 
diseases, such as Salmonella Dublin, bovine virus diarrhea virus and Q-fever, it has been shown that 
the level of antibodies in the BTM correlates well with the within-herd prevalence of antibody 
positive cows (Nielsen and Ersbøll, 2005; Muskens et al., 2011; Taurel et al., 2012). Increasing herd 
size has been shown to be a risk factor for presence of M. bovis infection (Thomas et al., 1981; Pinho 
et al., 2013).  On the other hand, antibodies might be diluted in herds with a large number of cows 
contributing milk to the BTM (Nekouei et al. 2015). Hence, herd size may have to be taken into 
account when evaluating BTM testing for herd diagnosis. 
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The objective of this study was to test the hypothesis that increasing within-herd prevalence of 
antibody positive lactating cows and increasing seroprevalence in young stock increases the BTM 
antibody ELISA values against M. bovis in Danish dairy herds. Furthermore, we wanted to test 
whether herd size affected the level of antibodies in BTM. 
 
Materials and Methods 
Populations 
The target population was all Danish dairy herds enrolled in the voluntary milk recording system 
(https://www.landbrugsinfo.dk/Kvaeg/RYK/Sider/RYK_English.aspx), which at the beginning of 
the study period consisted of approximately 3000 (90% of all) Danish dairy herds. Their average 
annual milk yield per cow was 9,663 kg milk and the average herd size was 166 lactating cows. The 
study population consisted of herds about which the Knowledge Centre for Agriculture (now SEGES, 
Aarhus, Denmark) had prior knowledge about M. bovis associated disease either from farmers or 
veterinarians. SEGES is the merger of the former Knowlegde Centre for Agriculture and the Danish 
Pig Research Centre, effective as per 1 January 2015. The company is owned by the farmers and 
provides knowledge, consultancy and technology to all Danish farmers (https//www.seges.dk/en). 
Only herds with more than 100 dairy cows were included. More than 100 cows were needed to 
make sure the herd had enough young stock to sample. The study population consisted of 39 dairy 
herds selected by a veterinarian at SEGES during the period March 2013-February 2014. The 
veterinarian at SEGES had prior knowledge about the herds from national screenings in 2012 and 
2013, where BTM from all dairy herds were tested for antibodies against M. bovis and with PCR, as 
well as information provided by the local consulting veterinarian in the herds. To ensure collection 
of data from herds with different severity and duration of disease, the following criteria were used 
to select herds to fit into 1 of 4 groups prior to enrollment in the field data collection part of the 
study:  
Control herds: negative in diagnostic tests (PCR, ELISA and BC), no history of clinical signs that 
could be related to M. bovis over the past 3 years; 8 herds. 
Case herds – acute: Recent clinical suspicion of disease associated with M. bovis, 14 herds. In these 
14 herds, the presence of M. bovis was confirmed by positive M. bovis PCR [PathoProof, Thermo 
Fisher Scientific, Waltham, MA: with a cycle threshold (Ct) <37] in milk samples from individual 
cows and/or BTM. In 4 herds the confirmation was performed in BTM, in 5 herds at individual cow 
level, and in 5 herds at both individual cow level and in BTM. In addition, 5 of the 14 herds were 
positive for M. bovis in BC of samples from individual animals. 
Case herds – previous: Previous clinical suspicion of disease associated with M. bovis; 7 herds. This 
group included herds with former M. bovis test positive clinically ill animals, but that no longer had 
any acutely diseased animals. In these 7 herds, the presence of M. bovis was confirmed by positive 
PCR [PathoProof PCR (Ct < 37)] in milk samples from individual cows and BTM in 3 herds, and in 
BTM in 4 herds.  
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Case herds – BTM: High ELISA value against M. bovis in BTM (Bio-X Bio K 302, Bio-X Diagnostics, 
Rochefort, Belgium; ELISA value >64 optical density measurement) in a national screening in 
summer 2013; 10 herds. 
The selection of farms was done as described above to ensure representation of all types of clinical 
signs, infection and test patterns in the study herds so that the full scale of BTM and 
seroprevalences were represented in the data set for analysis. The allocation to groups was not 
used in the analyses. 
The distribution of BTM optical density (ODC%) measurements from the different herds over time, 
divided into the abovementioned 4 categories are shown in Figure 1. We aimed to include herds of 
different sizes and geographical locations. However, systematic stratification according to these 
factors was not used. More than 90 % of the Danish dairy cattle are located on the peninsula of 
Jutland, and all herds enrolled in this study were located in Jutland. Because the prevalence of M. 
bovis infection is low, the selection criteria were used to ensure inclusion of herds with evidence of 
disease and/or spread of M. bovis.  
Each herd was visited 4-5 times approximately 3 mo apart. At each visit 65 young stock equally 
distributed in the age group 0-12 mo old were blood sampled. At the milk recording date closest to 
the herd visit date, 50 milk recording samples from individual lactating cows were randomly 
selected. A BTM was sampled as a representative sample while the bulk tank was emptied by the dairies’ milk truck drivers as part of the mandatory milk quality control scheme.  
    
Figure 1. Distribution of bulk tank milk (BTM) ELISA optical density measurements (ODC%) of 
antibodies against Mycoplasma bovis in herds initially selected as control herds, case herds with 
acute outbreaks, case herds with previous outbreak and case herds with high BTM. The lines 
connect results from the same herd. 
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Detection of Antibodies 
Milk samples from both individual animals and BTM, and serum samples from the young stock were 
analyzed for antibodies against M. bovis using the commercial kit Bio-X BIO K 302 Mycoplasma bovis 
ELISA kit at Eurofins-Steins Laboratory (Holstebro and Vejen, Denmark). A sample coefficient was 
calculated as: ODC% = (OD sample - OD negative control)/(OD positive control - OD negative 
control) x 100 %, where OD is the optical density measured by the ELISA reader for each test 
sample, and negative and positive control samples on the sample ELISA plate. For animal-level 
testing a sample coefficient ≥ 37 ODC% was considered positive, and a sample coefficient < 37 
ODC% was considered negative according to the recommendations of the manufacturer of the 
ELISA kit. The test has to the authors’ knowledge not been evaluated with regard to sensitivity (Se) 
and specificity (Sp) for animal level diagnosis in the field.  
It has been evaluated for use on BTM in national screening of dairy herds for national or regional 
prevalence estimation by Nielsen et al. (2015). The Se and Sp at cut-off 37 ODC% were 60.4 and 
97.3, respectively. At a cut-off of 50 ODC% the Se 43.5 and the Sp was 99.6. 
Description of Variables 
The outcome variable was the continuous M. bovis BTM ODC%. Four explanatory variables were 
tested as potential explanatory variables of the M. bovis BTM ODC%. 
 The apparent prevalence of antibody positive lactating cows: This variable was calculated as the 
proportion of cows with individual-ELISA ODC% ≥ 37 in milk out of all tested cows in the herd 
on the sampling d. 
 The apparent prevalence of antibody positive young stock: This variable was calculated as the 
proportion of young stock with individual-ELISA ODC% ≥ 37 in blood out of all tested young 
stock in the herd on the sampling d. 
 The apparent prevalence of antibody positive lactating cows > 50 ODC%: To assess if there was an 
effect of the ELISA cut-off used for apparent prevalence calculations, the apparent prevalence 
was also calculated as the proportion of cows with individual-ELISA ODC% > 50 (ELISA50) in 
milk. 
 Herd Size: Herd size was calculated as the average number of cows in the herd, in the quarter of 
the yr where the BTM sample was collected.  
An observation was excluded if it was not possible to match the date of the apparent prevalence 
with a BTM sample within ±30 days or if the number of animals for the prevalence calculations was 
low (n < 30). 
Statistical Analysis 
Scatter plots of all the explanatory variables plotted against each other were assessed in order to 
evaluate whether there were linear relationships between the variables. Variables which were 
highly correlated (ρ > 0.8) were not included in the same model.  
Two linear mixed effects models were created. The models were built by backwards stepwise 
elimination of non-significant variables and their 2-way interactions. The criteria for keeping a 
variable in the model was p < 0.05, and the model fit was assessed by Akaike´s Information Criteria 
(AIC), the lower AIC the better model. The p-values were calculated as an ANOVA comparison 
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between a model with all variables and a model without the specific variable and its interaction 
terms.  
Herd was included as a random effect to account for clustering of BTM samples originating from the 
same herd. The explanatory degree of the model was assessed by calculation of the ratio: (Re-
Rfm/Re), where Re is the residual variance of the model only containing the random effect of herd 
and Rfm is the residual variance of the final model. Data management and analyses were made using “R: A language and environment for statistical computing” version 3.0.2 (www.r-project.org). 
 
Results 
Descriptive Statistics 
Data selection yielded 113 observations distributed on 37 herds with 2-5 observations per herd, on 
average 3 observations per herd. Descriptive statistics of the outcome, M. bovis BTM ODC% and 
explanatory variables are shown in Table 1. A visual presentation of the raw data is provided in 
Figure 2, where the BTM ELISA ODC% is plotted against the apparent prevalence of antibody 
positive lactating cows. 
 
Figure 2. Descriptive statistics showing the bulk tank milk Mycoplasma bovis (M. bovis) ELISA 
optical density measurement (ODC%) is plotted against the apparent prevalence of antibody positive 
lactating cows. 
 
When adding the prevalence of antibody positive young stock to the dataset, many observations 
were lost when limiting the prevalence calculation to ±30 days from the BTM date. Therefore 
another dataset was created that only contained the prevalence of antibody positive young stock 
and the BTM samples closest to the date of the prevalence calculation (n=116). Descriptive statistics 
of the young stock prevalence are shown in Table 2. From Figure 3 it is apparent that the prevalence 
Manuscript I 
81 
  
of antibody positive young stock did not correlate well with the BTM M. bovis ELISA ODC%, and the 
variable was therefore not included in further analysis.  
 
Figure 3. Bulk tank milk Mycoplasma bovis (M. bovis) ELISA optical density measurement (ODC%) 
plotted against the apparent prevalence of antibody positive young stock.  
 
Table 1. Descriptive statistics of bulk tank milk (BTM) Mycoplasma bovis (M. bovis) ELISA optical 
density measurement (ODC%) and the explanatory variables tested in models for BTM M. bovis 
ELISA ODC% in 37 herds (113 observations).  
 
 Min Q1 Median Q3 Max 
BTM M. bovis ELISA ODC%  
 6 19 26 36 87 
Prevalence of antibody positive lactating cows (≥37 ODC%)  
 0 0.04 0.1 0.18 0.77 
Prevalence of antibody positive lactating cows (>50 ODC%)   
 0 0.02 0.05 0.1 0.49 
Herd size  
 76 201 273 367 779 
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Table 2. Descriptive statistics of the prevalence of Mycoplasma bovis antibody positive young stock 
(≥37 optical density measurement (ODC%)) in 39 herds (116 observations). 
Clinical signs  Min Q1 Median Q3 Max 
Prevalence of antibody positive young stock (≥37 ODC%) 
 
 0.00 0.12 0.28 0.38 0.66 
 
Analytical Statistics 
Collinearity was found between the apparent prevalence of antibody positive lactating cow and 
ELISA50, which were consequently not tested simultaneously, but with the same explanatory 
variables in different models.  
The resulting final model included only the apparent prevalence of antibody positive lactating cows. 
The model had the AIC closest to 0 and showed the best prediction when evaluating the plots of 
predicted vs. observed values visually. The final model explained 54% of the variation (Table 3). 
The predicted M. bovis ELISA ODC% in BTM is plotted against the observed values in Figure 4. 
Overall the model predicted the BTM values well, eventhough be a tendency towards 
overestimation of the high values, and underestimation of the low BTM values may have occured. 
 
Table 3. Results of the final model describing explanatory variables and random effects of bulk tank 
milk (BTM) ELISA optical density measurement (ODC%) for Mycoplasma bovis 
Variables (Explains 54% of the variation) 
Random effects Variance  S.D. 
Herd 19  4 
Residuals 80  9 
    
Fixed effects Estimate S.E. P-value 
BTM ELISA ODC% (intercept) 17 1.4 - 
Prevalence of AB positive lactating                   
cows (per 10% increase) 
9 0.7 < 0.001 
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Figure 4. Predicted bulk tank milk Mycoplasma bovis ELISA optical density measurement (ODC%) 
values plotted against observed values for the model (n=113). The line shows the regression line 
between observed and predicted values. 
 
Discussion 
Our objective was to test the associations of different factors with the variation in BTM antibodies 
against M. bovis in Danish dairy herds. We found that a rather large proportion of the variation 
could be explained by the apparent prevalence of antibody positive lactating cows. 
The prevalence of antibody positive lactating cows was positively associated with the BTM ODC%. 
Each time the prevalence increased by 10% the BTM ODC% increased by 9 ODC%. This means that 
with increasing number of antibody positive cows in the herd, indicative of recent spread of M. bovis 
bacteria, we can expect the BTM ODC% to increase. This association is in agreement with other 
studies on other infectious diseases in dairy herds (Nielsen and Ersbøll, 2005; Muskens et al., 2011; 
Taurel et al., 2012). For Salmonella Dublin, Nielsen and Ersbøll (2005) in addition found that the 
degree of explanation increased when including the prevalence or number of high ELISA-
responders and whether or not the herd had had a positive BC for Salmonella Dublin. In our study, 
the prevalence of high ELISA-responders could not be included in the same model as the prevalence 
and unfortunately we did not have sufficient BC-results for M. bovis from all farms or 
comprehensive and consistant systematic recordings of clinical disease associated with M. bovis in 
individual animals, which would have been interesting to study the effect of. 
Eventhough the prevalence of antibody positive cows is associated with the BTM ODC%, it is more 
ambiguous than seen with other diseases. In our dataset and according to our final model, the 
prevalence of antibody positive cows was above 30% before the BTM on average went above the 
cut-off of 37 ODC% (Table 3 and Figure 2) indicating that a large proportion of the cows had to have 
been exposed to M. bovis to make the BTM antibody testing able to detect it with reasonably Se and 
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Sp (Nielsen et al., 2015).  This hampers the ability to classify herds based on a BTM sample. A more 
persistent pattern has been found for Coxiella burnetii measurements in BTM where all samples 
above the cut-off value had a within-herd prevalence of at least 20% (Muskens et al., 2011). The 
discrepancy may arise because many M. bovis clinically diseased and medically treated cows do not 
contribute to the bulk tank. The apparent prevalence in our study stems from samples from 
individual cows at milk recording. Most of these cows would have contributed to the BTM on the 
day they were sampled. A minor part of medically treated cows could also have been part of milk 
recording, but the milk from those cows would not have entered the BTM due to procedures for 
preventing antibiotic residues entering the milk for consumption.   
As mentioned in the introduction, the use of antibodies to detect disease among individual animals 
is not straight forward, and clinical disease is not always followed by a rise in antibodies (Maunsell 
et al., 2011). Unfortunately, evaluation of antibody reactions in individual animals in field studies is 
sparse. On group level, however, antibody titers show correlation with disease in beef cattle (Martin 
et al., 1990), which would suggest that the same could be the case for dairy herds. There is also a 
lack of investigations of the correlation between antibodies in milk and serum in the literature, but 
the manufacturer of the used ELISA test states in a data-sheet about the test that the correlation is 
0.59 (http//www.biox.com/Default.aspx?tabid=64&udtid=215). In an unpublished field study (L. 
Nielsen, University of Copenhagen, Frederiksberg, Denmark) from Denmark 1442 paired serum and 
milk samples from 8 dairy herds had a correlation of 0.7. When considering the different clinical 
manifestations of M. bovis disease, it could be that antibodies in milk are not a good measure of on-
going disease in a dairy herd. A better understanding of the correlations between different clinical 
signs, extretion of bacteria and serum and milk antibodies would help interpret the BTM antibody 
response. 
Herd size was not associated with the BTM ODC% in herds in this study. Other studies have found 
an increasing probability of isolating M. bovis by BC from the BTM with increased number of 
lactating cows (Thomas et al., 1981; Pinho et al., 2013). This is probably related to the different 
outcomes in the studies, and the fact that in our model the presence of M. bovis is already taken into 
account by the within-herd prevalence. Our study investigated the factors associated with variance 
in BTM ODC%, while the other studies have investigated risk factors for a BC-positive BTM. With 
increasing herd size there is a risk that the contribution of antibodies to the BTM by 1 cow becomes 
diluted (Nekouei et al. 2015). For Salmonella Dublin a better explanation of the BTM ODC% was 
found when using the mean yield-corrected ODC%, also indicating a dilution effect in the BTM 
(Nielsen and Ersbøll, 2005). This was not the case in our study.  
As mentioned earlier, M. bovis can give rise to a variety of clinical signs in different age groups; thus 
a BTM sample may  or may not be able to detect all types of disease manifestations in a herd. Two 
questions arise from this: (1) is it possible to detect disease among young stock in the BTM, and (2) 
is it possible to detect all types of disease manifestations among cows in the BTM. We included the 
prevalence of antibody positive young stock as an explanatory variable to partially clarify this issue. 
The prevalence of antibody positive young stock did not correlate with the BTM ELISA ODC%, 
indicating that the status of young stock is not reflected in the BTM. Hence, to determine the status 
of the young stock, samples from individual animals are probably needed. Further studies on this 
matter are definitely warranted.  
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The other part of this question is whether or not disease among cows manifested primarily as e.g. 
arthritis will be detectable in a BTM sample. Unfortunately, we do not have systematically recorded 
information about the prevalence of the different disease manifestations in the different herds, so 
this issue cannot be further elucidated in this study. Further studies where the distinction in the 
expression of clinical disease can be made are warranted. 
 
Another model with the prevalence of lactating cows based on ELISA50 as the explanatory variable 
instead of the prevalence at the recommended cut-off at 37 ODC% was tried. This did not change 
the model fit when the other explanatory variables were the same (results not shown). The reason 
for exploring the effect of changing the cut-off is that there is a lack of evidence for the optimal 
ELISA cut-off at animal-level with regard to detection of infected or infectious animals within 
infected herds. A higher cut-off might detect more truly infected animals as opposed to previously 
exposed animals, and hence the ELISA50-prevalence might be better correlated with the BTM-
antibody level. However, this did not seem to be the case. We did not try with high cut-off values, 
because there were few cows with higher ELISA-responses.  To the best of the authors’ knowledge no studies have evaluated antibodies in BTM as a diagnostic 
tool for M. bovis in relation to the underlying disease manifestation in dairy herds. Nielsen et al. 
(2015) evaluated the overall performance of the BTM-test method for national or regional 
screening purposes and provided stimates of Se, Sp and predictive values. However, the estimates 
were associated with much uncertainty due to few test-positive herds in the dataset. The results of 
that study and the present study complement each other. Our study illustrates that the lack of Se 
may be due to the fact that quite high prevalences of affected animals are required for the BTM 
antibody level to increase. As discussed above the results from our study are in overall agreement 
with similar studies about other infectious diseases such as Salmonella Dublin, bovine viral diarrhea 
virus and Coxiella burnetii infections (Nielsen and Ersbøll, 2005; Muskens et al., 2011; Taurel et al., 
2012).  However, we also found some challenges that have to be addressed in order to use BTM-
ELISA testing as a tool in herd level M. bovis diagnosis of dairy herds.   
In most instances, the prevalence estimates were not based on the same date of sampling, but 
within ±30 d of the BTM sample. Hence, we cannot be certain that milk from all the individual cows 
used for calculating the prevalence was present in the BTM sample. To evaluate the limitation of 
this, a dataset consisting of 87 of the observations (75%) sampled within ±14 d of the BTM sample 
were used to rerun the final model. This rerun model yielded approximately the same estimates as 
the model based on the larger dataset, and did not make the predictions for the model better. 
Hence, our final model appeared to be robust to the uncertainties in the prevalence estimation 
related to the time of BTM sampling. In individual animals the antibody response can persist for at 
least 6 month (Nicholas et al. 2002). Nontheless, from our data it seems to be  important to realize 
that the BTM antibody level is actually quite dynamic, and a high response in BTM does not 
necessarily persist for long time (Figure 1). 
The repeated measurements in theory have a temporal structure, but this was ignored and a simple 
random effect used because any temporal effects from such a small number of repeated 
measurements were considered to be uninteresting and to have a small effect on the data. In 
addition, our primary interest was not to describe the nature of the dependency between the BTM-
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measurements, so the random effect was merely included to take potential dependencies into 
account in order not to overestimate the effect of the explanatory variables in the final model.  
Conclusions 
The objective was to identify factors that influence the variation in BTM ELISA ODC% against M. 
bovis in Danish dairy herds. Increasing prevalence of antibody positive cows was associated with 
increasing M. bovis BTM ELISA ODC%. In contrast, the prevalence of antibody positive young stock 
did not correlate with the BTM ODC%. Herd size was not associated with M. bovis BTM ELISA 
ODC%. A combination with distinction between different clinical signs would be very interesting, 
but the available data did not support such investigation. More studies to investigate risk factors for 
variance in BTM ELISA ODC% for M. bovis and potential combinations of test-procedures to use for 
herd classifications are warranted before this method can be deemed useful for disease control 
purposes. 
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Abstract 
In cattle, Mycoplasma bovis (M. bovis) is an important pathogen causing disease and substantial 
economic losses. However, knowledge of the dynamics of antibody responses in individual cows in 
the face of an outbreak is currently extremely limited. The use of commercial antibody tests to 
support clinical decision making and for surveillance purposes is therefore challenging.  
Our objective was to describe the dynamics of M. bovis antibody responses in four Danish dairy 
herds experiencing an acute outbreak of M. bovis associated disease, as well as to compare the 
antibody dynamics between dairy cows with different disease manifestations. A total of 120 cows 
were examined using a standardized clinical protocol and categorized into four disease groups: ‘Mastitis’, ‘Systemic’, ‘Non-specific’ and ‘None’. Paired blood and milk samples were collected and 
tested using a commercial M. bovis antibody detecting ELISA. Plots of raw data and generalized 
additive mixed models with cow and herd as random effects were used to describe serum and milk 
antibody dynamics relative to the estimated time of onset of clinical disease. 
Cows with mastitis had high optical density measurement (ODC%) of antibodies in both milk and serum at disease onset. The estimated mean ODC% in milk was below the manufacturer’s cut-off for the other groups for the entire study period. The estimated mean serum ODC% in the ‘Systemic’ 
group was high at onset of disease and stayed above the cut-off until 65 d after disease onset. 
However, the lower 95% confidence interval (CI) for the mean ODC% was only above the manufacturers’ cut-off between 7 to 17 d after onset of disease. The CI of the ‘Systemic’ and ‘None’ 
groups did not overlap at any time between the d of disease onset and 65 d after disease onset, and 
the estimated mean ODC% for both the ‘Non-specific’ and ‘None’ groups were generally below the 
cut-off for the majority of the study period. In conclusion, the serum antibody responses were 
highly dynamic and showed a high level of variation between individual cows. This strongly 
suggests that serology is unlikely to be useful for individual diagnosis of M. bovis associated disease 
in dairy cows. However, it might still be useful for herd- or group-level diagnosis. Antibodies in milk 
were only increased in cows with M. bovis mastitis, indicating that milk antibody measurements 
only have diagnostic utility for cows with mastitis. 
 
Keywords: Mycoplasma bovis, ELISA, antibody, BioX Bio K 302, dairy cow 
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Introduction 
Mycoplasma bovis (M. bovis) is an infectious disease of cattle that is associated with a diverse 
spectrum of clinical signs and substantial production losses worldwide (Nicholas, 2011). In cows, M. 
bovis typically causes mastitis, arthritis and pneumonia (Maunsell et al., 2011), whereas pneumonia, 
otitis media and arthritis are more commonly seen in calves (Maunsell and Donovan, 2009). The 
preferred method of diagnosing M. bovis has historically been bacteriological culture of body fluids 
(e.g. milk and joint fluids) or swabs (e.g. eye and nasal swabs) from individual animals, as well as 
bacteriological culture of bulk tank milk for herd-level diagnosis. Even though PCR is becoming 
more frequently used due to reductions in cost and processing time (Wawegama and Browning, 
2017), these methods can be poorly sensitive in practice due to intermittent shedding patterns, and 
difficulties in obtaining the best sample materials from the infected animals on which to apply these 
tests. Therefore there is an increasing interest in using serology for M. bovis diagnostics.  
In Denmark, serological assays such as ELISA are frequently used for testing dairy cows, because 
they are inexpensive and convenient, especially if applicable to milk samples routinely collected for 
other purposes. Two commercial ELISA kits are available from BioX Diagnostics in Belgium; one of 
these (BioX Bio K 260) has been shown to have little correlation with the occurrence of disease and 
with PCR and bacterial culture results (Szacawa et al., 2015; Szacawa et al., 2016). However, these 
studies aimed mainly to compare antibody measurements to other diagnostic tests using cross-
sectional study designs that are not suitable for the assessment of dynamics and persistence of 
antibodies. Nielsen et al (2015) found that for the BioX Bio K 302 ELISA it might be beneficial to 
raise the cut-off for herd-level diagnosis to 50 ODC% in bulk tank milk to increase the specificity, 
but no field study evaluations of cut-off values at animal level have been published. Therefore, the 
cut-off of 37 ODC% as recommended by the manufacturer is used in practice despite the lack of 
substantial documentation for the validity of this threshold. 
Appropriate interpretation of ELISA test results requires knowledge of the dynamics and duration 
of excretion of antibodies against M. bovis relative to the time of infection and onset of associated 
disease. However, as recently pointed out by Hazelton et al. (2018), there is currently a limited 
understanding of the dynamics of antibodies directed against M. bovis in terms of time to 
seroconversion and longevity in naturally exposed cattle. The antibody response has been shown to 
remain high in both milk and serum for as long as 20 weeks after both experimental inoculation in 
the udder and naturally occurring M. bovis-associated mastitis (Boothby et al., 1987; Byrne et al., 
2000). However, the M. bovis antibody response to systemic disease such as arthritis has not yet 
been fully described. Work in calves vaccinated against M. bovis with an experimental vaccine at the 
age of three weeks showed that the animals appeared to seroconvert within 14 d, and that a high 
IgG level was maintained for at least 42 d in serum (Nicholas et al., 2002). Apart from this work in 
individual animals, serology has been suggested to be useful for herd-level diagnostics (Le Grand et 
al., 2002; Martin et al., 1990).  
Further investigation of ELISA test result patterns in milk and serum from naturally exposed and 
diseased dairy cows is therefore warranted. In particular to understand how the ELISA response 
can be expected to develop over time in animals with varying clinical signs of M. bovis-associated 
disease compared to exposed animals without overt clinical signs. The objective of this study was 
therefore to describe the temporal dynamics of antibody responses to M. bovis in serum and milk 
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taken from individual dairy cows in herds experiencing a M. bovis disease outbreak, with a 
particular emphasis on differences in these patterns between groups of animals exhibiting different 
disease manifestations.  
 
Materials and Methods 
Study Design 
This study was a longitudinal observational study in Danish dairy cattle herds. To fulfill the 
objective of describing dynamics of antibody responses in exposed animals, only herds experiencing 
acute outbreaks of M. bovis- associated disease within the study period were eligible for inclusion. 
This was based on the likely presence of M. bovis-associated disease as diagnosed by the herd 
advisory veterinarian based on positive PCR or ELISA test results, and an outbreak was defined as 
having several animals with clinical signs of either mastitis (Maunsell et al., 2011), arthritis and/or 
subcutaneous swelling of the limbs (Henderson and Ball, 1999; Wilson et al., 2007) and/or 
pneumonia (Maunsell et al., 2011) and positive M. bovis ELISA or PCR tests.  
Four herds were identified as matching these criteria and permission was obtained from each herd 
to undertake an outbreak investigation. Each herd was visited five times, at approximately three-
week intervals, during the period 1st July 2015 to 5th April 2016. The herd visits were initiated as 
closely as possible following the presumed date of onset of the disease outbreak. At all visits, the 
aim was to assess the clinical status using a standard protocol and to collect paired blood and milk 
samples from selected individual cows. Where possible, the same animals were sampled at each 
visit. As many repeated samples as possible were obtained from as large a number of individual 
animals as the project budget would allow. Where it was not possible to resample the same animals, 
new animals were sampled.  
Study Population 
All four of the identified herds had a history of sudden onset of M. bovis related clinical signs in the 
cows and/or calves, and several strongly positive ELISA and/or PCR test results for M. bovis (Table 
1). During the study period, one or more cows from all study herds tested positive at least once in 
ELISA or PCR. Detailed farm information obtained before and after enrolment is given in Table 1.  
Although bacterial cultures were not included in the study design due to financial constraints, a few 
calves were euthanized due to severe disease and autopsies were performed. A calf from Herd 2 had 
chronic degenerative arthrosis in several joints, and bronchopneumonia with overlying pleuritis. M. 
bovis was cultured from joint fluid, and joint fluid and lung tissue were found positive for M. bovis by 
PCR. Two calves autopsied from Herd 4 had chronic omphalitis, bronchopneumonia, synovitis in 
several joints and bilateral otitis media. Mycoplasma spp. were cultured from both calves, and typed 
by PCR to be M. bovis. From Herd 3, two calves were autopsied and arthritis and otitis media were 
found in both animals, but no bacterial pathogens were isolated. 
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Table 1. Summaries of the four Danish dairy herds in the study and results of different diagnostic tests 
performed prior to and during the study period 1st of July 2015 to 5th of April 2016. 
Herd no. Herd 1 Herd 2 Herd 3 Herd 4 
Knowledge prior to enrolment 
Number of cows  177 174 182 391 
Primary clinical 
signs in cows 
Mastitis, 
pneumonia 
Mastitis,  
arthritis 
Arthritis Mastitis,  
arthritis 
Positive serum 
ELISA1 
Yes Yes Yes Yes 
Positive PCR2 Yes Yes No Yes 
Outbreak start 
(according to the 
farmer) 
Early June  
2015 
Early July  
2015 
Late November 
2015 
Mid December 
2015 
Knowledge after enrolment 
Data collection 
period 
1st July  
2015 - 
16th September 
2016 
20th July  
2015 - 
6th October  
2015 
8th December 
2015 - 
23th February 
2016 
20th January  
2016 - 
5th April  
2016 
Primary affected 
age group 
Cows Cows and calves Cows Cows and calves 
Primary clinical 
signs 
 
Cows Mastitis Mastitis, arthritis Arthritis Mastitis, arthritis 
Calves Pneumonia, 
otitis media 
Arthritis,  
otitis media, 
pneumonia 
 Arthritis,  
otitis media, 
pneumonia 
Diagnostic tests     
Positive ELISA3 
(total) 
    
Serum 35 (120) 35 (98) 52 (134) 48 (95) 
Milk 41 (119) 24 (87) 20 (130) 14 (94) 
Positive PCR2 
(total) 
8 (119) 15 (87) 6 (131) 30 (94) 
1 ODC% values ≥ 37 for Mycoplasma bovis antibodies in BioX Bio K 302 or 260 (BioX Diagnostics, Belgium)  
2 composite milk samples, Ct value ≤ 37 for M. bovis in PathoProof Mastitis Major-3 (Thermo Scientific, USA). 
3 ODC% values ≥ 37 for Mycoplasma bovis antibodies in BioX Bio K 302 (BioX Diagnostics, Belgium) 
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Sample Collection 
The project budget allowed for the inclusion of approximately 80 cows in total, with each being 
tested five times. However, during an outbreak of M. bovis it is likely that some cows would be 
culled due to clinical disease, so we therefore allowed for more cows to be included at the first or 
consecutive visits. Therefore, a minimum of 20 cows were identified from each farm during the first 
herd visit. The cows were sampled strategically to ensure that a sufficient number of cows with 
clinical suspicion of M. bovis-associated disease were included along with a sample of cows without 
such clinical disease suspicion. New cows suspected of having M. bovis-associated disease at 
subsequent visits were also included. The rationale behind this non-random sampling strategy was 
to maximize the chances of including sufficient numbers of animals with and without different 
clinical signs. 
At each visit, the selected cows were subject to a clinical examination focusing on the respiratory 
system, udder, and musculoskeletal system using a standardized clinical protocol (Appendix). The 
clinical examination was done by one of three veterinarians, of whom two had collaboratively 
developed the clinical protocol. At least one of these was present at each visit, and the use of the 
clinical protocol was demonstrated for the benefit of the third veterinarian that had not helped to 
develop the protocol. 
In addition to the clinical examination, a venous blood sample was collected in a 10 ml Vacutainer 
plain tube (Kruuse, Denmark), and one composite milk sample was collected in a bronopol coated 
tube from each cow. Samples were stored in a cool environment, and delivered to Eurofins Steins 
Laboratory (Vejen, Denmark) within 36 hours.  
Laboratory Test Methods 
All samples were analyzed for antibodies directed against M. bovis using the commercial kit BioX 
Bio K 302 (BioX Diagnostics, Rochefort, Belgium). The assay was performed according to the manufacturer’s instructions for use. The optical density coefficient was calculated as: 
ODC% = (ODsample – ODnegative control) / (ODpositive control – ODnegative control) x 100% 
where OD is the optical density measured by the ELISA reader of each test sample and the positive 
and negative control on the sample ELISA plate. An ODC% ≥ 37 was considered positive, as 
recommended by the manufacturer. The manufacturer has reported a sensitivity and specificity of 
the test at 100% based on a small sample of experimentally infected calves and negative control 
calves (Anonymous, 2017). However, lower accuracy has been reported under field conditions 
(Hazelton et al., 2018; Wawegama et al., 2016). 
Milk samples were analyzed for presence of M. bovis DNA with the commercial PCR kit PathoProof 
Mastitis Major-3 assay (Thermo Scientific, Waltham, USA) at Eurofins Steins Laboratory. A cycle 
threshold (Ct) value ≤ 37 was considered positive in the PCR, as recommended by the 
manufacturer.  
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Grouping of Cows for Analysis 
Following the completion of the data collection period, individual animals were categorized into 
disease groups to facilitate stratification of descriptive statistics and modeling of antibody response 
dynamics. The three primary groups were as follows: 
1) Likely M. bovis-associated mastitis (‘Mastitis’) 
2) Likely M. bovis-associated systemic disease (‘Systemic’) 
3) No disease believed to be associated with M. bovis (‘None’) 
In addition, a fourth group was defined for the remaining animals that could not be reliably 
assigned to any of the above groups 1-3: 
4) Disease that is not typically associated with M. bovis, but where M. bovis could not reasonably be excluded (‘Non-specific’). 
Classification was based on the recorded clinical signs and photographs taken of the selected cows 
during the herd visits, according to the specific inclusion criteria as follows: 
 1) Mastitis: cows with recordings of mastitis, defined as any visual abnormality in the milk 
and a M. bovis positive milk PCR at one or more herd visits; 
 2) Systemic: cows with clinical signs indicating systemic spread of M. bovis. All cows in this 
group had arthritis and/or subcutaneous edema in the limbs at one or more herd visits. In 
addition to these clinical signs from the musculoskeletal system, 3 cows had clinical signs of 
respiratory disease, 2 had drooping ears and 12 had mastitis. 
 3) None: cows with no clinical signs, and cows with only clinical signs that are not likely to 
be associated with M. bovis. These included hock lesions, wounds, claw lesions, cows with a 
dry quarter and lameness without joint swelling. However, due to the presence of clinical 
signs in co-managed animals, it is assumed that these animals were exposed to the pathogen. 
 4) Non-specific: cows that had clinical signs that are not typical for M. bovis, but where M. 
bovis could not be excluded. Clinical signs in this group were minor, short term limb 
swellings, and/or mastitis (without an M. bovis PCR positive test), mild/short term 
respiratory signs, keratoconjunctivitis and abscesses. 
 
All four groups were modeled separately in order to facilitate the focus on the differences of the 
temporal dynamics between groups. Twelve cows fulfilled the criteria for being in both the ‘Mastitis’ and the ‘Systemic’ group and they are subseqently referred to as ‘dual-syndrome’ cows. They are included in both the ‘Mastitis’ and the ‘Systemic’ group for analysis of antibody dynamics. 
Primary Explanatory Variable of ‘Days from disease onset’ 
 The primary explanatory variable for the longitudinal analysis was the number of d between the 
estimated disease onset in the individual cow and the sample date for the relevant ELISA result. It 
was not possible to determine this exactly, but was estimated from the first date of observed clinical signs in each cow. To make this as accurate as possible, records from the farmers’ electronic disease 
recording system and written records from the consulting veterinarians were used where available. 
In 39% of the cows, a similar diagnosis as the one given at the herd visit was recorded by farmer or 
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veterinarian within one week prior to the herd visit, and this d was then set as the d of disease 
onset. In 61% of the cows the d of disease onset was recorded as the date of the herd visit at which 
the clinical sign was detected for the first time. To be able to make comparisons between all groups, cows in the ‘Non-specific’ group were assigned a representative imputed date that was sampled 
from the distribution of estimated disease onset dates from the cows in the ‘Mastitis’ and ‘Systemic’ 
groups within the same herd.  
Modeling of Antibody Responses 
To investigate the potentially non-linear temporal patterns of antibody responses, we selected an 
explorative approach to avoid imposing a pre-specified functional form to the antibody dynamics 
over time. Four separate generalized additive mixed models (GAMM) were used for the two 
outcomes (serum and milk) in each of the four disease groups, i.e. eight models in total. ODC% was 
log-transformed to improve the normality of the residuals. To allow log-transformation of a small 
number of ELISA-values that were recorded as numerically 0, a fixed constant of 1 was added to all 
ODC%. The data used for the models were restricted to the most relevant time periods of between 
21 d prior to disease onset up to 80 d after disease onset (Figure 1). As well as reflecting the most 
relevant time period in relation to the presumed date of onset of clinical signs, this procedure also 
ensured that time periods were limited to those with observations from a minimum of three cows.  
A thin plate regression spline was used to fit the non-linear effect of d from disease onset, and 
random effects of cow identification number (Cow) and herd identification number (Herd) were 
included to account for repeated samples from the same cow and clustering of cows within herds. 
Confidence intervals for the predicted mean ODC% values (with random effects of herd and cow set 
to zero) were calculated and plotted for each disease group and outcome. Model fit was assessed for 
each model by evaluating the distribution of the residuals. All data management and analyses were 
done in R version 3.2.2 (R Core Team, 2016), using the gamm function in the mgcv package to 
implement the GAMM (Wood, 2011). 
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Results 
Descriptive Statistics 
In total, 120 cows were enrolled in the study, and 447 blood samples and 431 milk samples were 
collected. See Table 2 for detailed information about number of cows and samples stratified by 
herd. 
 
Table 2. Number of cows and samples in each disease group, stratified by herd.  
Herd no. 
Total ‘Mastitis’ ‘Systemic’ ‘Non-specific’ ‘None’ 
Serum Milk Serum Milk Serum Milk Serum Milk Serum Milk 
Herd 1            
Cows 29 29 2 2 0 0 16 16 11 11 
Samples 120 119 7 7 0 0 62 62 51 50 
Herd 2           
Cows 25 24 3 3 14 13 0 0 10 10 
Samples 98 87 9 7 54 46 0 0 43 40 
Herd 3           
Cows 32 32 1 1 19 19 6 6 6 6 
Samples 134 131 5 5 74 75 27 26 28 25 
Herd 4           
Cows 34 34 12 12 21 21 5 5 6 6 
Samples 95 94 16 16 53 52 19 19 21 21 
Total           
Cows 120 119 18 18 54 53 27 27 33 33 
Samples 447 431 37 35 181 173 108 107 143 136 
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Cows were sampled an average of 3.7 times, with Herd 4 having the lowest average number of 
observations per cow (2.8) (Table 3). This reflects the fact that many cows with mastitis were 
slaughtered or culled soon after disease onset in Herd 4. It was not possible to collect milk samples 
from cows that were dried off during the study period, but clinical examination and blood samples 
continued to be collected during the dry period. Reasons for loss from the study were culling, 
slaughter or movement to another property for drying-off.  
 
Table 3. Average number of samples per cow and the distribution of samples per cow, stratified by 
herd. 
 Average One  
sample 
Two 
samples 
Three 
samples 
Four 
samples 
Five 
samples 
Herd 1 4.1 0 6 1 5 17 
Herd 2 4 4 1 2 4 14 
Herd 3 4.2 4 0 1 8 19 
Herd 4 2.8 13 3 3 8 7 
Total 3.7 21 10 7 25 57 
 All but one of the cows in the ‘Mastitis’ group had a serum result that was well above the manufacturer’s cut-off on the day of disease onset, and most of the cows declined rapidly in ODC% 
following the date of onset (Figure 1A). 
A total of 27 out of 54 (50%) of the cows with systemic M. bovis-associated disease had serum 
results that were above the cut-off for the entire study period (Figure 1B). A total of 15 out of 54 
(28%) cows with systemic disease were not above the cut-off at any point in time, and 12 of the 54 
(22%) cows had some samples above and some below the cut-off during the study period. The 
antibody responses slowly declined for most of the cows, ending up below the cut-off before or at 
the last visit.  A total of 22 out of 33 (67%) of the cows in the ‘None’ group had serum results that were below the 
cut-off for the entire study period (Figure 1C). One out of 33 (3%) cows was above the cut-off for 
the entire study period, and 10 out of 33 (30%) cows had some samples above and some below the 
cut-off during the study period. A total of 2 out of 27 (7%) of the cows in the ‘Non-specific’ group had serum results that were above 
the cut-off for the entire study period (Figure 1D). A total of 8 out of 27 (30%) cows were below the 
cut-off at all points in time, and 17 of the 27 (63%) cows had samples above and below the cut-off during the study period. On average, the ODC% values in the ‘Non-specific’ group were lower than 
in the systemically diseased group.  
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Figure 1. Distribution of serum ELISA measurements for antibodies directed against Mycoplasma 
bovis in the four disease groups of dairy cows from four Danish herds. ‘Dual-syndrome’ cows are 
colored in grey. Horizontal dotted lines show the recommended ELISA cut-off (37 ODC%). Vertical 
dotted lines indicate the temporal limits for inclusion in the modeling of antibody response 
dynamics (d -21 and 80 relative to disease onset). ODC% = sample coefficient. Results from the 
same cow are linked by lines. 
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Figure 2. Distribution of milk ELISA measurements for antibodies directed against Mycoplasma 
bovis in the four disease groups of dairy cows from four Danish herds. ‘Dual-syndrome’ cows are 
colored in grey. Horizontal dotted lines show the recommended ELISA cut-off (37 ODC%). Vertical 
dotted lines indicate the temporal limits for inclusion in the modeling of antibody response 
dynamics (d -21 and 80 relative to disease onset). ODC% = sample coefficient. Results from the 
same cow are linked by lines. Three observations with ODC% > 250 are shown as 250 ODC%. 
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The overall pattern was less consistent for milk samples than for serum in the ‘Mastitis’ group. A 
total of eight out of 18 (44%) cows with M. bovis mastitis had milk results that were above the cut-
off for the entire study period. A total of seven out of 18 (39%) cows had milk results that were 
below the cut-off for the entire study period and two of the 18 (11%) cows had milk results above 
and below the cut-off during the study period (Figure 2A).  
A total of 11 out of 53 (20%) cows with systemic M. bovis disease had milk results that were above 
the cut-off for the entire study period (Figure 2B) and five of these cows also had M. bovis mastitis. A 
total of 22 out of 53 (42%) cows had milk results that were not above the cut-off at any time, and 20 
of the 53 (38%) cows had milk results above and below the cut-off during the study period.  A total of 23 cows out of 33 (70%) cows in the ‘None’ group had milk results that were below the 
cut-off for the entire study period (Figure 2C). A total of three out of 33 (9%) cows had milk results 
above the cut-off for the entire study period and 7 of the 33 (21%) cows had milk results above and 
below the cut-off during the study period. A total of 4 out of 27 (15%) cows in the ‘Non-specific’ group had milk results that were above the 
cut-off for the entire study period (Figure 2D), whereas 14 out of 27 (52%) cows had milk results 
that were below the cut-off at all times, and 9 of the 27 (33%) cows had milk results both above and 
below the cut-off during the study period.  
Modeling Results 
A total of eight separate models were used for the two outcomes (log-transformed milk and serum 
ODC%-values) and four disease groups, although meaningful results could not be obtained for the ‘Mastitis’ group models of either milk or serum samples due to sparse and highly variable data 
(Figures 1A and 2A). Visual inspection of residual plots indicated an acceptable model fit for the 
remaining six models, results of which are presented below. 
The estimated number of degrees of freedom (edf) for the smooth term describing the effect of d 
from disease onset indicates the complexity of the function, with values of 1 indicating a simple 
linear function. Based on the edf, substantial non-linearity was evident in the ‘Systemic’ group for both milk and serum and in the ‘None’ group for milk. The standard deviation associated with the 
random effect of Cow was larger than the residual standard deviation in all the models, and the 
random effect attributed to Herd was generally smaller than that attributed to Cow. However, the 
random effect of Herd is likely to be underestimated due to the small number of herds included in 
the study, so some of the true differences between herds are likely included in the Cow random 
effect estimate. We therefore consider only the combined effect of Cow and Herd relative to the 
residual standard deviation as a meaningful comparison (Table 4). 
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Table 4. Results of the final models with antibody optical density measurement (ODC%) for 
Mycoplasma bovis in serum and milk as outcome in different disease groups.  
Disease group ‘Systemic’ ‘None’ ‘Non-specific’ 
Serum Milk Serum Milk Serum Milk 
Random effect (SD)1    
Combined Cow/Herd level 0.88 1.14 0.49 0.80 0.62 1.08 
Residuals 0.43 0.65 0.35 0.47 0.46 0.53 
       
Smooth term (edf)2    
Days from onset of disease 4 2.3 1 1.6 1 1 
1 SD, standard deviation  
2 edf, estimated degrees of freedom 
 
The estimated mean ODC% in serum in the ‘Systemic’ group was estimated to be high at the time of disease onset, and remained above the manufacturers’ cut-off until 65 d after disease onset (Figure 
3, red line). The 95% confidence intervals (CI) follow the same pattern, but indicate that the mean 
ODC% was clearly above the cut-off only between 7 - 17 d after disease onset in this group. The estimated mean ODC% with 95% CIs in the ‘None’ group were below the cut-off for most of the time period, and there was no overlap of CI between the ‘Systemic’ and ‘None’ group between one week before d of disease onset and approximately 68 d after disease onset (Figure 3). The CI of the ‘Non-specific’ group overlapped with the ‘None’ group during the whole study period, and only differed markedly from the ‘Systemic’ group according to the CIs between 7-20 d after disease onset. 
Estimated ODC% in milk was below the cut-off for all disease groups for the entire time period, with 
wide 95% CIs that overlapped substantially between disease groups throughout the study period 
(Figure 4).  
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Figure 3. Estimated mean antibody response in serum (solid line) and 95% confidence intervals (shaded area) as measured by the BioX ELISA Bio K302. A (light grey) = ‘Systemic’ group (likely 
Mycoplasma bovis-associated systemic disease), B (dark grey) = ‘None’ group (no disease believed 
to be associated with M. bovis), C (black) = ‘Non-specific’ group (disease not typically associated 
with M. bovis, but where M. bovis could not be ruled out). The dashed black line shows the 
recommended ELISA cut-off (37 ODC%). 
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Figure 4. Estimated mean antibody response in milk (solid line) and 95% confidence intervals (shaded area) measured by the BioX ELISA Bio K302. A (light grey) = ‘Systemic’ group (likely 
Mycoplasma bovis-associated systemic disease), B (dark grey) = ‘None’ group (no disease believed 
to be associated with M. bovis), C (black) = ‘Non-specific’ group (disease not typically associated 
with M. bovis, but where M. bovis could not be ruled out). The dashed black line shows the 
recommended ELISA cut-off (37 ODC%). 
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Discussion 
This observational study is the first to illustrate and analyze the dynamics of the antibody response 
directed against M. bovis from milk and serum in naturally exposed and diseased dairy cows. The 
key findings were that the antibody responses varied markedly between cows and were very 
dynamic within individual cows. The serum antibody level generally declined within two months 
following the onset of clinical disease, even in cows with clear clinical signs of systemic M. bovis 
disease. The antibody level in milk was only high if cows had mastitis. 
In calves, the serum IgG-level has been found to rise between one and two weeks after vaccination 
(Nicholas et al., 2002) and intra-tracheal inoculation of M. bovis bacteria (Howard et al., 1986). The 
antibody responses observed in this study from cows that responded to infection were high from 
the estimated day of disease onset, which indicates either that the cows had been infected for a 
week or two before becoming sick, or that antibody responses in adult cows are faster and stronger 
than in young calves. In experimentally inoculated cows, the antibody responses in serum and milk 
have been found to increase within 7-10 d from inoculation (Boothby et al., 1986; Byrne et al., 
2005), indicating that the antibody responses in cows might be slightly faster than in calves. This 
also fits with the increasing pattern in estimated mean ODC% that can be observed in Figure 3 
between 0 to 14 d after disease onset. 
Antibodies against M. bovis in serum 
This study suggests that the level of serum antibodies generally increases in cows with M. bovis-
associated disease around the time of disease onset (Figures 1A, 1B and 3), which to our knowledge 
has not previously been described in naturally infected cows. For experimentally induced mastitis 
the same tendency has been found (Boothby et al., 1987), but no such studies about arthritis are 
published. It appears that ODC% in the ‘Mastitis’ group declined more quickly than the ‘Systemic’ group, but it is difficult to compare with so few samples in the ‘Mastitis’ group. Although we were 
not able to follow all cows until their antibody response declined below the cut-off, a faster decline 
in antibodies was seen for M. bovis relative to other diseases for which antibody measurements are 
commonly used in cattle, such as Salmonella Dublin (Nielsen, 2003) and bovine virus diarrhea virus 
(Fredriksen et al., 1999).  
The serum model for the ‘Systemic’ group was repeated excluding the 12 ‘dual-syndrome’ cows 
(with both mastitis and systemic disease) to assess the sensitivity of our results to the data from 
these animals. The shape of the curve was qualitatively similar, and the time period during which 
the confidence intervals did not overlap was the same, although the highest estimated mean declined by approximately 5 ODC% when excluding the 12 ‘dual-syndrome’ cows. Unfortunately it 
was not possible to repeat this procedure for the ‘Mastitis’ group, because excluding the ‘dual-syndrome’ cows left us with a sample size of only 6 animals in this group. However, we acknowledge that further investigation into specific features of antibody responses in ‘dual-syndrome’ cows exhibiting both sets of clinical signs, and how this differs from cows exhibiting only 
signs of mastitis, would be relevant for future studies.  Some of the cows in the ‘Systemic’ group did not exhibit an antibody response (Figure 1B). This included one of the 12 ‘dual-syndrome’ cows in this group, but that animal was only tested once. 
One explanation could be that the clinical signs in the non-responding cows were not due to M. bovis 
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infection, but some other pathogen/disease. We did not have the opportunity to diagnostically rule 
out other pathogens in this study. Another explanation for the lack of antibody responses could be 
that the ability to produce antibodies against M. bovis infection varies between individual cattle. It is 
unknown whether this difference between host responses is due to host (e.g. genetics) or pathogen 
factors, or a combination of the two. The antibody response to M. bovis has not been found to be 
correlated with treatment of bovine respiratory disease in calves (Rosendal and Martin, 1986), but 
no such studies have been conducted in cows. The antigenic variation in M. bovis bacteria is large 
and alterations of membrane surface lipoproteins occur during an outbreak, even between different 
sub clones of the same strain (Bürki et al., 2015). This might result in different antibody responses 
in cows with similar clinical signs. Despite the lack of a clear explanation for the fact that some cows 
did not produce measurable antibodies, this finding is in agreement with others who found little 
correlation between antibody measurements and clinical signs in cows (Szacawa et al., 2016). 
However, in that study the cows were not followed over time, so it was not possible to explain the 
missing correlation. 
Other authors have warned against using serology for individual M. bovis diagnosis (Maunsell et al., 
2011). Martin et al. (1990) suggested that antibodies directed against M. bovis are not correlated 
with disease in individual calves, but could be useful at group level. Our results also indicate that the 
ODC% are not well correlated with clinical disease in individual cows within herds with circulating 
M. bovis (Figure 1B). However, the estimated mean ODC% with corresponding 95% confidence 
intervals suggests that it is possible to use the average serum ODC% of a group of diseased animals 
to assess whether or not the clinical signs in the herd are likely to be associated with M. bovis 
infection for a period of up to 65 d after disease onset in the affected animals (Figure 3). It is beyond 
the scope of this study to identify optimal testing scenarios for group or herd diagnostics, but the 
results of the raw data for mastitis (despite the fact that a model could not be fit to these data) 
indicate that such a screening tool would also be relevant for outbreaks with mastitis cases, and not 
only systemic disease. 
Antibodies against M. bovis in Milk 
The level of antibodies against M. bovis in milk from cows other than those with M. bovis mastitis 
was low. Even if a cow had clear clinical signs of systemic spread of M. bovis, for example arthritis 
with antibodies detectable in serum, almost no antibodies were detectable in the milk. In contrast, 
the cows with mastitis had high levels of antibodies in both milk and serum, and the cows in the ‘Systemic’ group with high milk antibodies were primarily cows with both clinical signs of systemic 
disease and mastitis. Byrne et al. (2000) found that antibodies in milk remained high for a longer 
period in quarters infected with M. bovis compared to quarters not infected in the same cow, 
suggesting that the antibody response to M. bovis in the udder is primarily a local immune response, 
and to a lesser extent filtering of antibodies from serum to milk. Antibodies in milk can therefore 
only be used for diagnosis of cows with mastitis, and not for cows with systemic disease without 
mastitis. In mastitis cases in other studies, antibodies in milk lasted for at least 40 d (Boothby et al., 
1987; Byrne et al., 2000). We were not able to confirm this, as it was not possible to determine the 
duration of high antibody levels in milk in cows with mastitis due to culling/euthanasia of many of 
the cows with mastitis. 
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Our results explain why others have found limitations in the use of antibody measurements in bulk 
tank milk for diagnosis M. bovis at herd level (Nielsen et al., 2015; Parker et al., 2017; Petersen et al., 
2016). Usually cows with clinical signs of mastitis will not be milked into the bulk tank for delivery 
to the dairy and therefore do not contribute to the bulk tank milk antibody response. However, 
since the antibody level in milk after mastitis seem to last for at least 20 weeks (Boothby et al., 
1987; Byrne et al., 2000), they might contribute after clinical signs/treatment have ended. Different 
management factors, treatment and segregation strategies can then be the cause of variations in 
bulk tank milk antibody levels in herds experiencing an outbreak of M. bovis-associated disease. For 
this reason, bulk tank milk sampling is less suitable for identification of M. bovis infected herds than 
for other pathogens, which elicit stronger antibody responses in subclinically infected cattle. 
Cows with non-specific or no M. bovis associated disease To be as certain as possible that the cows in the ‘Systemic’ group represented M. bovis infected animals, and that cows in the ‘None’ group were not infected with M. bovis, an intermediate group 
was necessitated. Cows in this group may be a mix of cows that are infected with M. bovis without 
showing clear clinical signs, cows that have been infected earlier and not showing clinical signs 
anymore and cows that are not infected. It is therefore difficult to make too many firm conclusions 
regarding the dynamics in this group, and we note that the ODC % was generally estimated by the model as being somewhere between the ‘None’ and ‘Systemic’ groups (although closer to the 
former). Herd 1 was overrepresented in the ‘Non-specific’ group. This could be because herd visits were 
initiated for Herd 1 later in the outbreak than the other herds, so some cows might have shown 
clinical signs earlier and were recovering at the time we visited the herd. This could explain the 
intermediate antibody responses in many cows in this disease group and the slightly declining 
mean predicted ODC% (Figure 3).  Two cows from the ‘None’ and ‘Non-specific’ group stand out as having high ODC% in milk (Figures 
2C and 2D). The most likely explanation for these must be undiagnosed or subclinical mastitis (Fox, 
2012), since records in the electronic herd recording system did not reveal former treatment of mastitis. Given the fact that the mean for the ‘Non-specific’ group was closer to the mean of the ‘None’ group than the ‘Systemic’ group, it is more likely that these cows were either not infected or 
previously infected with M. bovis. 
Study Design and Limitations 
The aim of this study was purely to investigate the dynamics of antibodies directed against M. bovis 
under field conditions.  
Advice about how to handle the disease outbreak or specific cows was not given by any of the 
project veterinarians, and decisions regarding treatment and herd-specific disease control 
strategies were solely made by the farmer and his consulting veterinarian. We cannot be sure that 
our presence and interest in sampling did not influence the decisions about strategy, but it is not 
our impression that this has happened to a great extent. However, the culling strategies varied a lot 
between herds due to different local veterinary advice and differences in clinical signs and severity 
of disease. 
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In addition, we note that the predefined test-positive cut-off value of the BioX ELISA (37 ODC%) has 
not yet been substantially documented in naturally infected cattle. To evaluate which cut-off is 
meaningful, an overview of the variation between individual cows, as provided here, is needed as 
the first step. However, the proportion of test results that would be expected to be over a given 
arbitrary threshold based on our results can be calculated as follows: 
 
𝑃𝑃(+| 𝜇𝜇𝑔𝑔,𝑑𝑑, 𝜎𝜎𝑎𝑎, 𝜎𝜎𝑟𝑟, 𝑡𝑡) = 1 − Φ (
log (𝑡𝑡 + 1) − log (𝜇𝜇𝑔𝑔,𝑑𝑑)
√𝜎𝜎𝑎𝑎2 + 𝜎𝜎𝑟𝑟2
) 
 
where 𝜇𝜇𝑔𝑔,𝑑𝑑, is the estimated mean value for group g at time d (Figures 3 and 4), 𝜎𝜎𝑎𝑎& 𝜎𝜎𝑟𝑟  are the 
standard deviation associated with cow/herd and residual for the same group g (Table 4), t is the 
desired test threshold (for example 37 ODC%), and Φ is the standard normal distribution.  
 
Conclusions 
To our knowledge this is the first longitudinal observational field study of naturally infected herds 
in which the dynamics of the IgG response directed against M. bovis in dairy cows are described and 
compared between groups of animals with different disease manifestations. We conclude that 
antibody measurements in milk are only useful for differential diagnosis of mastitis, and that serum 
antibody responses are highly dynamic and variable between individual cows. Consequently, 
serology based on the BioX Bio K 302 ELISA is not likely to be of useful for individual diagnosis of M. 
bovis associated disease in dairy cows. However, this does not preclude use of the test for herd or 
group level diagnosis, which is supported by the fact that the estimated mean of the measured 
antibody response in the group of cows with M. bovis associated systemic disease was markedly 
higher than in cows without M. bovis associated disease between 7 and 17 d after disease onset in 
particular. Further studies are therefore warranted to identify optimal herd-level testing strategies 
based on the information provided here. 
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Appendix 
Herd no_______________  Cow no_____________             Date____________ 
 Levels 
General condition  
Level of alertness 0/1 (0 = bright and alert, 1 = depressed to apathetic) 
Body condition score 1 - 5 (1 = lean, 5 = fat) 
Rectal temperature Measured with a thermometer 
Head  
CNS, head position 0/1 (0 = normal, 1 = head tilt) 
Eye discharge 0/1 (0 = absent, 1 = visible ocular discharge) 
Nasal discharge 0/1 (0 = absent, 1 = visible nasal discharge) 
Cough 0/1 (0 = absent, 1 = present at examination) 
Respiratory system  
Respiration 
characterisation  
0/1 (0 = normal, 1 = abnormal breathing i.e. severe increase of frequency and 
intensity) 
Pulmonary auscultation 0/1 (0 = normal, 1 = abnormal lung sounds, e.g. crackles, wheezes) 
Cardiovascular system  
Auscultation 0/1 (0 = normal, 1 = abnormal heart sound/beat) 
Musculoskeletal system  
Limb swelling 0/1 (0 = absent, 1 = present) 
Skin on limbs 0/1/2 (0 = intact skin, 1 = hairless spots, intact skin, 2 = active/healed wounds) 
Lameness 0/1/2 (0 = not lame, 1 = lame, 2 = severely lame) 
Udder  
Inspection 0/1/3 (0 = symmetric, no wounds or swelling, 1 = asymmetric, wounds or 
swelling, 3 = cows with a dry quarter) 
Palpation 0/1/2/3 (0 = soft normal udder tissue, 1 = oedema in one or more glands, 2 = soft 
swelling, consistent with acute inflammation, 3 = hard swelling, consistent with 
chronic changes) 
Soreness 0/1 (0 = normal, 1 = sore when palpated) 
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Abstract 
Background 
Inexpensive and convenient diagnostic tests for use in clinical work and for the surveillance of 
infection with Mycoplasma bovis are in demand. The objective of this longitudinal field study was to 
gain knowledge about the dynamics of antibodies against M. bovis in sera from naturally exposed 
calves with and without different clinical signs, measured by two different ELISA tests.  
Results 
A total of 83 calves were subject to between one and five blood samples and clinical examinations 
using a standard protocol during five herd visits to each of four outbreak dairy herds. The blood 
samples were analysed for the presence of antibodies against M. bovis using the commercial IgG 
ELISA test BioX K302 (BioX) and an in-house indirect IgG ELISA test (MilA ELISA).Linear mixed 
models were used to describe and compare the antibody dynamics as measured by the two tests in 
relation to the disease status and age of the animals.The BioX ELISA response was below the 
recommended cut-off (37 ODC%) for the entire study period in many of the calves. The estimated 
mean ODC% increased slowly but did not reach the recommended individual animal cut-off in three 
of the four herds. The highest estimated ODC% was not reached until the calf was approximately 
120 days old. The MilA ELISA response rose above the recommended cut-off (135 antibody units 
(AU)) in almost all calves, and in two herds, the estimated mean was above the individual animal 
cut-off shortly after the birth of the calf. The highest estimated antibody concentration was reached 
when the calf was approximately 60 days old. Disease status of a calf was not significantly 
associated with the results of either test. 
Conclusions 
We conclude that the BioX ELISA cannot be recommended for use in calves below three month of 
age. The MilA ELISA was able to detect antibodies shortly after birth and is therefore a more 
sensitive test for M. bovis exposure in young calves. Neither ELISA seemed able to differentiate 
between calves with arthritis and/or otitis media, and respiratory disease. 
Keywords: Mycoplasma bovis, ELISA, BioX BioK 302, MilA ELISA, dairy calves, antibody  
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Background 
Mycoplasma bovis causes severe disease in cattle worldwide. The typical clinical manifestations in 
calves are pneumonia, otitis media and arthritis (Maunsell and Donovan, 2009). The primary 
diagnostic tool used in calves is bacterial culture of body fluid samples (Sachse et al., 2010), but this 
is too expensive and time-consuming for use in group or herd diagnostics or for surveillance 
purposes. Although bacterial DNA-detection tests (such as PCR assays) are becoming more popular, 
the diagnostic material used for this technique is more difficult to obtain and process than a blood 
sample. An ELISA for antibody-detection is easy to perform on serum samples and is often less 
expensive, and these assays are already commonly used for the diagnosis of other diseases in cattle. 
Knowledge about the dynamics of antibody response in infected animals in relation to disease and 
age is essential when using an ELISA as a diagnostic tool. This knowledge requires longitudinal 
studies of naturally exposed calves, involving repeated observations of clinical signs combined with 
samples being taken for laboratory testing. However, this is time-consuming, inconvenient and 
expensive, and therefore rarely implemented, meaning that our existing knowledge about antibody 
dynamics in calves comes mostly from experimental studies. Calves vaccinated with an 
experimental aerosol vaccine against M. bovis at three to four weeks and five to six months of age 
appeared to have a detectable immunoglobulin G (IgG) response against M. bovis within 14 days, 
and the antibody concentrations in serum remained at a high level for at least 42 and 30 days, 
respectively (Zhang et al., 2014).  
However, neither the M. bovis antibody response to systemic disease syndromes, such as arthritis, 
or the dynamics of the antibody response over time in naturally infected calves is clear. It is also 
crucial to know how to interpret ELISA results in young calves, since maternally derived antibodies 
against M. bovis might be present in uninfected calves. Furthermore, very young calves may not be 
able to generate an antibody response to bacterial infections (Roden et al., 1992). Other authors 
have found the antibody titres in young dairy calves to be low, suggesting low levels of passive 
transfer of antibodies from the dam (Van Donkersgoed et al., 1993; Virtala et al., 2000). No 
correlation has yet been found between clinical signs and antibody response in individual calves, 
but seroconversion to M. bovis has been shown to be predictive of disease at a group level in feedlot 
cattle (Martin et al., 1990; Wawegama et al., 2016). To date, there have been few evaluations of the 
use and interpretation of different M. bovis ELISA tests under field conditions. Recently, the 
dynamics of the antibody response in cows was found to be very dynamic, short-lasting and 
dependent on clinical signs in the cow (Petersen et al., 2018), but similar studies in calves under 
different herd and disease conditions lacks.  
An in-house IgG-detection ELISA (MilA ELISA) developed by Wawegama et al. (2014) has an 
estimated animal-level sensitivity and specificity of 94.3% and 94.4%, respectively using a cut-off of 
105 antibody units (AU) (Wawegama et al., 2016). This study compared the results from the MilA 
IgG ELISA with those obtained from the BioX K302 and K260 ELISA assays in two small groups of 
experimentally infected calves, and found that both BioX tests had low sensitivity.  
To the best of our knowledge, there has been no comparison of the responses measured using the 
MilA ELISA and the BioX K302 ELISA (BioX) in dairy calves, and knowledge about the generation of 
antibodies in serum in naturally exposed calves with and without different clinical signs is lacking. 
Therefore, the objective of this longitudinal field study was to describe and compare the dynamics 
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of antibody responses to M. bovis in the serum of dairy calves with different disease manifestations 
using two different ELISA tests.  
 
Methods 
Data for this study were collected from four dairy herds, from which both cows and calves were 
sampled. A description and an analysis of the data from cows are presented in Petersen et al. 
(Petersen et al., 2018), while analyses of the data from calves are presented here. The basic study 
design and herd selection were the same for the two studies. All farm owners were informed about 
the procedures in the study and gave written consent to use of their animals and farm data before 
study start. The study design was approved by the veterinary department of the agricultural 
advisory services, SEGES, before initiation.   
Study design 
A longitudinal observational study was carried out between 1st July 2015 and 5th April 2016 in four 
Danish dairy cattle herds with acute outbreaks of M. bovis-associated disease. Each herd was visited 
five times with an interval of approximately three weeks between each visit. The first visit was as 
close as possible to the onset of the disease outbreak. The clinical status of selected calves was 
assessed at each visit, and blood samples were collected from them. Where possible, the same 
animals were sampled again at each subsequent visit, allowing both between- and within-animal 
analysis over time. 
Study population 
The study herds were selected based on the detection of M. bovis-associated clinical signs by the 
herd advisory veterinarian and by diagnostic test results (positive in PCR assays on milk samples or 
in ELISA tests on sera from cows or calves). All herds had a recent history of sudden-onset of 
clinical signs indicative of M. bovis infection among the cows and/or calves, and several strongly 
positive ELISA and/or PCR test results for M. bovis.  
All herds tested positive in both an ELISA and a PCR assay on at least one occasion during the study 
period, but the clinical signs present in the herds and the affected age groups differed. Information 
about the farms is presented in Table 1.   
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Table 1: Summary description of the four Danish dairy herds and diagnostic test results prior to and 
during the study period. 
Herd no. 1 2 3 4 
Prior to enrolment 
Herd size (No. of 
cows)  
177 174 182 391 
Estimated start 
of outbreak  
Early Jun 2015 Early Jul 2015 Late Nov 2015 Mid Dec 2015 
After enrolment  
Data collection  1 Jul 2015 - 
16 Sep 2016 
20 Jul 2015 - 
6 Oct 2015 
8 Dec 2015 - 
23 Feb 2016 
20 Jan 2016 - 
5 Apr 2016 
 
Age group 
primarily 
affected   
 
 
Cows 
 
 
Cows and calves 
 
 
Cows 
 
 
Cows and calves 
 
Primary clinical 
signs 
 
Cows Mastitis Mastitis, arthritis Arthritis Mastitis, arthritis 
 
 
Calves 
 
 
Pneumonia, 
otitis media 
 
Arthritis,  
otitis media, 
pneumonia 
 
Few cases of 
arthritis and 
otitis media 
 
Arthritis,  
otitis media, 
pneumonia 
Diagnostic tests     
Positive samplesa      
BioXb 16/51 26/101 14/89 13/93 
MilAc 48/51 98/101 41/89 88/93 
Positive cultures 
(necropsied 
calves) 
 
0 
 
1 
 
0 
 
2 
a Number of seropositive samples out of all sera obtained during the study period 
b ODC% values > 37 in BioX Bio K 302 ELISA (BioX Diagnostics, Belgium)  
c AU > 135 in the MilA ELISA 
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Laboratory analysis of calves that were euthanised and necropsied outside the planned project 
activities revealed additional information about the study herds. One calf from Herd 2 had chronic 
degenerative arthrosis in several joints and bronchopneumonia with overlying pleuritis; M. bovis 
was cultured from joint fluid, and both joint fluid and lung tissue were PCR positive for M. bovis. 
Two calves in Herd 4 had chronic omphalitis, bronchopneumonia, synovitis in several joints and 
bilateral otitis media; Mycoplasma spp. were cultured from these calves and identified as M. bovis by 
PCR.  
Bacterial culture was negative for two calves from Herd 3 that were necropsied, even though 
arthritis and otitis media were observed in both animals. However, the presence of typical clinical 
signs (including arthritis/swelling of the limbs, and very high serum antibody titres against M. 
bovis) in multiple cows, and the failure to detect any other pathogens suggest that it is highly likely 
that the clinical signs were associated with M. bovis. 
No animals from Herd 1 were necropsied, but positive PCR results from milk from cows with 
mastitis were obtained before and during the study period. 
Sample collection 
During the first visit, the investigating veterinarian and the farmer selected 20 calves using the 
following standardised procedure. The farmer was told which clinical signs were considered 
indicative of infection with M. bovis (i.e. clinical signs consistent with arthritis, otitis media and 
pneumonia), and asked to identify ten calves that he believed were currently showing or had 
recently shown any of these clinical signs, and ten that he believed had not had any of these clinical 
signs. If ten calves with clinical signs could not be identified, additional calves were selected by the 
investigator to complete the cohort. All calves with the specified clinical signs at the first herd visit 
were included, even if there were more than ten. New calves suspected of having M. bovis-
associated disease at subsequent visits were also included.  
During the herd visits, each calf underwent a clinical examination with a focus on the respiratory 
and musculoskeletal system, using a standardised clinical protocol, which is available from the 
corresponding author. One of three veterinarians performed the clinical examinations, and at least 
one of the authors of the clinical examination protocol was present at each visit.   
In addition, a venous blood sample was collected from each calf using a 10 ml plain Vacutainer tube 
(Kruuse, Denmark). Blood samples were stored in a cool environment and delivered to the Eurofins 
Steins laboratory (Vejen, Denmark) within 36 hours of collection. The serum samples were frozen 
at -18°C. 
Detection of antibodies 
The serum samples were thawed at the National Veterinary Institute, in the Technical University of 
Denmark (DTU), Copenhagen, and analysed for antibodies against M. bovis using the commercial kit 
BioX Bio K 302 ELISA (BioX Diagnostics, Rochefort, Belgium) and the in-house indirect IgG ELISA 
test (MilA ELISA) developed at the University of Melbourne, Australia, by Wawegama et al. (2014).  
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The BioX assay was performed according to the manufacturer’s instructions. The test outcome was 
calculated as: 
ODC% = ((ODsample – ODnegative control) / (ODpositive control – ODnegative control)) x 100 
Where OD is the optical density. An ODC% > 37 was considered positive, as recommended by the 
manufacturer. The manufacturer reported the sensitivity and specificity of the test at this cut-off to 
be 100% in a small sample of experimentally infected and negative control calves (Anonymous, 
2017). However, other authors have found poor sensitivity in experimentally infected animals 
(Schibrowski et al., 2018) and the a recent field study in cows has supported this (Petersen et al., 
2018).  
The MilA ELISA was performed as described by Wawegama et al. (2014). The mean antibody 
concentration in antibody units (AU) was calculated by plotting the OD values on a standard curve 
derived from a set of known positive-control sera included on each plate. In feedlot cattle with BRD 
the sensitivity and specificity of this assay have been estimated at 94.3% (95% confidence interval: 
89.9-99.6%) and 94.4% (95% confidence interval: 90.3-99.6%), respectively, using 105 AU as cut-
off (Wawegama et al., 2016). However, the authors recommend using AU > 135 as cut-off for a test 
positive interpretation. 
Statistical analysis 
Individual calves were categorised into the following disease groups: 
1) Likely M. bovis-associated disease (‘M. bovis’) 2) Respiratory disease only (‘Respiratory’) 
3) No clinical signs of disease (‘Healthy’) 
This classification was based on the recorded clinical signs and photographs of each calf taken 
during the herd visits, using the following specific inclusion criteria: 
 M. bovis: calves with clinical signs indicating infection with M. bovis. All calves in this group had 
arthritis and/or otitis media at one or more herd visits, and some calves had in addition signs of 
respiratory disease. 
 Respiratory: calves with only clinical signs of respiratory disease that did not fall into the 
category given above. All calves had one or more of the following clinical signs at one or more 
herd visits: dyspnoea, abnormal lung sounds on auscultation, discharge from the nares or eyes 
and coughing. 
 Healthy: calves with no clinical signs of disease. 
Modelling of antibody responses 
Separate linear mixed models were used, with BioX and MilA ELISA results as the outcome 
variables. The ODC% and AU measurements were log transformed to improve the normality of the 
residuals, and a fixed constant of 1 was added to all results to enable log transformation of all 
values, including the small number of zero values.  
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For each of the two outcomes, model selection was used to find the most parsimonious model based 
on the potential explanatory variables and their two-way interactions. The fixed effects to be tested 
were: the disease group (categorical variable), the herd (categorical variable) and the age (in days) 
of the calf on the sampling date (pseudo-continuous variable). An additional quadratic effect of age 
was included in order to allow for a non-linear relationship between age and ELISA response. The 
final model was obtained using backward stepwise elimination based on Akaike´s information 
criterion (AIC). A random effect of calf identification number was included in all models in order to 
account for repeated samples from the same calf. Confidence intervals for the predicted mean ODC% and AU values (for an “average” calf) were calculated for each herd using parametric 
bootstrapping. 
Age intervals containing fewer than three observations from different calves in the same herd were 
removed. This was done because different age groups were sampled across the different herds, and 
to restrict the models to regions of parameter space with enough observations. As a result, herd-
specific graphs of predicted ELISA responses span different age intervals for each herd. Dashed 
vertical lines in Figures 1 and 2 illustrate the herd-specific age ranges included in the modelling. 
The goodness of fit of the model was estimated using marginal and conditional pseudo R2 for mixed 
models, which was estimated using the method described by Nakagawa and Schielzeth (2013). 
Using this method, the marginal R2 describes the variation explained by the fixed effects alone, and 
the conditional R2 describes the variation explained by both fixed and random effects. All data 
management and analyses were done in R version 3.2.2 (R Core Team, 2016), with linear mixed 
models implemented using the lme4 package (Bates et al., 2015). 
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Results 
Descriptive statistics 
In total, 83 calves were enrolled in the study and 334 blood samples were collected. Table 2 shows 
the number of calves stratified by herd and disease group. 
Of the 83 calves, 52 were sampled on five occasions, 16 on four occasions, 1 on three occasions, 6 on 
two occasions and 8 on one occasion. The primary reason for calves dropping out of the study was 
euthanasia (N=13), and eight calves were moved to another property during the study. Due to a 
laboratory error, samples from the first visit to Herd 1 were not analysed.  
The BioX ELISA response was below the recommended cut-off of 37 ODC% for the entire study 
period for 48 of the calves, above the cut-off for the entire study period for eight calves, and 27 
changed status (Figure 1). Few calves had an ODC% above the cut-off before they were 40-60 days 
old (Figure 1).  
 
Table 2: Distribution of calves by disease group and herd in a Danish longitudinal field study of four 
dairy herds with an outbreak of M. bovis-associated disease. 
Disease group ‘M. bovis’ Respiratory Healthy Total 
Herd 1     
Calves 2 13 0 15 
Samples 8 43 0 51 
Herd 2     
Calves 7 14 1 22 
Samples 29 70 2 101 
Herd 3     
Calves 6 11 3 20 
Samples 23 51 15 89 
Herd 4     
Calves 15 10 1 26 
Samples 49 40 4 93 
Total     
Calves 30 48 5 83 
Samples 109 204 21 334 
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Figure 1: Distribution of ELISA measurements in the BioX ELISA Bio K302 assay (ODC% = sample 
coefficient) of serum antibodies against M. bovis in four Danish dairy herds. Grey squares = “M. 
bovis”; black dots = “Respiratory”; green triangles = “Healthy”. Horizontal dashed lines show the 
recommended ELISA cut-off (37 ODC%). Vertical dotted lines indicate the limits for including 
observations in the modelling of antibody response dynamics. Results from the same calf are linked 
by lines. 
 
The MilA ELISA response was above the recommended cut-off of 135 AU throughout the entire 
study period for the majority of the calves (Figure 2). Only one calf was below the cut-off at the end 
of the study period. The MilA ELISA detected antibodies soon after birth (i.e. at approximately 20 
days of age), but as was evident in Herd 3, the antibodies did not increase quickly in all herds. The 
responses varied, but remained above the cut-off once it has been reached.  
Based on the raw data plots, there seems to be no association between disease group and antibody 
responses for either ELISA test (Figures 1 and 2).  
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Figure 2: Distribution of serum ELISA measurements in the MilA assay (AU = sample antibody 
units) of serum antibodies against M. bovis in four Danish dairy herds. Grey squares = “M. bovis”; black dots = “Respiratory”; green triangles = “Healthy”. Horizontal dashed lines show the 
recommended ELISA cut-off (135 AU). Vertical dotted lines indicate the limits for including 
observations in the modelling of antibody response dynamics. Results from the same calf are linked 
by lines. 
 
Results of the statistical modelling 
The final model with log transformed BioX ODC% as the outcome included the linear and quadratic 
effects of age, the fixed effect of herd, and the two-way interactions between herd and both the 
linear & quadratic effects of age (Table 3). The variance associated with the random effect of animal 
was considerable, although less so than the residual variance. There was a positive linear effect of 
age in all herds, but the sign of the quadratic effect was dependent on herd. Based on Figure 3, the 
mean estimate of ODC% in three of the four herds increased gradually with age and did not reach 
the recommended individual animal cut-off. In the remaining herd, the rate of increase in ODC% 
increased with the age of the calf. The highest mean estimate of ODC% was not reached until the 
calf was approximately 110-130 days old (depending on the herd), with some suggestion of a 
plateau and eventual decline above this age in three of the herds (Figure 3). However, a comparison 
of this relationship among herds is complicated by the difficulty in extrapolating the polynomial 
effect of age outside the observed parameter space, which was further compounded by the small 
differences in the ages of the calves among herds.    
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Table 3: Final model describing explanatory variables and random effects of log transformed BioX 
K302 ELISA optical density measurements (ODC%). The marginal R2 was 39% and conditional R2 
was 61%. 
Variables Variance 95% confidence interval  
Random effects     
Animal 0.28 0.13 - 0.38  
Residuals 0.47 0.37 - 0.54  
  Estimate SE P-value 
Fixed effects     
Intercept  2.55 0.26 < 0.001 
Age days (linear)  14.68 3.93 < 0.001 
Age days (quadratic)  -8.16 2.27 < 0.001 
Herd 1  0  - 
Herd 2  0.30 0.30 0.311 
Herd 3  -0.10 0.30 0.753 
Herd 4  0.37 0.31 0.229 
Age days (linear)*Herd 1  0  - 
Age days (linear)*Herd 2  -5.93 4.27 0.165 
Age days (linear)*Herd 3  7.11 4.59 0.123 
Age days (linear)*Herd 4  -8.15 5.06 0.108 
Age days (quadratic)*Herd 1  0  - 
Age days (quadratic)*Herd 2  4.80 2.65 0.072 
Age days (quadratic)*Herd 3  13.42 3.19 < 0.001 
Age days (quadratic)*Herd 4  13.95 3.31 < 0.001 
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Figure 3: Estimated mean antibody response in sera (solid line) and 95% confidence intervals 
(shaded area) as measured by the BioX ELISA Bio K302 assay for the herd-specific age ranges for 
which observations were available. Herd 1 is grey, Herd 2 is black, Herd 3 is blue and Herd 4 is 
green. The dashed line shows the recommended individual animal ELISA cut-off (37 ODC%). 
 
The final model with log transformed MilA AU as the outcome also included the linear and quadratic 
effects of age, the fixed effect of herd, and the two-way interactions between herd and both the 
linear & quadratic effects of age (Table 4). The variance associated with the random effect of animal 
was less than that estimated for the BioX ELISA. Again, there was a positive linear effect of age in all 
herds, but as for the BioX ELISA, the sign of the quadratic effect was dependent on herd. Based on 
Figure 4, it appears that the MilA ELISA detected antibodies in younger calves, and for two herds, 
the mean estimate of MilA AU was above the recommended animal cut-off value for animals less 
than ten days old. The overall shape of the relationship between age and estimated AU was similar 
in three of the four herds (Figure 4). It can be characterised by an initial phase of increase followed 
by a plateau and an eventual decrease, although the peak was reached at the older age of 110-120 
days in Herd 1, compared to approximately 60-80 days in Herds 2 and 4. A significantly different 
pattern, which was more similar to an exponential increase from an initially low MilA AU value, was 
estimated for Herd 3 (Figure 4).  
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Table 4: Final model describing explanatory variables and random effects of log transformed MilA 
ELISA antibody units (AU). The marginal R2 was 59% and conditional R2 was 65%. 
Variables Variance 95% confidence interval    
Random effect     
Animal 0.09 0.007 – 0.150  
Residuals 0.57 0.463 – 0.655  
  Estimate SE P-value 
Fixed effects     
Intercept  5.77 0.22 < 0.001 
Age days (linear)  12.91 3.53 < 0.001 
Age days (quadratic)  -8.25 2.18 < 0.001 
Herd 1  0  - 
Herd 2  0.61 0.25 0.015 
Herd 3  -0.83 0.25 0.001 
Herd 4  0.32 0.26 0.231 
Age days (linear)*Herd 1  0  - 
Age days (linear)*Herd 2  -11.90 3.89 0.003 
Age days (linear)*Herd 3  10.79 4.35 0.014 
Age days (linear)*Herd 4  -15.88 4.84  0.001 
Age days (quadratic)*Herd 1  0  - 
Age days (quadratic)*Herd 2  4.13 2.64 0.118 
Age days (quadratic)*Herd 3  14.71 3.29 < 0.001 
Age days (quadratic)*Herd 4  -2.19 3.40 0.520 
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Figure 4: Estimated mean antibody response in serum (solid line) and 95% confidence intervals 
(shaded area) as measured by the in-house MilA ELISA for the herd-specific age ranges for which 
observations were available. Herd 1 is grey, Herd 2 is black, Herd 3 is blue and Herd 4 is green. The 
dashed line shows the recommended individual animal ELISA cut-off (135 AU). 
 
Discussion 
This is the first observational study to illustrate and analyse the dynamics of serum antibody 
responses against M. bovis in naturally exposed and infected calves. In addition to a large variation 
in antibody responses among calves both within and between herds, the key findings were that the 
BioX ELISA rarely detected antibodies in calves under the age of two months, while the MilA ELISA 
was able to detect antibodies in the same calves soon after birth. Since the calves in these herds 
were all very likely to be truly exposed, we conclude that the MilA ELISA is a potentially useful test 
of M. bovis exposure. However, neither ELISA could differentiate between calves with arthritis 
and/or otitis, and respiratory disease, which indicates that the tests may be less useful for 
distinguishing animals with M. bovis-related diseases from those that have just been exposed to the 
pathogen. 
Antibody dynamics measured by the BioX ELISA 
In general, few calves seroconverted to values above the recommended cut-off of 37 ODC%, and the 
majority remained below the cut-off for the entire study period the BioX ELISA, despite the fact that 
these calves either showed signs of M. bovis-associated disease or were housed with diseased calves 
during acute outbreaks of disease caused by M. bovis. In Herd 2, several calves had severe arthritis, 
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and M. bovis was cultured from one necropsied calf. Despite this, the BioX ELISA did not detect 
antibodies above the recommended cut-off in sera from these calves (Figure 1; grey triangles). It is 
possible that because these calves were very young when they were infected, their immune system 
was not yet able to produce antibodies against the M. bovis antigen used in the BioX ELISA. A similar 
phenomenon has been seen with Salmonella Dublin (Roden et al., 1992). Virtala et al. (2000) also 
found that young calves often fail to seroconvert to common respiratory pathogens including M. 
bovis, although this was assessed using a different assay. The BioX ELISA was also used in a vaccine 
challenge study by Dudek et al. (2016). In the positive control group, which consisted of five- to six-
week-old heifers intratracheally challenged with M. bovis, the antibody response increased only 
slightly to a maximum of approximately 50 ODC% at four weeks after challenge, and thereafter 
declined slightly. By contrast, in the vaccinated group, which was inoculated subcutaneously with 
inactivated M. bovis mixed with two adjuvants, serum antibody concentrations rapidly increased 
within two weeks of vaccination and reached a maximum of around 200 ODC% in four weeks. This 
difference is likely to reflect the greater stimulation of the systemic immune response following 
inoculation with an adjuvanted whole cell vaccine compared to natural infection. 
Our study is the first to evaluate the dynamics of the BioX ELISA in calves under field conditions and 
we have shown that it is not a suitable test for reliable diagnosis of M. bovis in calves below three 
months of age. However, this does not rule-out that it can be useful for group diagnostics in younger 
calves if the cut-off is adjusted. Further studies in larger number of herds with different disease 
occurrence are warranted to explore this. 
Antibody dynamics measured by MilA ELISA 
The MilA ELISA detected antibodies above the cut-off in calves as young as approximately 20 days 
of age, with antibody concentrations rising markedly over a short timeframe, and at the end of the 
study period, all but one of the calves were above the cut-off. However, the MilA ELISA did not 
detect antibodies early in all four herds. In Herd 3, the antibody levels did not start to rise until the 
calves were 60-80 days of age, and then increased rapidly. No M. bovis-associated disease was found 
among the calves in this herd during the first two herd visits, indicating that they had managed to 
prevent transmission between cows and calves and had kept the infection pressure low around the 
calves. In addition, the first visit to Herd 3 was only one week after the appearance of clinical signs 
in the herd, and the farmer did not feed any waste milk to the calves. The later response detected by 
the MilA ELISA in this herd could be a result of initial infection among the cows and later 
transmission to the calves (i.e. around 40-60 days after the outbreak had started). The other herds 
were visited three to four weeks after the outbreak had started, and transmission to the calves had 
already occurred by this time. This could explain the high serum antibody concentrations in young 
calves in these herds. It can therefore be concluded that the MilA assay does not detect young calves 
as positive in non-infected groups of calves, which supports a reasonable specificity and therefore 
the usefulness of this test for confirmation and surveillance purposes. To substantiate this finding, 
control herds with no known M. bovis-associated diseases should be assessed for comparison. The 
high antibody concentrations detected in most calves in this study, including the healthy calves, 
suggests that the MilA test is very sensitive and probably detects exposure to M. bovis rather than M. 
bovis-associated disease. Both experimental and field studies of the MilA ELISA also suggest that 
this test has a high level of sensitivity (Wawegama et al., 2016). 
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The use of antibodies to detect infection with M. bovis 
Our study has shown that the M. bovis BioX and MilA ELISA tests give very different results for 
calves with the same exposure and disease status in calves younger than two months old indicating 
different immune reactions to the underlying infection (Herd 2 and 4 in Figures 1 and  2). In herds 
with clinical signs in older calves, the modelled antibody responses were similar in shape, indicating 
similar immune reactions to the underlying infection (Herd 1 and 3 in Figures 1 and 2). This is likely 
associated with the age-related development of immune competence in the calves, which is 
important for the interpretation of the test results for diagnosis.  
Clinical disease did not seem to correlate with the antibody response detected by either ELISA assay. The effect of “Herd” was retained during model selection, indicating that the different ELISA 
responses were mostly influenced by differences among the herds, and not differences in the 
underlying disease status of individual animals. Although Martin et al. (1990) performed their study 
using an indirect haemagglutination assay, they also concluded that serum antibodies against M. 
bovis were not indicative of disease at an individual level, only at group level. 
Only five calves were classified as being healthy, which is a small number to include in the models 
as a separate group, yet disease group was not found to be significant. To assess the robustness of the results, models were generated both without the ‘Healthy’ group, and with the healthy calves included in the ‘Respiratory’ group, and none of these variations altered the conclusions. The ‘Respiratory’ group consisted of many calves, and it is not possible to know whether the disease 
in this group was caused by M. bovis alone or in conjunction with other respiratory pathogens. At 
the time of sampling, the calves were housed in herds with an active or recent spread of M. bovis, so 
it is likely that the disease seen was at least partly attributable to infection with M. bovis. In Herds 2 
and 4, M. bovis was isolated from necropsied calves, and all herds were free of the likely differential 
diagnosis Salmonella Dublin throughout the study period, making it likely that the arthritis was 
caused by M. bovis. 
 
Conclusions 
This is the first study to evaluate the dynamics of antibody responses using the BioX ELISA in calves 
under field conditions and based on the data available for this study it cannot be recommended for 
use in calves below three month of age. The MilA ELISA was able to detect antibodies shortly after 
birth and is likely to be a good assay for detecting exposure to M. bovis. Neither ELISA could 
differentiate between calves with arthritis and/or otitis media, and respiratory disease. 
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ODC%  corrected optic density measurement 
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Summary 
Mycoplasma bovis infections cause disease and production losses in cattle worldwide. The long-term 
consequences are not well described despite being important for management decisions during and 
after disease outbreaks. We investigated the association between M. bovis antibody-positivity and 
undesired early departure (UED, i.e. death, euthanasia or slaughter) before first calving in a cohort 
of 636 heifers from 36 Danish dairy herds with and without a history of M. bovis-associated disease. 
The herds were visited 4 times at 3-month intervals and blood samples from young stock and milk 
samples from lactating cows were collected. Poisson regression was performed to examine the 
association with UED as outcome, logarithmic transformation of risk time as offset and herd as a 
random effect. Individual antibody measurements and group-level variables representing the 
infection level among young stock and cows, age and mortality variables were included in the 
model. The incidence rate ratio of UED increased by 1.23 times for every 10% increase in young 
stock seroprevalence, while the effect of individual antibody level was modified by age and 
influenced UED less. In conclusion, UED in heifers was associated with M. bovis antibody-positivity 
in young stock and should be controlled in dairy herds to reduce losses. 
 
Introduction 
Mycoplasma bovis (M. bovis) is a bacterium associated with severe, often untreatable disease in 
cattle of all ages and is associated with production losses and decreased animal welfare worldwide 
(Maunsell and Donovan, 2009). Clinical signs include pneumonia and arthritis in all age groups, 
otitis media in calves and mastitis in cows (Maunsell et al., 2011; Maunsell and Donovan, 2009) 
leading to increased mortality risk in both calves and cows, and to impaired growth and lower 
carcass weight in veal calves (3;4).  
A proportion of cattle diseased from M. bovis will have a humoral immune response that can be 
measured using ELISA testing of antibodies in serum samples soon after the clinical signs are 
observed (Nicholas et al., 2002; Petersen et al., 2018a; Petersen et al., 2018b). Therefore, antibody 
measurements might be used to confirm or rule-out that M. bovis infection is associated with the 
observed disease syndromes during disease outbreaks, and a question often raised by farmers and 
veterinarians is whether to cull antibody-positive cattle. However, the long-term consequences of 
individual M. bovis antibody positivity in cattle housed in dairy herds with current or previous M. 
bovis infections are not well described 
The associations between M. bovis antibody response, disease and production parameters have not 
been studied much in cattle and the findings are not clear. In one study, the seroconversion rate 
against M. bovis in a group of feedlot calves was associated with bovine respiratory disease (BRD) 
rates (Martin et al., 1990), whereas the M. bovis serostatus at arrival in a veal calf setting was not a 
predictor of development of BRD during the two weeks after arrival in another study (Pardon et al., 
2015). In a risk factor study, the seroprevalence of M. bovis in heifers and cows was not found to be 
associated with the incidence of respiratory disease in the calves (Raaperi et al., 2012). With regard 
to production parameters, a tendency for lower weight gain in M. bovis seropositive weaned beef 
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calves was seen in one study (Hanzlicek et al., 2011), while Martin et al. (1990) found no association 
between serostatus and growth of feedlot calves at group level. 
The above mentioned studies all focus on BRD and weight gain in beef calves, which implies that it 
is primarily concerning male calves, which usually have a shorter lifespan than heifer calves in dairy 
herds. The implications for calves in a dairy herd experiencing a severe M. bovis-associated disease 
outbreak could be different and, in this case, other herd factors should be taken into account such as 
active infection among the lactating cows, colostrum management and other biosecurity 
procedures. In addition, the long-term effect of the disease including potentially reduced growth in 
heifer calves has not been described in published literature. This information is needed in order to 
advice farmers about the impact of implementing proper management of heifer calves and young 
stock during an M. bovis outbreak in a dairy herd. Due to the economic losses associated with 
feeding and housing of heifers that will be culled later due to poor performance, it would be useful 
to be able to provide advice on which calves to keep in the herd and which to cull early. Under the 
hypothesis that infections with M. bovis result in antibody positivity in affected cattle and that M. 
bovis has long-term health effects on infected cattle, we aimed to investigate the association 
between individual and herd-level M. bovis antibody-positivity on undesired early departure (UED) 
before first calving in a cohort of dairy heifers.  
 
Methods 
Study design and study population 
The present study was based on a cohort of heifers in Danish dairy herds enrolled in a field project 
aiming to provide a better understanding of factors related to M. bovis-associated disease and 
interpretation of diagnostic methods. For a detailed description of how the study herds were 
selected, please see Petersen et al. (2016). In short, 39 Danish dairy herds were selected for the 
study aiming to be representative of a distribution of herds with different histories of M. bovis-
associated disease in terms of different outbreak sizes and durations as well as time since the 
outbreak ended, also including some with no history of M. bovis-associated disease. Data from 3 
herds had to be excluded from this study: one went out of business during the project and two had 
complex, multisite facilities with the animals being moved around between different properties 
between visits, making it impossible to connect milk samples to the same site that the calves were 
housed at. The herds were visited four times approximately 3 months apart. At each visit, blood 
samples were collected from 65 calves distributed in four age groups (Figure 1). At the first herd 
visit, a cohort of approximately 20 heifer calves were selected from the 0-3 months old calves (“cohort calves”) and followed with repeated sampling, if still in the herd at the consecutive herd 
visits. With 3 repeated visits this meant that at the last sampling round calves were 9-12 months 
old. The rest of the calves present were convenience sampled aiming for 15 calves being sampled 
per age group (i.e. 0-3, 3-6, 6-9, 9-12 months old). Fifty milk samples from randomly selected 
lactating cows in the same herd were collected at the milk recording date closest to the herd visit 
date, as also described in Petersen et al. (2016).  
 
Manuscript IV 
141 
  
 
 
 
Figure 1: Overview of the four sampling rounds in each of the 36 Danish dairy herds included in this 
study. Black arrows indicate herd visit with blood sampling, black bars indicate milk sampling from 
lactating cows. At each sampling round, blood and milk samples were collected from the 20 cohort 
calves, 45 other calves and 50 lactating cows. Mo = months old, *= cohort calves. 
 
Laboratory analysis 
All samples were transported to Eurofins Steins Laboratory in Vejen, Denmark, and analysed for 
antibodies against M. bovis using the commercial ELISA BioX Bio K302 (BioX 302) (BioX 
Diagnostics, Rochefort, Belgium). It was performed according to the manufacturers 
recommendations (Anonymous, 2017) and the optical density coefficient (ODC%) was calculated as 
 ODC% = (ODsample – ODnegative control) / (ODpositive control – ODnegative control) x 100% 
where OD is the optical density measured by the ELISA reader of each test sample and the positive 
and negative control on the sample ELISA plate. The manufacturer reported 100% sensitivity and 
specificity based on a small sample of experimentally infected calves and un-infected control calves 
(Anonymous, 2017). However, other experimental studies have estimated the sensitivity to be 0.37-
0.47 and the specificity to be 0.95-0.96 (Schibrowski et al., 2018; Wawegama et al., 2016).  No field 
study evaluations of cut-off values at animal level are available in the literature. However, the BioX 
302 should not be used in calves younger than 3 months, because they are infrequently able to 
produce an antibody response measureable by this test and it might be worth considering the 
antibody response as positive at a lower cut-off (e.g. 20 ODC%) in calves than in adults (Petersen et 
al., 2018b). 
Variables 
Outcome 
The outcome of interest was UED of individual cohort calves from the study herds due to either 
culling (slaughter or euthanasia) or death. Sold heifers were considered sold for profit (voluntary 
culling) and were censored on the day of departure. Information about date of birth, date of 
departure, departure destination and calving dates were collected from the Danish Cattle Database 
with written permission from the herd owners. Data entries for these variables were done by the 
farmer as required by law in Denmark. These entries are very reliable due to cross-check systems in 
place for EU-regulation determining agricultural subsidies.  
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Exposure 
Test results from blood samples collected from calves younger than 90 days were excluded, as were 
observations from calves that did not survive until sampling round number two and therefore did 
not have any individual antibody measurements (Figure 2). Age of the calves was divided into 3-
month intervals, with the first interval starting at date of birth plus 90 days (date of inclusion). 
Hence, the study period for analysis for each single calf started at date of inclusion and ended either 
at day of UED, or when censored due to first calving or being sold to another herd, whichever came 
first. Figure 2 shows examples of calves being included and excluded from the study.  
Individual ELISA ODC%: The individual antibody responses in each heifer in each of the sampling 
rounds measured by the BioX 302 ELISA. An aggregated variable was created with the highest 
ODC% ever observed in heifers older than 90 days being assigned to all sampling rounds for each 
individual animal as an indicator of whether it was likely to have been infected with M. bovis. This 
was to account for the fact that antibody responses can be slow in calves. 
Prevalence of antibody positive lactating cows (Cow-prevalence): This variable was calculated 
as the proportion of lactating cows with individual ELISA ODC% ≥ 37 in milk out of all cows tested 
in the herd at the day of sampling. An aggregated variable was created with the highest prevalence 
observed being assigned to all calves in the same herd as an indicator of the highest possible 
infection pressure in the adult cows during the study period. 
Seroprevalence of antibody positive young stock (YS-seroprevalence): This variable was 
calculated as the proportion of calves with individual ELISA ODC% ≥ 37 in serum out of all calves 
tested in the herd at the day of sampling. An aggregated variable was created with the highest 
seroprevalence observed being assigned to all calves in the same herd as an indicator of the highest 
possible infection pressure in the young stock during the study period. 
Potential confounders 
Age group: Age was included as a confounder using 3-month intervals with the first interval being 
age group 3-6 months and the last being the 3-month interval where the last culling, calving or 
censoring was observed for each heifer, whichever came first. 
Mortality-%: This variable was calculated as the average mortality risk for calves aged 0-14 days in 
the year before the fourth blood sampling rounds in the herd. It was categorized into the four 
categories, <1.3%, 1.3-2.6%, 2.7-4.2% and >4.2%, assuring an approximately equal distribution of 
events and time at risk in each category.   
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Figure 2: Schematic drawing showing examples of calves included in the study (not all types of 
observation patterns shown for included heifers) and the two possible sample combinations that 
led to exclusion of the heifer from the analysis dataset (n indicates the number of heifers excluded 
with a given exclusion pattern). Black circle = blood sample, black dot = age. 
 
Statistical analysis 
To examine the association between the exposure and confounder variables and incidence rate of 
UED, Poisson regression analyses were performed with UED as outcome and logarithmic 
transformation of time at risk as offset value. M. bovis-antibody-positivity as exposure was 
evaluated by including the continuous variables Individual ELISA ODC%, Cow-prevalence and YS-
seroprevalence in the model as fixed effects. The analyses were adjusted for confounding effects of 
Age group and Mortality-%. To evaluate whether the association between Individual ELISA ODC% 
and the incidence rate of UED differed between age groups, the interaction between Individual 
ELISA ODC% and Age group was included in the model and evaluated with Individual ELISA ODC% 
and Age group included as main effects in the model. The incidence rate ratio (IRR) and 95% 
confidence intervals were calculated for the fixed effects. The IRR for the effect of a 10% increase in 
the Individual ELISA ODC% on the incidence rate of UED was calculated for each Age group. Herd 
identifiers were included as random effect to account for clustering of heifers within herds. Follow-
up time was split by age resulting in approximately constant incidence rates. The assumption about 
linearity between each of the continuous variables and the outcome was evaluated by including the 
effect of the quadratic term in the model. A non-significant quadratic term was interpreted as 
linearity. Furthermore, the continuous variables were categorized and the parameter estimates 
were checked for rising/declining tendency. Data management and analyses were carried out in 
Statistical Analysis System (SAS version 9.4) and R version 3.2.2 (R Core Team, 2016). 
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Results 
Descriptive statistics 
In total 636 heifer calves were included of which 40 calves were sampled four times, 460 calves 
were sampled 3 times, 108 calves twice and 28 calves only once.  
Sampling of lactating cows was missing in the third sampling round in one herd, and the prevalence 
of lactating positive cows at the third sampling round was then calculated as the average of same 
variable in rounds 2 and 4.  
The mean seroprevalence of antibody-positive young stock was higher in the UED calves compared 
to censored calves, the mean individual ELISA ODC% was slightly higher in UED than censored 
calves, while the prevalence of antibody-positive lactating cows almost equal (Table 1). The 
incidence rate of culling was lowest from 9-18 months and increased from the age of 18-21 months, 
with a large increase from the age of 24 months and onwards. The time at risk for the age groups 
above 24 months was much lower than for the rest of the age groups mainly due to censoring of the 
heifers that calved. The incidence rate varied between the different Mortality-% groups (Table 2). 
 
Table 1: Descriptive statistics of the continuous variables, Individual ELISA ODC%, prevalence of 
antibody positive lactating cows (Cow-prevalence) and seroprevalence of antibody positive young 
stock (YS-seroprevalence. Mean and standard deviation (SD)  
Variable Mean SD 
Individual ELISA ODC%   
Undesired early departure 45 35 
Censored 43 30 
Cow-prevalence  
Undesired early departure 0.25 0.14 
Censored 0.24 0.17 
YS-seroprevalence  
Undesired early departure 0.48 0.20 
Censored 0.43 0.20 
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Table 2: Descriptive statistics of number of heifers with undesired early departures (UED), number 
of calf years and the incidence rate per 100 calf years overall, and stratified by mortality-% and age 
group. 
Variable Level N (UED) 
(Euthanized or 
dead/ 
slaughter) 
Time at risk 
in calf years 
Incidence rate  
(UED per 100 calf 
years) 
 
Overall  63 (20/43) 1090 5.8 
Mortality-% < 1.3% 14 (3/11) 302 4.6 
 1.3-2.6% 19 (2/17) 266 7.2 
 2.7-4.2% 11 (2/9) 285 3.9 
 > 4.2% 19 (13/6) 238 8.0 
Age group 3-6 months 6 (6/0) 156 3.8 
 6-9 months 6 (6/0) 153 3.9 
 9-12 months 3 (3/0) 152 2.0 
 12-15 months 3 (1/2) 150 2.0 
 15-18 months 3 (1/2) 148 2.0 
 18-21 months 12 (0/12) 144 8.3 
 21-24 months 9 (2/7) 120 7.5 
 24-27 months 10 (1/9) 48 20.9 
 > 27 months 11 (0/11) 19 59.2 
 
Analytical statistics 
Of the 3 variables measuring M. bovis-antibody-positivity, YS-seroprevalence and the interaction 
between Individual ELISA ODC% and Age group were significantly associated with UED. For a 10% 
increase in YS-seroprevalence, the incidence rate of UED increased by 23% (IRR=1.23, 95% CI: 
1.02;1.48). Age significantly modified the association between Individual ELISA ODC% and the 
incidence rate of UED. For a 10% increase in Individual ELISA ODC%, the incidence rate of UED 
increased by 27% for age 9-12 months (IRR=1.27, 95% CI: 1.01; 1.59) and decreased by 23% for 
age> 27 months (IRR=0.77, 95% CI: 0.59; 0.99) (Table 3).  
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Table 3: Association between undesired early departure and M. bovis-antibody-positivity measured by 
individual ELISA ODC%, prevalence of antibody positive lactating cows (Cow-prevalence), 
seroprevalence of antibody positive young stock (YS-seroprevalence) and adjusted for differences in age 
(Age group), and mortality percentage with herd included as a random effect.  
Fixed effects 
Incidence 
rate ratio 
95% 
Confidence 
interval 
P-value 
(Overall p-value of 
fixed effects) 
YS-seroprevalence (per 10% increase)            1.23 1.02; 1.48 0.030 
Cow-prevalence (per 10% increase) 0.95 0.77; 1.17 0.64 
Individual ELISA ODC% (per 10 ODC% increase) by Age group 0.047# 
 3-6 months: ELISA ODC% 0.87 0.62; 1.22  
 6-9 months: ELISA ODC% 0.63 0.38; 1.05  
 9-12 months: ELISA ODC% 1.27 1.01; 1.59  
 12-15 months: ELISA ODC% 0.47 0.19; 1.18  
 15-18 months: ELISA ODC% 0.93 0.61; 1.42  
 18-21 months: ELISA ODC% 1.09 0.94; 1.27  
 21-24 months: ELISA ODC% 1.03 0.84; 1.27  
 24-27 months: ELISA ODC% 0.95 0.76; 1.20  
 > 27 months: ELISA ODC% 0.77 0.59; 0.99  
Age group   < 0.001 
 3-6 months 0.37 0.03; 4.79  
 6-9 months 1.03 0.08; 13.44  
 9-12 months 1 (ref)  
 12-15 months 0.02 0.001; 0.53  
 15-18 months 0.15 0.01; 3.00  
 18-21 months 0.29 0.03; 3.14  
 21-24 months 0.36 0.03; 4.22  
 24-27 months 1.47 0.13; 16.71  
 > 27 months 11.14 0.98; 126.5  
   Mortality-%   0.27 
 < 1.3% 1 (ref)  
 1.3-2.6% 1.47 0.65; 3.32  
 2.7-4.2% 0.77 0.31; 1.92  
 > 4.2%  1.70 0.73; 3.94  
Random effect Estimate Standard error  
Herd 0.18 0.18  
# P-value for the interaction in a model including Individual ELISA ODC% and Age group as main 
effects 
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Discussion 
This study showed an association between the UED (including euthanasia, death and slaughter) rate 
in heifers and increasing seroprevalence among young stock, when accounting for the underlying 
natural culling patterns in dairy herds by inclusion of age and mortality percentage. There was a 
weaker association between the individual antibody response depending on age group and UED. 
Together this suggests that exposure to and infection with M. bovis increases the risk that heifers 
will have to be removed from dairy herds before the first calving.  
This is the first study to investigate the association between M. bovis antibody level and UED. 
However, other authors have investigated the association between the antibody response and 
disease and other production parameters. The findings of our study is in agreement with Martin et 
al. (1990) who found an association between the seroconversion rate against M. bovis in the group 
of feedlot calves and respiratory disease, which in itself might lead to death or euthanasia 
(Gulliksen et al., 2009). In contrast, Pardon et al. (2015) found no association between M. bovis 
serostatus at arrival at a feedlot and BRD. The difference between the conclusions can be due to 
difference in variables included and the timing of the serostatus measure in relation to disease 
development. Martin et al. (Martin et al., 1990) included the seroconversion rate in the first 28 days 
at the feedlot, while Pardon et al. (Pardon et al., 2015) only included the serostatus at arrival in a 
veal calf facility. Transmission from older calves to incoming calves is a source of infection with M. 
bovis (Maunsell et al., 2011) and it is likely that infection with M. bovis at least in some calves are 
seen after mixing with other calves at e.g. a rearing unit. In addition, the young age of the calves in 
Pardon et al. (Pardon et al., 2015) could have resulted in only few calves being seropositive and the 
serostatus might therefore not be representative for the infection status. The true effect of infection 
with M. bovis could therefore be masked in the study by Pardon et al. (Pardon et al., 2015). Both of 
these studies are conducted in feedlots and compared to the present study in dairy herds, there are 
probably differences in culling pattern and mortality that can have affected the conclusions. 
The fact that age significantly modified the association between Individual ELISA ODC% and the 
incidence rate of UED, means that increasing individual ELISA ODC% had different effects in 
different age groups. Increasing ELISA ODC% was associated with increased UED at age 9-12 
months, while in heifers > 27 months of age increasing ELISA ODC% was negatively associated with 
UED. Young calves are primarily euthanized/dies due to different diseases and management factors 
and the mortality percentage decreases with age (Gulliksen et al., 2009). An explanation for the 
positive association between ELISA ODC% and UED in age group 9-12 months can be that the calves 
in this age group are in general less vulnerable and less likely to die than younger calves, so the 
effect of M. bovis infection, which can be chronic and have a prolonged effect (Maunsell and 
Donovan, 2009), even if the heifers were infected as young, is then more evident than when 
confounded by other diseases or risk factors. Martin et al. (Martin et al., 1990) also included the 
individual antibody response, but did not find an association with disease. Their conclusion was 
that this could either be because M. bovis only has an effect at group level, or it may reflect the level 
of statistical control in the models. It could also be due to the fact that the calves were not followed 
for longer than 28 days and the effect of M. bovis was therefore not evident yet. The positive 
association between Individual ELISA ODC% and UED in heifers > 27 months old is more difficult to 
interpret biologically. One potential explanation could be that heifers that survived until around 
Manuscript IV 
148 
  
calving were the ones not as severely affected by M. bovis as the ones that were culled/died earlier. 
Despite an elevated antibody response they were healthy and deemed capable of continuing in the 
herd as lactating cows, despite haven been exposed to M. bovis at a younger age.  
Other authors have investigated the association between M. bovis and weight gain, and no 
association between seroconversion rate and weight gain was found in feedlot calves (Martin et al., 
1990), while a tendency for lower weight gain in M. bovis seropositive weaned beef calves has been 
found (Hanzlicek et al., 2011). The reason for these rather inconsistent results could be that M. bovis 
is often harmless by itself but enhances the pathogenicity of other organisms (Martin et al., 1990). 
The impact of M. bovis serostatus is therefore dependent on other pathogens present in the included 
animals and this is impossible to unify or control for in field studies unless many pathogens are 
screened for simultaneously. 
The outcome of interest, UED, consisted of both involuntary culling (slaughter or euthanasia) and 
death. As seen in Table 2, the distribution of specific events was different. Death/euthanasia 
happened mainly during early age, while slaughter mainly happened later. There were probably 
different underlying reasons for e.g. slaughter and death, with death/euthanasia usually happening 
in more severe cases of disease or injury, and the antibody response could have different impact on 
different reasons for UED of heifers. Euthanasia and slaughter of a heifer is a decision made by the 
farmer in contrast to death, and culling decisions are known to be affected by many different factors 
apart from poor health of the animals (Haine et al., 2017). An analysis of each of the specific events, 
slaughter, death and euthanasia separated would have been relevant, but it was not possible with 
the available data due to few events in each age-category. The decision of culling could in principle 
have been affected by the ELISA ODC% of the heifers, as these were made available to the farmer 
after the herd visits. However, during the study period no recommendations about use of the 
antibody results in relation to management were given, and farmers did not seem to know what to 
do with the results during the field study period. Furthermore, the last blood sample results were 
collected around the age of 1 year, and most of the heifers were slaughtered at least 6 months after. Taken together we find it not likely that the results of the blood samples have influenced farmer’s 
choice of culling. If this is the case, it is more likely that it was in fact the health or production 
performance effect of M. bovis infection that was reflected in the results.  
Samples taken when the calves were less than 90 days of age were excluded, because the 
interpretation of the ELISA response is uncertain in this age-group when using the BioX 302 ELISA 
(Petersen et al., 2018b). This means that calves that died before the age of 90 days were also 
excluded. That could have resulted in exclusion of young calves that actually died because of M. 
bovis-associated disease in the herd. This effect will primarily be seen in the herds with a recent 
history of M. bovis-associated disease outbreak. Many of the herds were more than 2 months past 
the disease outbreak when sampling was initiated, and therefore this is considered a minor issue. 
On the other hand, calves are proposed as being the reservoir for keeping the infection on-going in 
the herd (Maunsell et al., 2011), which suggests that on-going infection and disease caused by M. 
bovis can be expected in many of the included herds. Including the calves below 3 months old would 
have been preferable and would also have resulted in more events, which would have strengthened 
the statistical analyses. 
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To account for the M. bovis-associated disease status among all calves in the herd the maximum 
seroprevalence of all sampled calves observed in the herds was also included. This variable reflects 
the M. bovis status among calves aged 3-12 months in the herd. Despite antibodies against M. bovis 
are not recommended for individual diagnosis (Maunsell and Donovan, 2009), an increase in 
antibody titre occur after exposure to M. bovis (Kanci et al., 2017) and the seroprevalence in a group 
of calves is assumed to be a useful measure of exposure to M. bovis.  
The level of M. bovis infection among the cows in the herds was accounted for by including the 
maximum prevalence of antibody positive lactating cows observed in the herds. The antibody level 
in milk samples reflects the presence of M. bovis infections in udders and no other clinical 
syndromes such as arthritis and pneumonia (Petersen et al., 2018a). To include a measure of 
systemic infections among the cows it would have been relevant to include the seroprevalence of 
cows. However, this was unfortunately not possible with the available data. In fact many of the 
Danish M. bovis-associated disease outbreaks happening from 2011-2014 were characterised by 
systemic disease (Jensen, 2015) and being able to take this into account in the model could possibly 
have had a significant effect on UED in the herds. The effect of living in a herd during a M. bovis-
associated disease outbreak might therefore be underestimated because all disease manifestations 
among cows in the herd have not been taken into account.  
The mortality percentage was included to account for the mortality in the young calves that could 
not have their serostatus evaluated due to lack of immune-competence. Death in young calves can 
have various causes e.g. acute diarrhoea and other infectious diseases, as well as physical and 
psychological stressors dependent on management (Gulliksen et al., 2009; Uetake, 2013). By 
including the mortality percentage in the young calves it was attempted to take different 
management in the herds into account, however, having said this we are aware that other factors  
than management also influence the calf mortality.  
In conclusion, despite this study being limited in sample size and number of UED events per herd 
overall it points to a negative effect of having active M. bovis-infection causing disease among calves 
in dairy herds. A higher M. bovis seroprevalence in the group of calves and young stock increased 
the risk of heifers being culled, euthanized or dying before the first calving in this study, while the 
effect of the individual antibody responses was dependent on age. The long-term effect of M. bovis is 
most pronounced at group-level and management and preventive actions should be implemented to 
reduce the risk of infection and exposure in the group of calves, rather than focusing on the status of 
the individual calf.  
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9 Appendices 
 
Appendix I – Questions used for sampling activity #1 
Appendix II – Clinical protocol used for sampling activity #2
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Farmer interview regarding Mycoplasma bovis-associated 
disease 
CHR nr: 
Disease outbreak: 
1. When did you become aware of M.bovis-associated disease in your herd? 
a. Start__________________________________________________________ 
b. End _________________________________________________________ 
c. There are still M. bovis-associated disease problems 
d. I think the actual outbreak has ended, but some animals with M. bovis-associated 
disease are occasionally found 
e. I have never seen M. bovis-associated disease in the herd 
 
2. How did you detect the disease? 
a. Diseased animals, not confirmed by diagnostic testing  
b. Diseased animals, confirmed by diagnostic testing (PCR, antibody measurements, 
bacterial culture) 
Blood Joint fluid  Milk 
c. Bulk tank milk samples (PCR, antibody measurements, bacterial culture) 
d. Individual samples (PCR, antibody measurements, bacterial culture) 
e. Accidental finding during………………………………….. 
 
3. Who made the diagnosis of M. bovis-associated disease? 
Veterinarian Consultant         Others 
 
4. Which clinical signs have you experienced in the herd in the different age groups (note 
approximate number)? 
 
 Clinical sign  
 Joint Respiratory Ear/udder Euthanised Slaughtered Treated Recovered 
Calves        
Heifers        
Cows        
  
Other clinical signs____________________________________________________________________ 
5. How did you treat diseased animals at the beginning of the disease outbreak?  
a. Culling of all clinically ill animals without medical treatment 
b. Culling of the worst cases 
c. Culling of PCR positive animals 
d. Culling of antibody-positive animals 
e. Medical treatment and culling if unresponsive 
f. Has medical treatment been attempted? 
a. If yes, on which criteria? 
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b. Which age groups and clinical signs have been treated? 
c. Which drugs have you used?  
_________________________________________________________________________ 
 
6. Did the treatment strategy change during the disease outbreak?  
If yes: 
a. Culling of all clinically ill animals without medical treatment 
b. Culling of the worst cases 
c. Culling of PCR positive animals 
d. Culling of antibody-positive animals 
e. Medical treatment and culling if unresponsive 
 
7. Have you received money from an insurance company?   
 
8. Did the insurance company influence the treatment/culling strategy? 
Questions about the herd: 
9. How many different people work with milking, calf management, feeding and management 
in the herd? 
 
10. Housing conditions: 
a. Tie-stall 
b. Loose housing with mattresses 
c. Loose housing with bedding 
 
11. Do the cows go on pasture? 
 
12. Do you use sick pens for cows, heifers and calves suspected of M. bovis infection? 
 
Yes, for cows Yes, for heifers Yes, for calves  No
  
 
13. Did this change during the M. bovis outbreak? 
 
14. How many cows are present in the calving area at the same time? 
      1  2  More 
15. Are there sick cows in the calving area? 
Never  Occasionally  Always 
 
16. When is the calf removed from the cow?  
≤ 1t   1 - 6t    > 6t 
 
17. Do you keep the bull calves to slaughter? 
Yes  No, they are sold No, they are euthanised 
Did you change this routine during the M. bovis outbreak? 
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Milk-fed calves 
18. Receives the calf colostrum < 6 hours after birth?  
Yes  No 
a. How many litres?  
b. As much as they can drink 
c. Nasopharyngeal tube if they cannot drink the full amount 
d. Nasopharyngeal tube 
 
19. How is the colostrum stored?     
a. Fed directly from the cow      
b. Coloquick-system       
c. Colostrum bank, quality tested     
d. Colostrum bank, not quality tested 
 
20. Who is responsible for colostrum? _____________________________________ 
 
21. Is the colostrum pasteurised? 
Yes No 
If yes: 
a. Temperature:___________________________ 
b. Duration:___________________________________ 
c. Is the quality checked? 
a. If yes, how? 
 
22. Have there been changes in colostrum supply during the M. bovis outbreak? 
 
23. How are the calves fed after colostrum is received?   
a. Waste milk e.g. milk from treated cows, cows with high SCC, colostrum 
b. Milk from the bulk tank    
c. Milk replacer  
d. Same management routines regarding housing and feeding for milk-fed heifer and 
bull calves? 
If no, what are the differences?  
 
24. Is the milk pasteurised? 
Yes  No 
If yes: 
d. Temperature:___________________________ 
e. Duration:___________________________________ 
f. Is the quality checked? 
a. If yes, how? 
 
25. Were there changes in milk supply during the M. bovis outbreak? 
 
26. How and how often are the drinking trough/feeding bucket/automatic milk feeder cleaned? 
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a. Daily with clean water, always same equipment for the same calf 
b. Changed daily 
c. Weekly with clean water, always same equipment for the same calf 
d. Changed weekly 
e. Daily, with possibly contaminated water (e.g. milk and saliva from other animals)  
f. Weekly, with possibly contaminated water (e.g. milk and saliva from other animals) 
g. Cleaned when the calf is removed, always same equipment for the same calf 
h. Not cleaned between calves 
  
27. How is the calf pen/hutch cleaned before a new calf enters? 
a. Cleaned, washed, dried and disinfected 
b. Cleaned, washed, dried and disinfected for every 2nd or 3rd calf 
c. Cleaned, washed, dried and disinfected occasionally 
d. Cleaned, washed and dried, but not disinfected 
e. Cleaned, but not washed, dried or disinfected 
f. Cleaned occasionally 
 
28. Were there any changes in management routines during the M. bovis outbreak? 
Weaned calves 
29. Are the heifers at a ‘heifer-hotel’? 
Yes  No Only heifers from my herd Heifers from more herds 
Which CHR? 
 
30. How are the heifers’ housing conditions? 
a. All in – all out, small groups (2-8), no contact between groups 
b. All in – all out, small groups (2-8), contact between groups (e.g. only separated by 
bars) 
c. All in – all out, large groups (> 8), no contact between groups 
d. All in – all out, large groups (> 8), contact between groups (e.g. only separated by 
bars) 
e. All heifers in the barn 
 
31. Do the calves go on pasture? 
Yes  No  
If yes, age groups: ________ 
 
32. Do calves and cows share pasture? 
a. Never 
b. Occasionally 
c. Yes 
 
33. Were there changes in the heifer management during the M. bovis outbreak? 
 
External biosecurity 
34. Which of the following hygiene facilities are placed at the entrance to the cow barn? 
a. Visitors can wash their boots with warm water and soap 
b. No place for boot washing 
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c. Visitors can wash hands with warm water and soap 
d. No place for hand wash 
 
35. Are any hygiene steps required for visitors to enter the stables? 
a. Visitors wear protective clothing and boots made available by the herd  
b. Visitors have to wear clean clothing and boots 
c. Visitors have to wash and disinfect boots before entering the stables 
d. Nothing is required from visitors 
 
36. Purchase of animals to the herd? 
a. No, never 
b. Yes, when? 
1. Only buy animals that are free of  
M. bovis  Salmonella Dublin B-strep Para-tb 
 
2. Animals are bought without consideration of disease status 
 
37. Were there any changes in the external biosecurity during the M. bovis outbreak? 
 
Independent perception of the property 
The flow of animal movements is drawn on a Google Maps picture of the herd, along with the 
number of pens and contact between groups of animals. Apply where the feeding truck, DAKA, 
manure truck and slaughter is driving. 
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Appendix B 
Herd no_______________  Cow no_____________             Date____________ 
 Levels Comments - Describe 
any anomaly 
General condition   
Level of alertness 0/1 (0 = bright and alert, 1 = depressed to 
apathetic) 
 
Body condition score 1-5 (1 = lean, 5 = fat)  
Rectal temperature Measured with a thermometer  
   
Head   
CNS, head position 0/1 (0 = normal, 1 = head tilt)  
Eye discharge 0/1 (0 = absent, 1 = visible ocular discharge)  
Nasal discharge 0/1 (0 = absent, 1 = visible nasal discharge)  
Cough 0/1 (0 = absent, 1 = present at examination)  
   
Respiratory system   
Respiration 
characterisation  
0/1 (0 = normal, 1 = abnormal breathing i.e. 
severe increase of frequency and intensity) 
 
Pulmonary 
auscultation 
0/1 (0 = normal, 1 = abnormal lung sounds, 
e.g. crackles, wheezes) 
 
   
Cardiovascular 
system 
  
Auscultation 0/1 (0 = normal, 1 = abnormal heart 
sound/beat) 
 
   
Musculoskeletal 
system 
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Limb swelling 0/1 (0 = absent, 1 = present)  
Skin 0/1/2 (0 = intact skin on limbs, 1 = hairless 
spots, intact skin, 2 = active/healed wounds) 
 
Lameness 0/1/2 (0 = not lame, 1 = lame, 2 = severely 
lame) 
 
   
Udder (only cows)   
Inspection 0/1/3 (0 = symmetric, no wounds or 
swelling, 1 = asymmetric, wound or swelling, 
3 = cows with a dry quarter) 
 
Palpation 0/1/2/3 (0 = soft normal udder tissue, 1 = 
oedema in one or more glands, 2 = soft 
swelling, consistent with acute inflammation, 
3 = hard swelling, consistent with chronic 
changes) 
 
Soreness 0/1 (0 = normal, 1 = sore when palpated)  
 
 
 
 
 
 
 
 
 
